SAIC Inc.
Annual Report 2022

FY22 ANNUAL REPORT   //   1
DEAR FELLOW 
SHAREHOLDERS,
At SAIC, we are committed to going beyond our fiduciary responsibility and taking a human-centric approach to all of 
our efforts, including our engagement with shareholders, employees, customers, and the global community. As we go to 
press with this report, we are all witnessing the unfathomable events taking place in Ukraine. Our thoughts are with the 
courageous people of Ukraine who are experiencing an unthinkable human toll. We are taking action to support them – 
to date, SAIC and our employees have donated more than $125,000 to humanitarian relief efforts in the region. We join 
the global community in a single, united call for peace.
And, now, we turn to our financial results. We are proud of the performance we delivered in Fiscal Year 2022 
(FY22) as we were able to meet our financial objectives, invest to support growth in the future, and make progress 
against important environmental, social, and governance (ESG) goals. Three things we are known for at SAIC are our 
extraordinarily smart and passionate people who are dedicated to always doing the right thing, a commitment to the 
government mission, and bold thinking that delivers innovative solutions by using advanced technology.
It’s important to recognize the people who have contributed to the success of the business, our employees,  
particularly their resiliency and commitment through a prolonged, challenging environment. Our business is only  
as strong as our people and their dedication to the customer’s mission, the organization’s values, and the company’s 
purpose. SAIC’s approximately 26,000 innovative employees work tirelessly to create a better world, challenging 
boundaries, and redefining excellence. 
It’s important to recognize our customers as well, who also contribute to the success of our business through the trust they 
put into our ability to deliver outcomes. We are grateful for that confidence and their partnership, and strive every day to 
ensure we are supporting all of their mission critical efforts – from the depths of the ocean to the farthest reaches of space. 

2  //  FY22 ANNUAL REPORT
For all of our fellow shareholders, know that we continue to be future focused – 
whether that is architecting the future for our customers, or reinventing the future of 
work for our employees. We’ve invested in both and you’ll see the benefits of those 
investments reflected in our financial results. We are proud of the steps taken during 
the year to drive long-term value, while continuing to live the values that are at the 
core of SAIC. 
FINANCIAL PERFORMANCE
We continue to be focused on driving sustained, profitable growth and investing capital 
to maximize long-term shareholder value. Our solid organic revenue growth, margin 
expansion, and strong free cash flow are evidence of the progress we made in FY22. 
We also invested in strategic acquisitions, giving us access to new capabilities, customers, 
and markets. Our focus continues to be on investing, and ensuring that free cash flow is 
deployed in ways that generate the highest return on capital for our shareholders. 
It is critical that we reinvest in the business now to support future growth. The 
investments we made in innovation, through the launch of the company’s Innovation 
Factories, set us apart in the areas of artificial intelligence (AI), engineering, and digital 
capabilities. The acquisitions of Koverse and Halfaker demonstrate our ability to find 
new ways to deliver solutions and evolve our “go-to-market” strategies to meet our 
customers’ critical mission needs.
In FY22, SAIC delivered revenue growth, record profitability, and strong cash 
generation, while keeping free cash flow solid. The company grew total revenue by 5% 
to $7.4 billion in FY22 and achieved strong increases in adjusted EBITDA, earnings per 
share, and solid free cash flow. Because of our continued strong ability to generate 
cash, we deployed $333 million of capital, consisting of share repurchases of $211 
million or 2.4 million shares of our common stock, cash dividends of $86 million and 
$36 million of capital expenditures.
5% 
ANNUAL REVENUE  
GROWTH
REVENUES
FY20
FY21
FY22
11% 
DECREASE FROM 
PRIOR YEAR
FREE CASH FLOW
FY20
FY21
FY22
9.3% 
MARGIN UP FROM 
8.9% PRIOR YEAR 
ADJUSTED EBITDA
FY20
FY21
FY22
12% 
INCREASE FROM 
PRIOR YEAR
TOTAL BACKLOG
FY20
FY21
FY22
119% 
INCREASE FROM 
PRIOR YEAR
CAPITAL DEPLOYED
FY20
FY21
FY22
$6.4B
$7.1B
$7.4B
$437M
$524M
$467M
$538M
$627M
$686M
$15.3B
$21.5B
$24.1B
$285M
$152M
$333M
OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION
WOMEN IN 
LEADERSHIP 
(IN FY22)
PEOPLE OF COLOR 
IN LEADERSHIP 
(IN FY22)
27%
22%
64% OF OUR BOARD OF DIRECTORS ARE 
WOMEN AND/OR PEOPLE OF COLOR
(IN FY22)

FY22 ANNUAL REPORT   //   3
BEST PLACES TO 
WORK FOR LGBTQ 
EQUALITY
(FOUR CONSECUTIVE YEARS 
WITH A PERFECT SCORE)
2022 AMERICA'S BEST 
LARGE EMPLOYERS
(EVERY YEAR SINCE 2019)
#5 
2021 AMERICA'S BEST 
EMPLOYERS FOR 
VETERANS  
(BEST IN OUR INDUSTRY,  
23% OF SAIC’S WORKFORCE ARE 
U.S. MILITARY VETERANS)
#412 
UP 54 SPOTS FROM 2020 
IN FORTUNE 500
2021 AMERICA'S BEST 
EMPLOYERS FOR 
DIVERSITY 
(EVERY YEAR SINCE 2019)
By continuing to balance our contract mix to be representative of demand, and 
increasing our composition of higher value work, we are driving growth that is 
sustainable over the long term.
PEOPLE AND CULTURE:  
Significant events in our world are impacting global economic prosperity, 
innovation, and security, making diversity, equity, and inclusion (DE&I) and 
employee well-being critical business imperatives.
This commitment extends throughout every level of the organization, up to 
and including our board of directors. It is important to note the diversity of 
our board, which features not only ethnic and gender diversity, but also a deep 
breadth of critical skills and live experiences. With this tone set at the very 
top of the organization, the leadership team is well positioned to ensure this 
business imperative is achieved, and importantly, we believe it is one of SAIC’s 
many competitive advantages.
Women and people of color continue to be disproportionally impacted by 
the pandemic. SAIC is committed to increasing representation of women and 
people of color throughout all levels of our leadership because the strength of 
our leadership is greatest when it fully reflects the diversity of our workforce. 
We understand the importance of diversity of thought and experiences on 
technological advancements, productivity, and overall business results. To that 
end, we are holding ourselves accountable for DE&I outcomes, not only because 
it’s the right thing to do, but because we know it’s also good for business. 
In fiscal year 2022, we established goals to achieve parity in the representation 
of women and people of color between our leadership and non-leadership 
roles within five years. We made meaningful progress toward our goals this 
year, with women now representing 27% of our leadership and people of color 
representing 22%. 
We are committed to being transparent and intentional in our efforts to 
increase leadership diversity through strategic recruiting and retention efforts. 
We seek to drive tangible change through our commitments to:
•	 Fighting racism, bias, and prejudice in our workplace
•	 Making SAIC more inclusive and diverse
•	 Supporting non-profit organizations that are uplifting minorities  
in our communities
•	 Measuring and holding ourselves accountable for results
The well-being of our employees is paramount. As part of our future of 
work efforts, we conduct an annual Employee Culture Survey. Based on the 
most recent feedback, we implemented a number of benefits designed to 
differentiate our employee experience by enriching their lives. We believe 
listening to our employees, understanding their desire for flexibility, and 
providing benefits enhancements that meet their needs, make SAIC the 
employer of choice for exceptional talent. More specifically, in FY22, we added 
new benefits which include expanding flexible work schedules to 4/10 while 
keeping 9/80 and traditional work week options, holding medical premiums 
flat, providing backup child and elder care, adding Juneteenth as a paid holiday, 
and increasing family leave for all employees.
These efforts are just a sample of what can be achieved when a company 
makes employee well-being a priority. 

4  //  FY22 ANNUAL REPORT
CORPORATE RESPONSIBILITY
Corporate responsibility is embedded in our culture, vision, and 
mission, and continues to be integral to what we do at SAIC. Our 
legacy of philanthropy and employee volunteerism is a natural 
outgrowth of our values. Ethical behavior and acting with integrity 
are non-negotiables in our culture and we embrace a broad scope 
of ESG imperatives in the company’s daily operations because we 
believe it makes our business, employees, and communities better. 
We believe taking a long-term approach to corporate philanthropy 
is best, targeting programs that specifically address our three pillars 
of focus: military heroes, community wellness, and STEM (Science, 
Technology, Engineering, and Mathematics). Our SAIC Charitable 
Foundation, created by employees for employees and with 
corporate support, is focused on helping our employees and their 
dependents in times of need. 
Additional information relating to SAIC’s initiatives can be found 
in our 2021 Corporate Responsibility Report available in the 
Corporate Responsibility section of investors.saic.com. SAIC will 
publish the next Corporate Responsibility Report in mid-2022.
IN CLOSING
In FY22, our company delivered strong financial performance and 
invested to drive shareholder value over the long term. We believe 
our success is attributable to our people-first approach, whether it’s 
our shareholders, customers or employees. 
Our approximately 26,000 visionary employees use science and 
technology to solve our customers’ most complex problems. Our 
talent and commitment make us an ideal partner for our customers, 
creating and enabling their transformation and mission success, and 
we are relentless in the pursuit of both. 
Yes, we took bold steps this past year to ensure employee  
well-being and equity were measured and enhanced. These efforts 
differentiate us and the results are worth it. Every day, we live our 
values in our communities through both time and treasure, doing 
our part to make the world a better place for our customers, 
employees, the community at large, and you, our shareholders.  
We are honored to have the opportunity to do so. 
3.8M 
EQUIVALENT 
MEALS 
DONATED TO FEEDING 
AMERICA BY SAIC AND ITS 
EMPLOYEES
21K HOURS 
VOLUNTEERED BY SAIC 
EMPLOYEES
$300K+
PERSONAL FUNDS 
DONATED BY SAIC 
EMPLOYEES
STEM 
DISCIPLINE
MIDDLE AND HIGH 
SCHOOL STUDENTS 
MENTORED BY SAIC 
EMPLOYEES
Donna S. Morea 
CHAIR OF THE BOARD
Nazzic S. Keene 
CHIEF EXECUTIVE OFFICER

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 28, 2022
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission 
File Number
Exact Name of Registrant as Specified in its Charter, Address 
of Principal Executive Offices and Telephone Number
State or other 
jurisdiction of 
incorporation or 
organization
I.R.S. Employer 
Identification No.
001-35832
Science Applications
International Corporation
Delaware
46-1932921
12010 Sunset Hills Road, Reston, VA 20190 
703-676-4300 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Science Applications International Corporation
Common Stock, Par Value $.0001 Per Share
SAIC
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☒No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the 
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was 
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be 
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such 
shorter period that the registrant was required to submit such files).
Yes ☒No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, 
smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated 
filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company ☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying 
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the 
effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 
7262(b)) by the registered public accounting firm that prepared or issued its audit report. 
Yes ☒No ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐No ☒
As of July 30, 2021 (the last business day of the registrant’s most recently completed second quarter), the aggregate market value of the 
registrant’s common stock (based upon the closing stock price) held by non-affiliates was $4.9 billion.
The number of shares issued and outstanding of the registrant’s common stock as of March 4, 2022 was 56,049,904 shares ($.0001 par 
value per share).
DOCUMENTS INCORPORATED BY REFERENCE
Portions of Science Applications International Corporation’s Definitive Proxy Statement for the 2022 Annual Meeting of Stockholders are 
incorporated by reference in Part III of this report. 

Page
Part I
Item 1.
Business
1
Item 1A. Risk Factors
9
Item 1B. Unresolved Staff Comments
19
Item 2.
Properties
19
Item 3.
Legal Proceedings
19
Item 4.
Mine Safety Disclosures
19
Part II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of 
Equity Securities
20
Item 6.
[Reserved]
21
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
22
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
33
Item 8.
Financial Statements and Supplementary Data
34
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
34
Item 9A. Controls and Procedures
34
Item 9B. Other Information
37
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
37
Part III
Item 10.
Directors, Executive Officers and Corporate Governance
38
Item 11.
Executive Compensation
39
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder 
Matters
39
Item 13.
Certain Relationships and Related Transactions, and Director Independence
40
Item 14.
Principal Accounting Fees and Services
40
Part IV
Item 15.
Exhibits, Financial Statement Schedules
41
Item 16.
Form 10-K Summary
41
Signatures
42
Index to Consolidated Financial Statements
F-1
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
FORM 10-K
TABLE OF CONTENTS
i

Part I
Item 1. Business
The Company
Science Applications International Corporation (herein referred to as “SAIC,” the “Company,” “we,” “us,” or “our”) is a 
leading provider of technical, engineering and enterprise information technology (IT) services primarily to the 
U.S. government. As a technology integrator, we provide engineering, systems integration and information 
technology offerings for large, complex government projects and offer a broad range of services with a targeted 
emphasis on higher-end, differentiated technology services. Our end-to-end enterprise IT offerings span the entire 
spectrum of our customers' IT infrastructure. 
Our business has a long and successful history of over 50 years serving all branches (Army, Air Force, Navy, 
Marines and Coast Guard) and agencies of the Department of Defense (DoD), National Aeronautics and Space 
Administration (NASA), U.S. Department of State, Department of Justice, Department of Homeland Security and 
several sensitive intelligence community agencies. Our long-standing customer relationships have enabled us to 
achieve an in-depth understanding of our customers’ missions and provide differentiated service offerings to meet 
our customers’ most complex requirements. Our offerings include: engineering; technology integration; IT 
modernization; maintenance of ground and maritime systems; logistics; training and simulation; operation and 
program support services; and end-to-end services spanning the design, development, integration, deployment, 
management and operations, sustainment and security of our customers’ entire IT infrastructure. We serve our 
customers through approximately 1,900 active contracts and task orders. We have approximately 26,000 
employees that are led by an experienced executive team of proven industry leaders.
On July 2, 2021, the Company completed the acquisition of Halfaker and Associates, LLC (Halfaker), a mission 
focused, pure-play health IT company, which grows the Company's digital transformation portfolio. Additionally, on 
May 3, 2021, the Company acquired Koverse, a software company that provides a data management platform 
enabling artificial intelligence and machine learning on complex sensitive data.
On March 13, 2020, we completed the acquisition of Unisys Federal, a former operating unit of Unisys Corporation, 
which enhances our capabilities in government priority areas, expands our portfolio of intellectual property and 
technology-driven offerings, and increases our access to current and new customers. 
Our core strengths have supported our successful performance on programs of national importance. Those 
strengths include:
Enduring Customer Relationships and Mission-Orientation. We have strong and long-lasting customer 
relationships throughout the U.S. government. Our track record of serving the missions of our government 
customers spans decades, including several enduring customer relationships that have lasted 20 years or 
more. Our employees, many of whom are deployed at customer sites, work closely with our customers in 
fulfilling their missions. Our strong customer relationships enable us to develop deep customer knowledge and 
translate our mission understanding into successful program execution that fosters continued demand for our 
services.
Full Life Cycle Offerings. We integrate technologies and deliver services that provide our customers with 
seamless end-to-end solutions. Our expertise includes initial requirements definition, development and 
integration services, training, logistics and sustainment. These full life cycle offerings, combined with deep 
customer knowledge, allow us to more effectively support our customers’ missions.
Significant Scale and Diversified Contract Base. With approximately $7.4 billion in revenue in fiscal 2022, we 
are one of the largest pure-play technology service providers to the U.S. government. Our significant scale 
advantage enables us to serve as a prime systems integrator on large, complex programs and to allocate 
resources toward further developing and expanding our repeatable, proven solutions and differentiated 
technical capabilities. Our diversified revenue base consists of programs ranging from research and 
development to operations and maintenance.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
1

Technical Experts Led by Experienced Management. The quality, training and knowledge of our employees are 
important competitive assets. Our skilled workforce ranges from entry-level technicians to expert-level 
professionals in network engineering, software design and development, IT modernization, logistics, 
technology integration and systems engineering. Additionally, the majority of our workforce holds an active 
security clearance, which is required on many of our existing programs and future program opportunities.
Our workforce is led by a talented and experienced senior leadership team with a long history of solving our 
customers’ most difficult challenges. Our executive team consists of members who have served as senior 
leaders in public companies and are recognized as leaders in their respective markets by customers and 
partners.
Repeatable Methodologies and Certified Processes. Our technical excellence is driven by our proven, 
repeatable, disciplined processes for management, engineering, technical support and services. We deploy 
our tools and processes enterprise-wide and emphasize a consistent approach to planning, designing and 
delivering solutions and services to our customers. We hold certifications from the International Organization 
for Standardization (including ISO 9001, ISO/IEC 27001, ISO 20000-1 and AS9100D), and from the Capability 
Maturity Model Integration Institute as a CMMI®-DEV Maturity Level 3 organization.
The Company is organized as a matrix comprised of two customer facing operating sectors supported by an 
enterprise solutions and operations organization. The two operating sectors are responsible for customer 
relationships, business development and program management, and delivery and execution, while the enterprise 
solutions and operations organization manages the development of our offerings, solutions and capabilities. Each of 
the Company’s two operating sectors is focused on providing the Company’s comprehensive technical, engineering 
and enterprise IT service offerings to one or more agencies of the U.S federal government. The Company's 
operating sectors are aggregated into one reportable segment for financial reporting purposes. 
For additional discussion and analysis related to recent business developments, see “Economic Opportunities, 
Challenges and Risks” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” 
in Part II of this report.
Key Customers
In each of fiscal 2022, 2021 and 2020, 98% of our total revenues were attributable to prime contracts with the U.S. 
government or to subcontracts with other contractors engaged in work for the U.S. government. Substantially all of 
our revenues were earned by entities located in the United States.
The U.S. Army and U.S. Navy each generated more than 10% of our revenues during each of the last three fiscal 
years. The percentages of total revenues for the U.S. government, its agencies and other customers, including 
those comprising more than 10% of total revenues for each of the periods presented were approximately:  
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
U.S. Army
 15 %
 17 %
 21 %
U.S. Navy
 12 %
 11 %
 12 %
Other DoD
 21 %
 19 %
 19 %
Other federal government
 50 %
 51 %
 46 %
Total U.S. government
 98 %
 98 %
 98 %
Other
 2 %
 2 %
 2 %
Total
 100 %
 100 %
 100 %
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
2

Regulation
Our business is heavily regulated and we must comply with and are affected by laws and regulations, including 
Federal Acquisition Regulations (FAR) and Cost Accounting Standards (CAS), relating to the award, administration 
and performance of U.S. government and other contracts. These regulations set forth policies, procedures and 
requirements for the acquisition of goods and services by the U.S. government and impose a broad range of 
requirements, many of which are unique to government contracting and include procurement, import and export, 
security, contract termination and adjustment, and audit requirements. In addition, these regulations govern contract 
pricing and reimbursable costs by, among other things, requiring certification and disclosure of cost or pricing data 
in connection with certain contract negotiations, defining allowable and unallowable costs, and otherwise governing 
the right to reimbursement under various flexibly priced contracts. These laws and regulations impose specific cost 
accounting practices that may increase accounting and internal control costs associated with compliance with 
government standards. The U.S. government may revise its procurement practices or adopt new contract rules and 
regulations at any time. Our compliance with these regulations is monitored by the Defense Contract Management 
Agency (DCMA)  and the Defense Contract Audit Agency (DCAA).
The U.S. government has the ability to cancel contracts at any time through a termination for the convenience of the 
U.S. government. Most of our contracts have cancellation terms that would permit us to recover all or a portion of 
our incurred costs and contract profit for work performed when the U.S. government issues a termination for 
convenience.
Some of our operations and service offerings involve our access to and use of personally identifiable information 
and protected health information, which activities are regulated by extensive federal and state privacy and data 
security laws requiring organizations to provide certain privacy protections and security safeguards for such 
information.
Internationally, we are subject to foreign government laws and regulations, and U.S. government laws, regulations, 
and procurement policies and practices (including laws and regulations relating to bribery of foreign government 
officials, import and export control, investments, exchange controls and repatriation of earnings). We are also 
susceptible to varying political and economic risks.
In order to help ensure compliance with these complex laws and regulations, we have established policies and 
procedures that address our approach to meeting these requirements and also administer a robust ethics and 
compliance training program to maintain a compliance-oriented workforce.
These regulations and risks affecting our business are described in more detail under “Risk Factors” in this report.
Contracts
We must comply with and are affected by laws and regulations relating to the formation, administration and 
performance of U.S. government and other contracts. The U.S. government procurement environment has evolved 
due to statutory and regulatory procurement reform initiatives. Budgetary pressures and reforms in the procurement 
process have increasingly caused many U.S. government agencies to purchase services and solutions using 
contracting processes that give them the ability to select multiple winners or pre-qualify certain contractors to 
provide various services or solutions on established general terms and conditions rather than through single award 
contracts. The predominant contracting methods through which U.S. government agencies procure services and 
solutions include the following:
Single Award Contracts. U.S. government agencies may procure services and solutions through single award 
contracts, which specify the scope of work that will be delivered and identify the contractor that will provide the 
specified services. When an agency has a requirement, interested contractors are solicited, qualified and then 
provided with a request for proposal. The process of qualifying prospective bidders, soliciting proposals and 
evaluating contractor bids requires the agency to maintain a large, professional procurement staff and the 
bidding and selection process can take a year or more to complete. This method of contracting may provide 
the contractor with greater certainty of the timing and amounts to be received at the time of contract award 
because it generally results in the customer contracting for a specific scope of work from the single successful 
awardee.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
3

Indefinite Delivery, Indefinite Quantity (IDIQ) Contracts. The U.S. government uses IDIQ contracts to obtain 
commitments from contractors to provide certain services or solutions on pre-established terms and conditions. 
The U.S. government then issues task orders under the IDIQ contracts to purchase the specific services or 
solutions it needs. IDIQ contracts are awarded to one or more contractors following a competitive procurement 
process. Under a single award IDIQ contract, all task orders under that contract are awarded to one pre-
selected contractor. Under a multi-award IDIQ contract, task orders can be awarded to any of the pre-selected 
contractors, which can result in further limited competition for the award of task orders. Multi-award IDIQ 
contracts that are open for any government agency to use for the procurement of services are commonly 
referred to as “government-wide acquisition contracts.” IDIQ contracts often have multi-year terms and 
unfunded ceiling amounts that enable, but not commit, the U.S. government to purchase substantial amounts 
of services or solutions from one or more contractors. At the time an IDIQ contract is awarded (prior to the 
letting of any task orders), a contractor may have limited or no visibility as to the ultimate amount of services or 
solutions that the U.S. government will purchase under the contract, and, in the case of a multi-award IDIQ, the 
contractor from which such purchases may be made.
U.S. General Services Administration (GSA) Schedule Contracts. The GSA maintains listings of approved 
suppliers of services and solutions with pre-negotiated prices for use throughout the U.S. government. In order 
for a company to provide services under a GSA Schedule contract, a company must be pre-qualified and 
awarded a contract by the GSA. When an agency uses a GSA Schedule to meet its requirements, the agency 
(or the GSA on behalf of the agency) conducts the procurement and bidders are limited to GSA Schedule-
qualified contractors. GSA Schedule contracts are designed to provide the user agency with reduced 
procurement time and lower procurement costs. Similar to IDIQ contracts, at the time a GSA Schedule contract 
is awarded, a contractor may have limited or no visibility as to the ultimate amount of services or solutions that 
customers will ultimately purchase under the contract.
Contract Types
Generally, the type of contract used for the acquisition of our services and solutions is determined by or negotiated 
with the U.S. government and may depend on certain factors, including: the type and complexity of the work to be 
performed; degree and timing of the responsibility to be assumed by the contractor for the costs of performance; the 
extent of price competition; and the amount and nature of the profit incentive offered to the contractor for achieving 
or exceeding specified standards or goals. We generate revenues under several types of contracts, including the 
following:
•
Cost-reimbursement contracts provide for reimbursement of our direct contract costs and allocable indirect 
costs, plus a fee (contract profit). This type of contract is generally used when uncertainties involved in 
contract performance do not permit costs to be estimated with sufficient accuracy to use a fixed-price 
contract. Cost-reimbursement contracts usually subject us to lower risk and generally require us to use our 
best efforts to accomplish the scope of the work within a specified time and amount of costs.
•
Time-and-materials (T&M) contracts typically provide for negotiated fixed hourly rates for specified categories 
of direct labor plus reimbursement of other direct costs. This type of contract is generally used when there is 
uncertainty of the extent or duration of the work to be performed by the contractor at the time of contract 
award or it is not possible to anticipate costs with any reasonable degree of confidence. On T&M contracts, 
we assume the risk of providing appropriately qualified staff to perform these contracts at the hourly rates set 
forth in the contracts over their period of performance.
•
Firm-fixed price (FFP) contracts provide for a predetermined price for specific solutions. These contracts offer 
us potential increased profits if we can complete the work at lower costs than planned. While FFP contracts 
allow us to benefit from cost savings, these contracts also increase our exposure to reduced profits or losses 
from increased or unexpected costs.
Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues 
derived from each type of contract, the nature of services or solutions provided, as well as the achievement of 
performance objectives and the stage of performance at which the right to receive fees is finally determined. Given 
the relative amount of risk assumed by the contractor, cost-reimbursement and T&M contracts generally have lower 
profitability than FFP contracts. For the proportionate amount of revenues derived from each type of contract for the 
last three fiscal years, see “Other Key Performance Measures—Contract Types” in “Management’s Discussion and 
Analysis of Financial Condition and Results of Operations” in Part II of this report.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
4

Backlog
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is 
performed. Our backlog consists of funded backlog and negotiated unfunded backlog. At January 28, 2022 and 
January 29, 2021 our total backlog was $24.1 billion and $21.5 billion, respectively. For a complete description of 
our backlog, see “Other Key Performance Measures—Net Bookings and Backlog” in “Management’s Discussion 
and Analysis of Financial Condition and Results of Operations” in Part II of this report.
Competition
Competition for contracts is intense and we often compete against a large number of established multinational 
companies, which may have greater name recognition, financial resources and larger technical staffs than we do. 
We also compete against smaller, more specialized companies that concentrate their resources on particular areas, 
as well as the U.S. government’s own capabilities. As a result of the diverse requirements of the U.S. government, 
we frequently collaborate with other companies to compete for large contracts and bid against these same 
companies in other situations. Our principal competitors include the following:
•
the engineering and technical services divisions of large defense contractors that provide IT services in 
addition to other hardware systems and products, which include companies such as General Dynamics 
Corporation, Northrop Grumman Corporation, and Raytheon Technologies Corporation;
•
contractors focused principally on technical and IT services, such as Booz Allen Hamilton Inc., CACI 
International, Inc., Leidos Holdings, Inc., ManTech International Corporation, and Serco Group plc;
•
diversified commercial providers that also provide U.S. government IT services, such as Accenture plc and 
International Business Machines Corporation; and
•
contractors providing supply chain management and other logistics services, such as Agility Logistics 
Corporation and SupplyCore.
We compete on various factors, which include: our technical expertise and qualified and/or security-cleared 
personnel; our ability to deliver innovative cost-effective solutions in a timely manner; successful program execution 
on previous programs; our reputation and standing with customers; pricing; and the size and geographic presence 
of our Company.
Competition within the government services industry has intensified, which has led to fewer sole-source awards and 
an increased emphasis on cost competitiveness and affordability. In addition, procurement initiatives to improve 
efficiency, refocus priorities, increase small business awards and enhance best practices could result in fewer new 
opportunities for our industry as a whole, which would intensify competition within the industry as companies 
compete for a more limited set of new programs.
Patents and Proprietary Information
Our technical services and solutions are not generally dependent on patent protection, although we do selectively 
seek patent protection. We claim a proprietary interest in certain of our solutions, software programs, methodologies 
and know-how. This proprietary information is protected by copyrights, trade secrets, licenses, contracts and other 
means. We selectively pursue opportunities to license or transfer our technologies to third parties.
In connection with the performance of services, the U.S. government has certain rights to inventions, data, software 
codes and related material that we develop under U.S. government-funded contracts and subcontracts. Generally, 
the U.S. government may disclose or license such information to third parties, including, in some instances, our 
competitors. In the case of some subcontracts that we perform, the prime contractor may also have certain rights to 
the programs and solutions that we develop under the subcontract.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
5

People and Culture
Overview
SAIC’s purpose is to advance the power of technology and innovation to serve and protect our world. We achieve 
our purpose with and through our people, who are fundamental to our success. Our values underpin our culture and 
are at the heart of how we operate:
•
Passion: Love what you do
•
Empowerment: Decide and act
•
Integrity: Be real
•
Inclusion: Embrace differences
•
Innovation: Think courageously
Attracting and retaining top talent is an essential element of SAIC’s business strategy and our value proposition for 
our shareholders, customers, and employees. To deliver on this strategy, we seek to be a company that provides 
meaningful work and purpose, and creates a fulfilling and differentiated experience for our employees. Our 
investments in our employees drive a productive, innovative and inclusive culture, where our people are empowered 
to be their best authentic selves and to do their best work. 
As of January 28, 2022, we employed approximately 26,000 employees, of which 93% are full time with the majority 
located in the United States. 
To cultivate a differentiated employee experience, we are focused on fostering a flexible work environment, 
strengthening diversity, equity and inclusion (DE&I), and enhancing employee well-being.
Fostering flexibility
The pandemic has caused people to re-evaluate their priorities and expectations about work. Flexibility of work 
schedule and location is a key reason why people join and stay at companies, and we are creating an environment 
at SAIC where our employees can use the power of flexibility to thrive. 
We implemented flexible work schedules including a 4-day workweek and other schedule options and increased 
remote and hybrid work opportunities. Our definition of flexibility is not a one-size fits all, rather it is tailored and 
nurtured through the engagement between our employees and their leaders. 
Flexibility has helped us widen the talent pool and attract and retain highly skilled people in extremely sought after 
disciplines such as science, technology, engineering and cybersecurity. During fiscal 2022, we hired more than 
5,800 new employees and kept voluntary turnover below our industry’s average rate. 
Strengthening diversity, equity, and inclusion
Our ongoing diversity, equity, and inclusion efforts demonstrate our continuing promise to share our intentions, to 
hold ourselves accountable, and to be transparent about both our progress and our areas of opportunity. We believe 
diversity creates unparalleled innovation and is critical to the delivery of exceptional business results. 
We seek to drive tangible change through our commitments to:
1.
Fight racism, bias, and prejudice in our workplace.
2.
Make SAIC more inclusive and diverse. 
3.
Support non-profit organizations that are uplifting people of color in our communities. 
4.
Measure and hold ourselves accountable for results. 
The strength of our leadership is greatest when it fully reflects the diversity of our workforce. In fiscal 2022, we 
established goals to achieve parity in the representation of women and people of color between our leadership and 
non-leadership roles within five years. We made meaningful progress toward our goals this year, with women now 
representing 27% of our leadership and people of color representing 22%. 
While we have achieved parity between women in leader and non-leader roles and made considerable progress 
toward our people of color leader representation goal, we know there is more work to be done. To hold ourselves 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
6

accountable for results, SAIC’s executive compensation incentive plans are tied to meeting our diversity goals. As of 
January 28, 2022, our diversity representation was:
SAIC Leaders
27% Women
22% People of Color
SAIC Non-leader Employees
27% Women
33% People of Color
To build our diversity pipeline, we instituted a new approach to ensure SAIC job descriptions, recruiting tools and 
processes eliminated the potential for bias, and we required a diverse slate of candidates for leadership roles. We 
launched the AcceleratHER Women's Leadership Academy, a nomination-based development and mentoring 
program focused on accelerating the advancement of SAIC's high-potential women. 
Among our efforts to fight racism, bias, and prejudice in the workplace, we added unconscious bias training as a 
requirement for all new employees and continued to require that all leaders complete our “From Unconscious Bias 
to Inclusion” training course.
As an important demonstration of SAIC’s commitment to advance diversity, equity and inclusion, we added 
Juneteenth as a paid holiday for our employees, being one of the first in our industry to do so. Our employees are 
encouraged to actively participate in our multiple employee resource groups (ERG) where they can enhance their 
personal networks and their sense of belonging. This year, we added a new accessibility ERG to advocate and 
support employees and their family members with visible and non-visible disabilities including mental health and 
neurodiversity.
Our progress on our DE&I initiatives has been recognized: SAIC is a Forbes 2022 Best Large Employers; a Forbes 
America’s Best Employers for Veterans; a Human Rights Campaign Best Places to Work for LGBTQ Equality; and a 
Forbes Best Employers for Diversity. We are honored that 23% of our employees are veterans of the U.S. armed 
forces. 
Enhancing employee well-being
Through our annual culture survey, we gather confidential feedback from our employees to learn how we can 
improve our efforts to provide an exceptional employee experience. To ensure all levels of management understand 
employee sentiment, every individual leader receives aggregated results to develop an action plan to address their 
team’s needs. Strengths and opportunities are identified leading to focused investments to build on our cultural 
strengths and address areas for improvement. Training to upskill our leaders in coaching, enhancing team well-
being, and engaging hybrid teams inclusively was implemented this year as a result of survey feedback.
Additionally, we invest in our people through technical and professional skills training, leadership development 
programs, higher education programs and tuition assistance programs for continuing education or industry 
certification. In fiscal 2022, our employees completed approximately 134,000 hours of training including 55,000 
hours of ethics and compliance training. Our leaders completed over 11,000 hours of leadership development 
training. 
SAIC provides wide-ranging options to support employees’ well-being, including an Employee Assistance Program 
and a wellness program. This year, based on employee feedback, we substantially raised paid family leave to 
further support parents and multi-generational families and offered company-subsidized backup child and elder 
care. Additionally, for the second year in a row, SAIC is fully covering the increased costs of employee premiums in 
the Company’s medical insurance plans and holding employee premiums flat.
Employee health and safety is paramount to our business and contributes to our employees’ well-being. We 
encourage employees to prevent workplace hazards and engage in health and wellness initiatives. Throughout the 
COVID-19 pandemic, our priority has been the safety and well-being of our employees and business partners. We 
continue to closely monitor COVID-19 matters and provide comprehensive resources and programs for managing 
through the pandemic, working virtually and handling associated stress as well as sharing timely information on the 
topic. 
Research and Development
For information related to our research and development activities, see Note 1 to the consolidated financial 
statements contained within this report.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
7

Seasonality
The U.S. government’s fiscal year ends on September 30. It is not uncommon for U.S. government agencies to 
award extra tasks or complete other contract actions leading up to the end of its fiscal year in order to avoid the loss 
of unexpended fiscal year funds, which may favorably impact our third fiscal quarter. In addition, revenues may be 
unfavorably impacted during our fourth fiscal quarter due to a greater number of holidays and higher utilization of 
vacation time.
Environmental Matters
Our operations are subject to various foreign, federal, state and local environmental protection and health and 
safety laws and regulations. 
SAIC is committed to being a good steward of the environment through assessing, mitigating and reducing the 
impact we have on the world around us. Due to the nature of our business, SAIC has limited exposure to 
environmental risks, yet we set self-imposed goals related to the reduction of greenhouse gas emissions, energy 
conservation, recycling and other important environmental initiatives. In 2014, SAIC set a goal of reducing 
greenhouse gas emissions by 15% by 2025 and exceeded that goal by reaching the reduction of 25% in 2016. To 
further encourage cuts to our carbon footprint, we used 2019 as a new baseline and made significant progress in 
reducing emissions in 2020. Specifically, direct emissions from owned or controlled sources (Scope 1) were 25% 
below 2019 emissions levels, and indirect emissions from purchased electricity (Scope 2) were 21% below 2019 
levels. For energy conservation, SAIC’s efforts are sharply focused on electrical energy consumption. We track and 
evaluate electricity consumption and efficiency at those facilities over which we have operational control. In calendar 
year 2020, partially due to decreased facility use as a result of the COVID-19 pandemic, SAIC reduced its electrical 
energy consumption by 3% from 2019 levels, with a total consumption of 34,813,703 kWh. 
For additional information regarding environmental matters, see SAIC's 2022 Corporate Responsibility Report, 
which is expected to be issued during the second quarter of fiscal 2023 and will be available on our website at 
www.saic.com. The information on our website is not incorporated by reference into and is not a part of this report.
Although we do not currently anticipate that compliance costs or the liabilities associated with environmental laws or 
climate change will adversely affect our business, financial position, and results of operations and/or cash flows, it is 
possible that we may incur material costs or liabilities in the future. These regulations and risks are described in 
more detail under “Risk Factors” in this report.
Executive Officers
For information about our executive officers, see “Directors, Executive Officers and Corporate Governance” in Part 
III of this report.
Company Website and Available Information
Our corporate headquarters is located at 12010 Sunset Hills Road, Reston, VA 20190. Our phone number is (703) 
676-4300 and our homepage is www.saic.com, which contains information about our Company and operations. 
Through a link on the Investor Relations section of our website, copies of each of our filings with the Securities and 
Exchange Commission (SEC) can be viewed and downloaded free of charge as soon as reasonably practicable 
after the reports and amendments are electronically filed with or furnished to the SEC. The information on our 
website is not incorporated by reference into and is not a part of this report.
You may also request hard copies of the materials referenced in the preceding paragraph, at no cost, by emailing 
investor relations at InvestorRelations@saic.com.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
8

Item 1A. Risk Factors
In your evaluation of our Company and business, you should carefully consider the risks and uncertainties 
described below, together with information included elsewhere within this report and other documents we file with 
the SEC. These risks, as well as additional risks and uncertainties not currently known to us or that we currently 
believe are immaterial also may materially harm our business, financial condition or operating results and result in a 
decline in the price of our stock.
Industry and Economic Risks
We depend on U.S. government agencies as our primary customer and, if our reputation or relationships 
with these agencies were harmed, our future revenues and cash flows would be adversely affected.
We generated either as a prime contractor or a subcontractor to other contractors engaged in work for the U.S. 
government 98% of our total revenues during each of the last three fiscal years from contracts with the U.S. 
government. We expect to continue to derive substantially all of our revenues from work performed under U.S. 
government contracts. Our reputation and relationship with the U.S. government, and in particular with the agencies 
of the DoD, are key factors in maintaining and growing these revenues. Negative press reports or publicity, 
regardless of accuracy, could harm our reputation. If our reputation is negatively affected, or if we are suspended or 
debarred from contracting with government agencies for any reason, the amount of business with government and 
other customers would decrease and our future revenues, cash flows, and financial results would be adversely 
affected.
A decline in the U.S. government defense budget, changes in spending or budgetary priorities, the failure to 
approve U.S. government budgets on a timely basis or delays in contract awards and other procurement 
activity may significantly and adversely affect our future revenues, cash flow and financial results.
Because we generate substantially all of our revenues from contracts with U.S. government agencies, our operating 
results could be adversely affected by spending caps or changes in budgetary priorities, as well as by delays in the 
government budget process, program starts or the award of contracts or task orders under contracts. Current U.S. 
government spending levels for defense-related and other programs may not be sustained beyond government 
fiscal year (GFY) 2022. Future spending and program authorizations may not increase or may decrease or shift to 
programs in areas in which we do not provide services or are less likely to be awarded contracts. Such changes in 
spending authorizations and budgetary priorities may occur as a result of shifts in spending priorities. A 
reprioritization may reduce defense-related and other programs as a result of competing demands for federal funds 
and the number and intensity of military conflicts or other factors.
When the U.S. Congress does not complete a budget before the end of the fiscal year, government operations 
typically are funded through one or more continuing resolutions that authorize agencies of the U.S. government to 
continue to operate, but do not authorize new spending initiatives. When the U.S. government operates under a 
continuing resolution, contract awards may be delayed, canceled, or funded at lower levels, which could adversely 
impact our operations, cash flows and financial results. While the federal government is currently funded in full 
through the end of GFY 2022, there is a strong possibility that GFY 2023 will begin under a continuing resolution  
lasting several weeks or months. 
In addition, it is possible that an impasse on policy issues could threaten continuous government funding past 
September 30, 2022 or result in another federal government shutdown, which could cause us to incur labor or other 
costs without reimbursement under customer contracts or the delay or cancellation of key programs, and could 
adversely affect our operations, cash flows and financial results.
The U.S. government also conducts periodic reviews of U.S. defense strategies and priorities, which may shift DoD 
budgetary priorities, reduce overall spending or delay contract or task order awards for defense-related programs 
from which we would otherwise expect to derive a significant portion of our future revenues. A significant decline in 
overall U.S. government spending, a significant shift in spending priorities, the substantial reduction or elimination of 
particular defense-related programs or significant budget-related delays in contract or task order awards for large 
programs could adversely affect our future revenues and limit our growth prospects.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
9

We face aggressive competition that can impact our ability to obtain contracts and may affect our future 
revenues, profitability and growth prospects.
We expect that a majority of the business that we seek in the foreseeable future will be awarded through a 
competitive bidding process as the U.S. government increasingly relies on IDIQ, GSA Schedule and other multi-
award contracts, which has resulted in greater competition and increased pricing pressure. The competitive bidding 
process involves substantial costs and a number of risks, including significant cost and managerial time to prepare 
bids and proposals for contracts that may not be awarded to us, or that may be awarded but for which we do not 
receive meaningful task orders. Following contract award, we may encounter significant expense, delay, contract 
modifications or even contract loss as a result of our competitors protesting the award of contracts to us in 
competitive bidding. Any resulting loss or delay of startup and funding of work under protested contract awards may 
adversely affect our revenues and/or profitability. In addition, multi-award contracts require that we make sustained 
post-award efforts to obtain task orders under the contract. As a result, we may not be able to obtain these task 
orders or recognize revenues under these multi-award contracts. Our failure to compete effectively in this 
procurement environment would adversely affect our revenues and profitability.
We compete with larger companies that have greater name recognition, financial resources and larger technical 
staffs and with smaller, more specialized companies that are able to concentrate their resources on particular areas. 
Additionally, we may compete with the U.S. government’s own capabilities. To remain competitive, we must 
consistently provide superior service, technology and performance on a cost-effective basis to our customers and 
there is no assurance that we will do so.
Our earnings and profitability may vary based on the mix of our contracts and may be adversely affected by 
our failure to accurately estimate and manage costs, time and resources.
We generate revenues under various types of contracts, which include cost-reimbursement, T&M and FFP 
contracts. Our earnings and profitability may vary materially depending on changes in the proportionate amount of 
revenues derived from each type of contract, the nature of services or solutions provided, as well as the 
achievement of performance objectives and the stage of performance at which the right to receive fees, particularly 
under incentive and award fee contracts, is finally determined. Cost-reimbursement and T&M contracts generally 
have lower profitability than FFP contracts. To varying degrees, each of our contract types involves some risk that 
we could underestimate the costs and resources necessary to fulfill the contract. Our profitability is adversely 
affected when we incur costs on cost-reimbursement and T&M contracts that we cannot bill to our customers. While 
FFP contracts allow us to benefit from cost savings, these contracts also increase our exposure to the risk of cost 
overruns. Revenues derived from FFP contracts represented approximately 26% of our total revenues for fiscal 
2022. When making proposals on FFP contracts, we rely heavily on our estimates of costs and timing for 
completing the associated projects, as well as assumptions regarding technical issues. In each case, our failure to 
accurately estimate costs or the resources and technology needed to perform our contracts or to effectively manage 
and control our costs during the performance of work could result, and in some instances has resulted, in reduced 
profits or in losses. More generally, any increased or unexpected costs or unanticipated delays in connection with 
the performance of our contracts, including costs and delays caused by contractual disputes or other factors outside 
of our control (such as performance failures of our subcontractors, rising inflation, natural disasters or other force 
majeure events including the outbreak of the coronavirus disease 2019 (COVID-19)) could make our contracts less 
profitable than expected or unprofitable.
We use estimates in recognizing revenues and, if we make changes to estimates used in recognizing 
revenues, our profitability may be adversely affected.
A significant portion of our revenues are recognized on performance obligations using a cost input measure, which 
requires estimates of total costs at completion, fees earned, or both. Particularly due to the technical nature of the 
services being performed and the length of certain performance obligations, this estimation process is complex and 
involves significant judgment. Adjustments to original estimates are often required as work progresses, experience 
is gained and additional information becomes known, even though the scope of the work required under the 
performance obligation may not change. Any adjustment as a result of a change in estimate is recognized 
immediately. Changes in the underlying assumptions, circumstances or estimates could result in adjustments that 
may adversely affect future financial results.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
10

Legal and Regulatory Risks
Our failure to comply with a variety of complex procurement rules and regulations could result in our being 
liable for penalties, including termination of our U.S. government contracts, disqualification from bidding 
on future U.S. government contracts and suspension or debarment from U.S. government contracting.
We must comply with various laws and regulations relating to the formation, administration and performance of U.S. 
government contracts, which affect how we do business with our customers and may impose added costs on our 
business. 
Many of our U.S. government contracts contain organizational conflict of interest (OCI) clauses that may limit our 
ability to compete for or perform certain other contracts or other types of services for particular customers. OCI 
arises when we engage in activities that may make us unable to render impartial assistance or advice to the U.S. 
government, impair our objectivity in performing contract work or provide us with an unfair competitive advantage. 
Existing OCI, and any OCI that may develop, could preclude our competition for or performance on a significant 
project or contract, which could limit our opportunities.
The U.S. government may adopt new contract rules and regulations or revise its procurement practices in a 
manner adverse to us at any time.
Our industry continues to experience significant changes to business practices as a result of an increased focus on 
affordability, efficiencies and recovery of costs, among other items. U.S. government agencies may face restrictions 
or pressure regarding the type and amount of services that they may obtain from private contractors. Legislation, 
regulations and initiatives dealing with procurement reform, mitigation of potential OCI’s, deterrence of fraud, and 
environmental responsibility or sustainability could have an adverse effect on us. Federal and state laws, 
regulations and mandates that require significant progress to reduce the impact of climate change through carbon 
pollution-free electricity, net-zero emissions in vehicles, buildings, procurement and operations, and similar actions 
could diminish or weaken our ability to attain new contracts or garner renewals. As a government services provider, 
we anticipate that requirements around supply chain management and specific procurement strategies to reduce 
contractor emissions and emissions in products used or acquired could impair the Company from effectively 
competing. Further, requirements around the disclosure of greenhouse gas emissions, particularly Scope 3 
emissions, emission reduction targets, climate risk, and other climate sustainability actions could potentially have a 
negative impact to our business and the ability to secure certain contracts or contract renewals. The risk of more 
rapidly shifting or changing government policies could have an equally adverse effect on government contractors 
such as ourselves. Moreover, shifts in the buying practices of U.S. government agencies (such as increased usage 
of fixed price contracts, multiple award contracts and small business set-aside contracts) could have adverse effects 
on government contractors, including us. Any of these changes could impair our ability to obtain new contracts or 
contract renewals. Any new contracting requirements or procurement methods, including those related to climate 
change, could be costly or administratively difficult for us to implement and could adversely affect our future 
revenues, profitability and prospects.
Our business is subject to reviews, audits and cost adjustments by the U.S. government, which, if resolved 
unfavorably to us, could adversely affect our profitability, cash flows or growth prospects.
The DCAA, DCMA and others routinely audit and review a contractor’s performance on government contracts, 
indirect cost rates and pricing practices, and compliance with applicable contracting and procurement laws, 
regulations and standards. They also review the adequacy of the contractor’s compliance with government 
standards for its business systems, which are defined as the contractor’s accounting, earned value management, 
estimating, materials management, property management and purchasing systems. A finding of significant control 
deficiencies in a contractor’s business systems or a finding of noncompliance with CAS can result in decremented 
billing rates to U.S. government customers until the control deficiencies are corrected and their remediation is 
accepted by the DCMA. The agencies conducting these audits and reviews have come under increased scrutiny. As 
a result, audits and reviews have become more rigorous and the standards to which we are held are being more 
strictly interpreted, which has increased the likelihood of an audit or review resulting in an adverse outcome.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
11

Government audits and reviews may conclude that our practices are not consistent with applicable laws and 
regulations and result in adjustments to contract costs and mandatory customer refunds. Such adjustments can be 
applied retroactively, which could result in significant customer refunds. Receipt of adverse audit findings or the 
failure to obtain an “approved” determination on our various business systems could significantly and adversely 
affect our business by, among other things, restricting our ability to bid on new contracts and, for those proposals 
under evaluation, diminishing our competitive position. A determination of noncompliance could also result in the 
U.S. government imposing penalties and sanctions against us, including withholding of payments, suspension of 
payments and increased government scrutiny. Increased scrutiny could adversely impact our ability to perform on 
contracts, affect our ability to invoice for work performed, delay the receipt of timely payment on contracts, and 
weaken our ability to compete for new contracts with the U.S. government.
The indirect cost audits by the DCAA of the Company’s business remain open for certain prior years and the current 
year. We have recorded contract revenues based on an estimate of costs that we believe will be approved on final 
audit. However, we do not know the outcome of any ongoing or future audits or whether future adjustments will 
exceed our reserves for potential adjustments. 
Our business is subject to governmental review and investigation, which could adversely affect our 
profitability, cash position and growth prospects.
We are routinely subject to governmental investigations relating to our contracts and operations. If a review or 
investigation identifies improper or illegal activities, we may be subject to civil or criminal penalties or administrative 
sanctions, which could include the termination of contracts, forfeiture of profits, the triggering of price reduction 
clauses, suspension of payments, fines, and suspension or debarment from doing business with governmental 
agencies. We may suffer harm to our reputation if allegations of impropriety are made against us, which would 
impair our ability to win new contract awards or receive contract renewals. Penalties and sanctions are not 
uncommon in our industry. If we incur a material penalty or administrative sanction or otherwise suffer harm to our 
reputation, our profitability, cash position and future prospects could be adversely affected.
The U.S. government may terminate, cancel, modify or curtail our contracts at any time and, if we do not 
replace them, we may be unable to achieve or sustain revenue growth and may suffer a decline in revenues 
and profitability.
Many of the U.S. government programs in which we participate as a contractor or subcontractor may extend for 
several years and include one or more base years and one or more option years. Under our contracts, the U.S. 
government generally has the right not to exercise options to extend or expand our contracts and may otherwise 
terminate, cancel, modify or curtail our contracts at its convenience. Any decision by the U.S. government not to 
exercise contract options or to terminate, cancel, modify or curtail our major programs or contracts would adversely 
affect our revenues, revenue growth and profitability.
We have experienced and continue to experience periodic performance issues under certain of our contracts. If a 
government customer terminates a contract for default, we may be exposed to liability, including for excess costs 
incurred by the customer in procuring undelivered services and solutions from another source. Depending on the 
nature and value of the contract, a performance issue or termination for default could cause our actual results to 
differ from those anticipated and could harm our reputation.
Our use of net operating loss carryforwards and other tax attributes to offset future taxable income may 
become limited in the event that we or the IRS determines that we have experienced an ownership change.
As of January 28, 2022, we have estimated $343 million of gross net operating loss (NOL) carryforwards and tax 
basis in our acquired amortizable goodwill and other intangible assets of approximately $1.6 billion. Under Sections 
382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an 
“ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-
change tax attributes may be limited.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
12

Legal disputes could require us to pay potentially large damage awards and could be costly to defend, 
which would adversely affect our cash balances and profitability, and could damage our reputation.
We are subject to a number of lawsuits and claims described under “Legal Proceedings” in Part I of this report. We 
are also subject to, and may become a party to, a variety of other litigation or claims and suits that arise from time to 
time in the ordinary course of our business. The Department of Justice and other enforcement agencies of the U.S. 
government may bring claims or lawsuits against us in connection with our performance of government contracts or 
our billing or record-keeping relating to those contracts. The Department of Justice has considerably more 
resources at its disposal than we do, and can bring suspension and debarment proceedings against us that would 
prevent us from working for some or all U.S. government customers. In addition, certain statutes under which the 
Department of Justice may bring claims (like the False Claims Act) provide for treble damages and penalties on a 
per invoice basis against government contractors. These circumstances generally give the Department of Justice 
significantly more leverage in any legal dispute with us than if we were defending ourselves against claims brought 
by a commercial enterprise. Adverse judgments or settlements in some or all of these legal disputes may result in 
significant monetary damages or injunctive relief against us. Any claims or litigation could be costly to defend, and 
even if we are successful or if fully indemnified or insured, could damage our reputation and make it more difficult to 
compete effectively or obtain adequate insurance in the future. Litigation and other claims, including those 
described under “Legal Proceedings” in Part I of this report, are subject to inherent uncertainties and management’s 
view of these matters may change in the future.
Our business is subject to numerous legal and regulatory requirements and any violation of these 
requirements or any misconduct by our employees, subcontractors, agents or business partners could 
harm our business and reputation.
In addition to government contract procurement laws and regulations, we are subject to numerous other federal, 
state and foreign legal requirements on matters as diverse as data privacy and protection, employment and labor 
relations, immigration, taxation, anti-corruption, import/export controls, trade restrictions, internal and disclosure 
control obligations, securities regulation and anti-competition. Compliance with diverse and changing legal 
requirements is costly, time-consuming and requires significant resources. Violations of one or more of these 
requirements in the conduct of our business could result in significant fines and other damages, criminal sanctions 
against us or our officers, prohibitions on doing business and damage to our reputation. Violations of these 
regulations or contractual obligations related to regulatory compliance in connection with the performance of 
customer contracts could also result in liability for significant monetary damages, fines and/or criminal prosecution, 
unfavorable publicity and other reputational damage, restrictions on our ability to compete for certain work and 
allegations by our customers that we have not performed our contractual obligations.
Misconduct by our employees, subcontractors, agents or business partners could subject us to fines and penalties, 
restitution or other damages, loss of security clearance, loss of current and future customer contracts and 
suspension or debarment from contracting with federal, state or local government agencies, any of which would 
adversely affect our business and our future results. Such misconduct could include fraud or other improper 
activities such as falsifying time or other records, failure to comply with our policies and procedures or violations of 
applicable laws and regulations.
Business and Operational Risks
A failure to attract, train, retain and utilize skilled employees and our senior management team would 
adversely affect our ability to execute our strategy and may disrupt our operations.
Our business relies heavily upon the expertise and services of our employees. Our continued success depends on 
our ability to recruit and retain highly trained and skilled engineering, technical and professional personnel. 
Competition for skilled personnel is intense and competitors aggressively recruit key employees. In addition, many 
U.S. government programs require contractors to have security clearances. Depending on the level of required 
clearance, security clearances can be difficult and time-consuming to obtain and personnel with security clearances 
are in great demand. Particularly in highly specialized areas, it has become more difficult to retain employees and 
meet all of our needs for employees in a timely manner, which may affect our growth in the current and future fiscal 
years. Although we intend to continue to devote significant resources to recruit, train and retain qualified employees, 
we may not be able to attract, effectively train and retain these employees. Any failure to do so could impair our 
ability to efficiently perform our contractual obligations, timely meet our customers’ needs and ultimately win new 
business, all of which could adversely affect our future results. In addition, salaries and related costs are a 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
13

significant portion of the cost of providing our services and, accordingly, our ability to efficiently utilize our workforce 
impacts our profitability. If our employees are under-utilized, our profitability could suffer.
We believe that our success also depends on the continued employment of a highly qualified and experienced 
senior management team and that team’s ability to retain existing business and generate new business. The loss of 
key personnel in critical functions could lead to lack of business continuity or disruptions in our business until we are 
able to hire and train replacement personnel.
We may make acquisitions, investments, joint ventures and divestitures in the future that involve numerous 
risks, which if realized, may adversely affect our business and our future results.
We may make strategic acquisitions, engage in joint ventures or divest existing businesses, which could cause us to 
incur unforeseen expenses and have disruptive effects on our business and may not yield the benefits we expect. 
Our Credit Facility also imposes limitations on our ability to make other acquisitions. Subject to those limitations, we 
may selectively pursue additional strategic acquisitions, investments and joint ventures in the future. Any future 
acquisitions, investments and joint ventures may pose many risks that could adversely affect our reputation, 
operations or financial results, including:
•
we may not retain key employees (including those with needed security clearances), customers and business 
partners of an acquired business in the future;
•
we may fail to successfully integrate acquired businesses, such as failing to successfully implement IT and 
other control systems relating to the operations of any acquired business;
•
we may not generate sufficient earnings to meet the required Leverage Ratio under the Credit Facility, which 
would give lenders the right to, among other things, foreclose on our assets;
•
acquisitions normally require a significant investment of time and resources, which may disrupt our business 
and distract our management from other important responsibilities;
•
we may not be able to accurately estimate the financial effect of any acquisitions and investments on our 
business and we may not realize anticipated revenue opportunities, cost savings, or other synergies or 
benefits, or acquisitions may not result in improved operating performance; and
•
we may assume known as well as unknown material liabilities, legal or regulatory risks that were not identified 
as part of our due diligence or for which we are unable to receive a purchase price adjustment or 
reimbursement through indemnification;
If any acquisitions, investments or joint ventures fail, perform poorly or their value is otherwise impaired for any 
reason, including contractions in credit markets and global economic conditions, our business and financial results 
could be adversely affected.
In addition, we may periodically divest businesses, including businesses that are no longer a part of our ongoing 
strategic plan. These divestitures similarly require significant investment of time and resources and may disrupt our 
business, distract management from other responsibilities and may result in losses on disposal or continued 
financial involvement in the divested business, including through indemnification, guarantee or other financial 
arrangements, for a period of time following the transaction, which could adversely affect our financial results.
We will incur direct and indirect costs as a result of the acquisitions of Engility Holdings, Inc. (Engility), 
Unisys Federal, Halfaker, and Koverse. 
We will incur substantial expenses in connection with and as a result of the acquisitions and, over a period of time 
following the completion of the acquisitions, we expect to incur substantial expenses in connection with coordinating 
our businesses, operations, policies and procedures. While we have assumed that a certain level of transaction 
expenses will be incurred, factors beyond our control could affect the total amount or the timing of these expenses. 
Many of the expenses that will be incurred, by their nature, are difficult to estimate accurately.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
14

Our business and financial results could be negatively affected by cyber or other security threats.
As a U.S. government contractor and a provider of IT services operating in multiple regulated industries and 
geographies, we handle a variety of sensitive information including personally identifiable information, personnel 
information, protected health information, classified information and controlled unclassified information, and financial 
information, concerning our business and employees and those of our customers. We are continuously exposed to 
cyber and other security threats, including malware/computer viruses, ransomware, phishing attacks, insider threats 
and physical break-ins. Any unauthorized electronic or physical intrusion or other security threat may jeopardize the 
protection of sensitive or other information stored or transmitted through our IT systems and networks. This could 
lead to disruptions in mission-critical systems, unauthorized release of sensitive information and the theft or 
corruption of data. Although we have implemented and regularly update and improve policies, procedures and other 
controls to monitor, protect against, detect and mitigate cyber and other security threats, attempts to gain 
unauthorized access to our IT systems and networks are becoming more prevalent and sophisticated. We, however, 
proactively seek to detect, investigate, mitigate and remediate all security events.
In addition, we work with the defense industrial base industry and the U.S. government to gather and share threat 
intelligence and promote increased awareness and enhanced protections against cybersecurity threats. However, 
because of the evolving nature of these security threats, there can be no assurance that our policies, procedures 
and other controls will detect or prevent them, and we cannot predict their full impact. We may experience similar 
security threats to the IT systems that we develop, install or maintain under customer contracts, including customer 
contracts under which we may have access to or management responsibility for customer databases or networks 
that contain sensitive information relating to our customers, their employees or related third parties. Although we 
work cooperatively with our customers to seek to minimize the impacts of cyber and other security threats, we must 
usually rely on the safeguards used or required by those customers. In the event of unauthorized access to 
sensitive information for which we are responsible under customer contracts, our customers, their employees, or 
third parties may seek to hold us liable for any costs or other damages associated with the unauthorized access. In 
addition, government agencies may bring legal actions against us for violation of or noncompliance with regulatory 
requirements relating to any unauthorized access to sensitive information. Any remediation costs, damages or other 
liabilities related to unauthorized access of sensitive information of ours or our customers caused by cyber or other 
security threats may not be fully insured or indemnified by other means or our insurers. Occurrence of any 
unauthorized access caused by these security threats could adversely affect our reputation, business operations, 
and impact our financial results.
We face various risks related to health epidemics, pandemics and similar outbreaks, which may have 
material adverse effects on our business, financial position, results of operations and/or cash flows.
We face various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of 
COVID-19. If significant portions of our workforce are unable to work effectively due to illness, quarantines, 
government actions, facility closures or other reasons in connection with COVID-19, our operations will likely be 
impacted. We may be unable to perform fully on our contracts and some of our costs may not be fully recoverable 
or adequately covered by insurance. In addition, the resulting volatility in the global capital markets could restrict our 
access to capital and/or increase our cost of capital.
It is possible that the continued spread of COVID-19 may also further cause disruption in our supply chain; cause 
delay, or limit the ability of, the U.S. government and other customers to perform, including making timely payments 
to us; impact investment performance; and cause other unpredictable events.
We continue to work with our stakeholders (including customers, employees, suppliers and local communities) to 
address the impacts of COVID-19. We continue to monitor the situation, to assess further possible implications to 
our business, supply chain and customers, and to take actions in an effort to mitigate adverse consequences.
At this time, we cannot predict the overall impact of COVID-19, but it could have a material adverse effect on our 
business, financial position, results of operations and/or cash flows.
Customer systems failures could damage our reputation and adversely affect our revenues and profitability.
Many of the systems and networks that we develop, install and maintain for our customers involve managing and 
protecting personal information and information relating to national security and other sensitive government 
functions. While we have programs designed to comply with relevant privacy and security laws and restrictions, if a 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
15

system or network that we develop, install or maintain were to fail or experience a security breach or service 
interruption, whether caused by us, third-party service providers, cybersecurity threats or other events, we may 
experience loss of revenue, remediation costs or face claims for damages or contract termination. Any such event 
could cause serious harm to our reputation and prevent us from having access to or being eligible for further work 
on such systems and networks. Our errors and omissions liability insurance may be inadequate to compensate us 
for all of the damages that we may incur and, as a result, our future results could be adversely affected.
We depend on our teaming arrangements and relationships with other contractors and subcontractors. If 
we are not able to maintain these relationships, or if these parties fail to satisfy their obligations to us or the 
customer, our revenues, profitability and growth prospects could be adversely affected.
We rely on teaming relationships with other prime contractors and subcontractors in order to submit bids for large 
procurements or other opportunities where we believe the combination of services, products and solutions provided 
by us and our teammates will help us to win and perform the contract. Our future revenues and growth prospects 
could be adversely affected if other contractors eliminate or reduce their contract relationships with us, or if the U.S. 
government terminates or reduces these other contractors’ programs, does not award them new contracts or 
refuses to pay under a contract. Companies that do not have access to U.S. government contracts or experience 
with our customers may perform services as our subcontractor that we cannot otherwise provide ourselves, and that 
exposure could enhance such companies’ prospect of securing a future position as a prime U.S. government 
contractor, which could increase competition for future contracts and impair our ability to win these contracts. 
Whenever our subcontractors fail to timely meet their contractual obligations, have regulatory compliance or other 
problems, our ability to fulfill our obligations as a prime contractor or higher tier subcontractor may be jeopardized. 
We have only a limited ability to protect our intellectual property rights, which are important to our success. 
Our failure to adequately protect our proprietary information and intellectual property rights could 
adversely affect our competitive position.
We rely principally on trade secrets to protect much of our intellectual property in cases where we do not believe 
that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although our 
employees are subject to confidentiality obligations, this protection may be inadequate to deter or prevent 
misappropriation of our confidential information. We may be unable to detect unauthorized use of our intellectual 
property or otherwise take appropriate steps to enforce our rights. Failure to obtain or maintain trade secret 
protection could adversely affect our competitive business position. If we are unable to prevent third parties from 
infringing or misappropriating our copyrights, trademarks or other proprietary information, our competitive position 
could be adversely affected. In addition, in connection with the performance of services, the U.S. government has 
certain rights to inventions, data, software codes and related material that we develop under government-funded 
contracts and subcontracts, which may permit the U.S. government to disclose or license this information to third 
parties, including, in some instances, our competitors.
In the course of conducting our business, we may inadvertently infringe the intellectual property rights of others, 
resulting in claims against us or our customers. Our contracts generally indemnify our customers for third-party 
claims for intellectual property infringement by the services and solutions we provide. The expense of defending 
these claims may adversely affect our financial results.
We face risks related to climate change if associated increases in extreme weather events prohibit or 
adversely affect our employees’ ability to work.
Severe storms, increased precipitation and flooding, heat waves and other weather-related obstacles due to climate 
change could adversely affect our ability to execute our strategy and may disrupt our operations. Any failure of our 
employees’ ability to work could potentially impair our capability to efficiently perform and meet our contractual 
obligations, timely address our customers’ needs and ultimately win new business, all of which could adversely 
affect our business, financial position, results of operations, and/or cash flows. While we have a distributed 
workforce with employees working remotely across the U.S., we do have employees who, because of client 
requirements or contractual obligations, must work at specified locations. In these instances, if there was a severe 
weather event that impacted such a location we may not be able to meet the client’s requirements or our contractual 
obligations. In the shorter term, a climate-related event could temporarily suspend our ability to do the required work 
in person, produce operational or other unforeseen challenges, and in the longer term, threaten our ability to 
perform contracts in a timely manner or meet other requirements of the contract, any of which could harm our 
business and its results. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
16

Although SAIC has business continuity plans and other safeguards in place, there is no assurance that such plans 
and safeguards will be effective or that such measures will not adversely affect our operations or long-term plans. In 
addition, local conditions and regulations may delay the return of employees to business sites, which could impede 
our ability to meet the client’s requirements or our contractual obligations. The ability of individual employees, based 
on how severely the climate-related event has impacted them, may also impede our ability to meet the client’s 
requirements or our contractual obligations.
Our customers, both government and civil, may shift priorities, requirements and business processes in 
response to climate change, which could affect our business and revenues.
Customers could change priorities and approaches due to their operations experiencing a direct climate-change 
impact, have future concerns about their long-term sustainability, face external legislative or regulatory pressure, or 
other external market factors such as investor, consumer or societal requests or demands that a customer may feel 
obliged to respond to. Such changes and responses by our customers have the potential to adversely impact our 
future revenues, profitability and prospects.
We could incur significant liabilities and suffer negative publicity if our detection systems fail to operate as 
intended or our assessment reports prove to be inaccurate.
We have developed and sold tsunami buoys and related services that are designed to assist in the detection of 
tsunamis or large waves that may have catastrophic consequences to coastal communities. Our buoys have been 
deployed by the U.S. National Oceanic and Atmospheric Administration and non-U.S. governments in other areas 
around the world. There are many factors, some of which are beyond our control, which could result in the failure of 
these buoys. We may develop other products or provide services for the detection of natural or man-made threats 
that could have catastrophic consequences if the threats are realized. In addition, we prepare reports for various 
government customers in the evaluation or assessment of the consequences of certain threats or natural disasters. 
The failure of our products and services to help detect the threats for which they were designed or the failure of our 
reports to accurately assess the consequences of certain threats could contribute to injury, death and extensive 
property damage and may lead to product liability, professional liability, or other claims against us. Further, if our 
products, services or reports fail to, or are perceived to have failed to help detect or adequately assess a threat, the 
negative publicity from such incident could have a material adverse effect on our business.
Our services and operations sometimes involve using, handling or disposing of hazardous substances or 
dangerous materials, which could expose us to potentially significant liabilities.
Some of our services and operations involve the use, handling or disposal of hazardous substances or dangerous 
materials, including explosive, chemical, biological, radiological or nuclear materials. These activities generally 
subject us to extensive foreign, federal, state and local environmental protection and health and safety laws and 
regulations, which, among other things, require us to incur costs to comply with these regulations and could impose 
liability on us for handling or disposing of hazardous substances or dangerous materials. Furthermore, failure to 
comply with these environmental protection and health and safety laws and regulations could result in civil, criminal, 
regulatory, administrative or contractual sanctions, including fines, penalties or suspension or debarment from 
contracting with the U.S. government or could cause us to incur costs to change, upgrade, remediate and/or close 
some of our operations or properties. Although we do not have extensive real estate holdings, our ownership and 
operation of real property also subjects us to environmental protection laws, some of which hold current or previous 
owners or operators of businesses and real property liable for hazardous substance releases, even if they did not 
know of and were not responsible for the releases. If we have any violations of, or incur liabilities pursuant to, these 
laws or regulations, our financial condition and operating results could be adversely affected.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
17

We face risks associated with our international business.
Our international business operations may be subject to additional and different risks than our U.S. business. 
Failure to comply with U.S. government laws and regulations applicable to international business such as the 
Foreign Corrupt Practices Act or U.S. export control regulations could have an adverse impact on our business with 
the U.S. government and could expose us to administrative, civil or criminal penalties and may expose us to 
potentially significant contract losses. In addition, we provide services and solutions in support of U.S. government 
customers in countries with governments that may be or may become unstable or are in areas of active military or 
intelligence operations. Operating in such environments may increase the risk of an incident resulting in injury or 
loss of life, or damage or destruction of property, or inability to meet our contractual obligations. Although our 
international operations have historically generated a small proportion of our revenues, we do not know the impact 
that these regulatory, geopolitical and other factors may have on our business in the future and any of these factors 
could adversely affect our business.
Pension funding and costs are dependent upon several economic assumptions, which if changed may 
cause our future earnings and cash flow to fluctuate significantly.
As a result of the acquisition of Engility, which closed on January 14, 2019, we assumed the obligations under 
Engility's defined benefit pension plan (the Pension Plan). The impact of the Pension Plan on our U.S. generally 
accepted accounting principles (GAAP) earnings may be volatile in that the amount of expense we record for the 
Pension Plan may materially change from year to year because those calculations are sensitive to funding levels as 
well as changes in several key economic assumptions, including interest rates, rates of return on plan assets, and 
other actuarial assumptions including participant mortality estimates. Changes in these factors also affect our plan 
funding, cash flow, and stockholders’ equity. In addition, the funding of the Pension Plan may be subject to changes 
caused by legislative or regulatory actions.
We will make contributions to fund the Pension Plan when considered necessary or advantageous to do so. The 
macro-economic factors discussed above, including the return on assets and the minimum funding requirements 
established by government funding or taxing authorities, or established by other agreement, may influence future 
funding requirements. A significant decline in the fair value of the assets in the Pension Plan, or other adverse 
changes to the Pension Plan could require us to make significant funding contributions and affect cash flows in 
future periods.
As a result of the acquisition of Engility, we also assumed the obligations under a Retiree Health Reimbursement 
Account plan (RHRA). The impact of Engility’s RHRA on our GAAP earnings may be volatile in that the amount of 
expense we record for the plan may materially change from year to year because those calculations are sensitive to 
several key economic assumptions including interest rates and actuarial assumptions related to participant mortality, 
retirement and termination.
CAS govern the extent to which postretirement costs and plan contributions are allocable to and recoverable under 
contracts with the U.S. government. On December 27, 2011 the U.S. government’s Cost Accounting Standards 
Board published a final rule that harmonizes CAS pension cost reimbursement rules with the Pension Protection Act 
of 2006 (PPA) funding requirements. The rule is expected to eventually mitigate the mismatch between CAS costs 
and PPA-amended Employee Retirement Income Security Act of 1974 (ERISA) minimum funding requirements, and 
result in an acceleration of allowable CAS pension costs as compared to the prior rules. We anticipate that 
government contractors will be entitled to an equitable adjustment for any additional CAS contract costs resulting 
from the final rule. As a result, we have sought and expect to continue to seek reimbursement from the U.S. 
government for a portion of our postretirement costs and plan contributions. For additional information related to our 
pension funding and costs, see Note 9 to the consolidated financial statements contained within this report.
Goodwill and intangible assets represent a significant amount of our total assets and any impairment of 
these assets would negatively impact our results of operations.
Goodwill and intangible assets are tested for impairment annually or whenever events or changes in circumstances 
indicate that the carrying value may not be recoverable. Examples of events or changes in circumstances indicating 
that the carrying value of goodwill may not be recoverable could include a significant adverse change in legal 
factors or in the business climate, an adverse action or assessment by a regulator, unanticipated competition, loss 
of key contracts, customer relationships, or personnel that affect current and future operating cash flows of the 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
18

reporting unit. Any future impairment of goodwill or other intangible assets would have a negative impact on our 
profitability and financial results.
Forward-Looking Statement Risks
You may not be able to rely on forward-looking statements.
This report contains forward-looking statements that are based on our management’s belief and assumptions about 
the future in light of information currently available to our management. In some cases, you can identify forward-
looking statements by words such as “may,” “will,” “should,” “expects,” “projects,” “intends,” “plans,” “anticipates,” 
“believes,” “estimates,” “predicts,” “potential,” “continue,” “outlook,” and similar words or phrases or the negative of 
these words or phrases. These statements relate to future events or our future financial performance, and involve 
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, 
performance or achievements to be materially different from any future results, levels of activity, performance or 
achievements expressed or implied by these forward-looking statements. Although we believe that the expectations 
reflected in the forward-looking statements are reasonable when made, we cannot guarantee future results, levels 
of activity, performance or achievements. There are a number of important factors that could cause our actual 
results to differ materially from those results anticipated by our forward-looking statements, which include, but are 
not limited to, the risk factors discussed above.
We do not undertake any obligation to update or revise any of the forward-looking statements to reflect events, 
circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those 
statements or to conform these statements to actual results.
Item 1B. Unresolved Staff Comments
No information is required in response to this item.
Item 2. Properties
We occupy approximately 4 million square feet of floor space, substantially all of which is leased. Our corporate 
headquarters is located in Reston, Virginia. Our principal locations outside of Reston, Virginia include Chantilly, 
Virginia, Huntsville, Alabama, Oak Ridge, Tennessee, El Segundo, California and Annapolis Junction, Maryland. As 
of January 28, 2022, we conducted our operations in approximately 160 offices located in 31 states, the District of 
Columbia, and various foreign countries. We consider our facilities suitable and adequate for our present needs, 
which are generally limited to office, warehouse and computer laboratory spaces.
Item 3. Legal Proceedings
We have provided information about legal proceedings in which we are involved in Note 17 to the consolidated 
financial statements contained within this report.
We are also routinely subject to investigations and reviews relating to compliance with various laws and regulations. 
Additional information regarding such investigations and reviews is described under the heading “Government 
Investigations, Audits and Reviews” in Note 17 to the consolidated financial statements contained within this report.
Item 4. Mine Safety Disclosures
No information is required in response to this item.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
19

Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity 
Securities
Our common stock is listed on the New York Stock Exchange under the ticker symbol “SAIC”. As of March 4, 2022, 
there were approximately 24,000 holders of record of our common stock. The number of holders of record of our 
common stock may not be representative of the number of beneficial owners due to shares that may be held by 
depositories, brokers or nominees.
Stock Performance Graph
The following graph compares the total cumulative return on our common stock, from the beginning of fiscal year 
2017 through fiscal year 2022, to two indices: (i) the Russell 1000 Index and (ii) the Dow Jones US Computer 
Services Index. The graph assumes an initial investment of $100 on February 3, 2017 and that dividends have been 
reinvested. The comparisons in the graph are required by the U.S. Securities and Exchange Commission (SEC), 
based upon historical data and are not intended to forecast or be indicative of possible future performance of our 
common stock.
Date
Dollars
SAIC
Russell 1000 Index
Dow Jones US Computer Services Index
02/03/17
02/02/18
02/01/19
01/31/20
01/29/21
01/28/22
$60
$80
$100
$120
$140
$160
$180
$200
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
20

Purchases of Equity Securities
We may repurchase shares on the open market in accordance with established repurchase plans. Whether 
repurchases are made and the timing and amount of repurchases depend on a variety of factors including market 
conditions, our capital position, internal cash generation and other factors.
The following table presents repurchases of our common stock during the three months ended January 28, 2022:
Period(1)
Total Number of 
Shares (or Units) 
Purchased(2)
Average Price 
Paid per Share 
(or Unit)
Total Number of 
Shares (or Units) 
Purchased as 
Part of Publicly 
Announced Plans 
or Programs
Maximum 
Number of 
Shares (or Units) 
that May Yet Be 
Purchased Under 
the Plans or 
Programs(3)
October 30, 2021 - December 3, 2021
 
316,960 $ 
88.06  
316,960  
2,559,585 
December 4, 2021 - December 31, 2021
 
271,702  
83.36  
271,702  
2,287,883 
January 1, 2022 - January 28, 2022
 
252,397  
85.18  
252,397  
2,035,486 
Total
 
841,059 $ 
85.68  
841,059 
(1)
Date ranges represent our fiscal periods during the current quarter. Our fiscal quarters typically consist of one five-week 
period and two four-week periods.
(2)
Includes shares purchased on surrender by stockholders of previously owned shares to satisfy minimum statutory tax 
withholding obligations related to stock option exercises and vesting of stock awards in addition to shares purchased 
under our publicly announced plans or programs.
(3)
On March 27, 2019, the number of shares that may be purchased increased by approximately 4.6 million shares, bringing 
the total authorized shares to be repurchased under the plan to approximately 16.4 million shares. As of January 28, 
2022, we have repurchased approximately 14.4 million shares of common stock under the program.
Item 6. [Reserved]
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
21

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations, and quantitative and 
qualitative disclosures about market risk should be read in conjunction with our consolidated financial statements 
and the related notes included in this Form 10-K, as well as Part II, Item 7 "Management’s Discussion and Analysis 
of Financial Condition and Results of Operations” of our Form 10-K for the year ended January 29, 2021, which 
provides additional information on comparisons of fiscal 2021 and 2020. It contains forward-looking statements 
(which may be identified by words such as those described in “Risk Factors—Forward-Looking Statement Risks” in 
Part I of this report), including statements regarding our intent, belief, or current expectations with respect to, among 
other things, trends affecting our financial condition or results of operations; backlog; our industry; government 
budgets and spending; market opportunities; the impact of competition; and the impact of acquisitions. Such 
statements are not guarantees of future performance and involve risks and uncertainties, and actual results may 
differ materially from those in the forward-looking statements as a result of various factors. Risks, uncertainties and 
assumptions that could cause or contribute to these differences include those discussed below and elsewhere in 
this report, particularly in “Risk Factors” in Part I of this report. Due to such risks, uncertainties and assumptions, 
you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date 
hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any 
changes to our forward-looking statements due to future results or developments.
We use the terms "SAIC," the “Company,” “we,” “us” and “our” to refer to Science Applications International 
Corporation and its consolidated subsidiaries.
The Company utilizes a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters 
typically consisting of 13 weeks. Fiscal 2022 began on January 30, 2021 and ended on January 28, 2022, fiscal 
2021 began on February 1, 2020 and ended on January 29, 2021, and fiscal 2020 began on February 2, 2019 and 
ended on January 31, 2020. 
Business Overview
We are a leading technology integrator providing full life cycle services and solutions in the technical, engineering 
and enterprise information technology (IT) markets. We developed our brand by addressing our customers’ mission 
critical needs and solving their most complex problems for over 50 years. As one of the largest pure-play technology 
service providers to the U.S. government, we serve markets of significant scale and opportunity. Our primary 
customers are the departments and agencies of the U.S. government. We serve our customers through 
approximately 1,900 active contracts and task orders and employ approximately 26,000 individuals who are led by 
an experienced executive team of proven industry leaders. Our long history of serving the U.S. government has 
afforded us the ability to develop strong and longstanding relationships with some of the largest customers in the 
markets we serve. Substantially all of our revenues and tangible long-lived assets are generated by or owned by 
entities located in the United States.
Economic Opportunities, Challenges, and Risks
In fiscal 2022, we generated 98% of our revenues from contracts with the U.S. government, including subcontracts 
on which we perform. Our business performance is affected by the overall level of U.S. government spending and 
the alignment of our offerings and capabilities with the budget priorities of the U.S. government. Appropriations 
measures passed in March 2022 provided full funding for the federal government through the end of government 
fiscal year 2022. The August 2019 Bipartisan Budget Act agreement suspended the Federal debt ceiling until July 
31, 2021. In October 2021, the Federal debt ceiling was increased by $480 billion and in December 2021 was 
further increased by $2.5 trillion which is expected to allow the U.S. government to operate into 2023. It is unlikely 
but possible these measures could expire without extension and lead to a partial or full government shutdown. 
Adverse changes in fiscal and economic conditions could materially impact our business. Some changes that could 
have an adverse impact on our business include the implementation of future spending reductions (including 
sequestration), delayed passage of appropriations bills resulting in temporary or full-year continuing resolutions, 
extreme inflationary increases adversely impacting fixed price contracts, inability to increase or suspend the Federal 
debt ceiling, and potential government shutdowns. 
Spending packages, including the infrastructure bill and future potential spending packages, may provide additional 
opportunity in areas of SAIC focus such as broadband, cyber, and climate resiliency.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
22

The U.S. government has increasingly relied on contracts that are subject to a competitive bidding process 
(including indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules, and 
other multi-award contracts), which has resulted in greater competition and increased pricing pressure. We expect a 
majority of the business we seek in the foreseeable future will be awarded through a competitive bidding process.
Despite the budget and competitive pressures affecting the industry, we believe we are well-positioned to protect 
and expand existing customer relationships and benefit from opportunities that we have not previously pursued. Our 
scale, size, and prime contractor leadership position are expected to help differentiate us from our competitors, 
especially on large contract opportunities. We believe our long-term, trusted customer relationships and deep 
technical expertise provide us with the sophistication to handle highly complex, mission-critical contracts. SAIC’s 
value proposition is found in the proven ability to serve as a trusted adviser to our customers. In doing so, we 
leverage our expertise and scale to help them execute their mission.
We succeed as a business based on the solutions we deliver, our past performance, and our ability to compete on 
price. Our solutions are inspired through innovation based on adoption of best practices and technology integration 
of the best capabilities available. Our past performance was achieved by employees dedicated to supporting our 
customers' most challenging missions. Our current cost structure and ongoing efforts to reduce costs by strategic 
sourcing and developing repeatable offerings sold "as a service" and as managed services in a more commercial 
business model are expected to allow us to compete effectively on price in an evolving environment. Our ability to 
be competitive in the future will continue to be driven by our reputation for successful program execution, 
competitive cost structure, development of new pricing and business models, and efficiencies in assigning the right 
people, at the right time, in support of our contracts.
On July 2, 2021, we completed the acquisition of Halfaker and Associates, LLC (Halfaker). The acquisition of 
Halfaker, in alignment with our long-term strategy, grows the Company's digital transformation portfolio while 
expanding its ability to support the government's healthcare mission.
On March 13, 2020, we completed the acquisition of Unisys Federal, a former operating unit of Unisys Corporation. 
The acquisition of Unisys Federal, in alignment with our long-term strategy, positions SAIC as a leading government 
services technology integrator in digital transformation, and is highly accretive across all key financial metrics.
See “Risk Factors” in Part I of this report for additional discussion of our industry and regulatory environment.
Impacts of the COVID-19 Pandemic
We are continuing to monitor the ongoing outbreak of the coronavirus disease 2019 (COVID-19) and we continue to 
work with our stakeholders to assess further possible implications to our business, supply chain and customers, and 
to take actions in an effort to mitigate adverse consequences.
Section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act provides a mechanism to recover 
our labor costs where our employees are ready and able to work but unable to access required facilities due to 
COVID-19. This support from the CARES Act expired on September 30, 2021. Reduced activity on contracts, 
including travel and other direct costs, caused revenues to be approximately $125 million lower for fiscal 2022 (net 
of $62 million of labor recovered under the provisions of the CARES Act described above to maintain our workforce 
in a stand-ready state).
We are generally not able to bill profit on those costs and, in some cases, funding limitations and the necessity for 
contract modifications may cause us not to be able to recover all of the labor costs. As a result, operating income for 
fiscal 2022 was reduced by approximately $8 million.
In addition, the CARES Act allowed for the deferral of certain payroll tax payments through December 31, 2020 and 
we deferred total payments of approximately $103 million. The first installment ($51 million) of these deferred payroll 
taxes was paid during fiscal 2022 with the remaining amounts due in the fourth quarter of fiscal 2023.
In September 2021, the President issued an executive order which requires all federal employees and contractors 
to be fully vaccinated by January 18, 2022, unless an employee is legally entitled to an accommodation. In 
December 2021, a federal district judge issued an order, which temporarily enjoined the federal contractor vaccine 
mandate. We had taken steps to comply with the vaccine mandate across our workforce until it was enjoined. We 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
23

are continuing to monitor the impact that the enforcement of this executive order will have on our workforce and 
operations, but at this point the impact has not been material.
We have not experienced a significant impact to our liquidity or access to capital as a result of the COVID-19 
pandemic. As discussed in “Liquidity and Capital Resources” we believe that our existing cash on hand, generation 
of future operating cash flows, and access to bank financing and capital markets will provide adequate resources to 
meet our short-term liquidity and long-term capital needs. As of January 28, 2022 we were in compliance with our 
debt covenants and we have not been required to obtain additional financing, or make significant modifications to 
our capital deployment strategy, as a result of the COVID-19 pandemic.
While we continue to navigate the impacts of the COVID-19 pandemic, COVID-19 did not have as significant an 
impact on revenues and operating income as compared to the prior year. The full extent of the impact of COVID-19 
on our business and our operational and financial performance will depend on future developments, including the 
duration and spread of the pandemic, all of which are uncertain and cannot be predicted.
See “Risk Factors” in Part I of this report for additional discussion of the risks associated with the COVID-19 
pandemic.
Management of Operating Performance and Reporting
Our business and program management process is directed by professional managers focused on serving our 
customers by providing high quality services in achieving program requirements. These managers carefully monitor 
contract margin performance by constantly evaluating contract risks and opportunities. Throughout each contract’s 
life cycle, program managers review performance and update contract performance estimates to reflect their 
understanding of the best information available. For performance obligations satisfied over time, updates to 
estimates are recognized on inception-to-date activity, during the period of adjustment, resulting in either a favorable 
or unfavorable impact to operating income.
We evaluate our results of operations by considering the drivers causing changes in revenues, operating income 
and operating cash flows. Given that revenues fluctuate on our contract portfolio over time due to contract awards 
and completions, changes in customer requirements, and increases or decreases in ordering volume of materials, 
we evaluate significant trends and fluctuations in these terms. Whether performed by our employees or by our 
subcontractors, we primarily provide services and, as a result, our cost of revenues are predominantly variable. We 
also analyze our cost mix (labor, subcontractor or materials) in order to understand operating margin because 
programs with a higher proportion of SAIC labor are generally more profitable. Changes in costs of revenues as a 
percentage of revenue other than from revenue volume or cost mix are normally driven by fluctuations in shared or 
corporate costs, or cumulative revenue adjustments due to changes in estimates.
Changes in operating cash flows are described with regard to changes in cash generated through the delivery of 
services, significant drivers of fluctuations in assets or liabilities and the impacts of changes in timing of cash 
receipts or disbursements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
24

Results of Operations
The primary financial performance measures we use to manage our business and monitor results of operations are 
revenues, operating income and cash flows from operating activities. The following table summarizes our results of 
operations:
Year Ended
January 28, 
2022
Percent 
change
January 29, 
2021
Percent 
change
January 31, 
2020
(dollars in millions)
Revenues
$ 7,394 
 5 % $ 7,056 
 11 % $ 6,379 
Cost of revenues
 
6,535 
 4 %  
6,264 
 10 %  
5,673 
As a percentage of revenues
 88.4 %
 88.8 %
 88.9 %
Selling, general and administrative expenses
 
344 
 (2) %  
352 
 22 %  
288 
Acquisition and integration costs
 
56 
 4 %  
54 
 13 %  
48 
Other operating income
 
(3) 
 (25) %  
(4) 
 100 %  
— 
Operating income
 
462 
 18 %  
390 
 5 %  
370 
As a percentage of revenues
 6.2 %
 5.5 %
 
 5.8 %
Net income attributable to common stockholders
$ 
277 
 33 % $ 
209 
 (8) % $ 
226 
Cash flows provided by operating activities
$ 
518 
 (31) % $ 
755 
 65 % $ 
458 
Revenues. Revenues increased $338 million from fiscal 2021 to fiscal 2022 due to ramp up on new and existing 
contracts, the acquisitions of Unisys Federal (which occurred in the first quarter of the prior year period) and 
Halfaker, net favorable changes in contract estimates, and the accelerated amortization on certain off-market liability 
contracts, partially offset by contract completions. Adjusting for the impact of acquired revenues and divested 
revenues, revenues grew 2.5% primarily due to new awards and net increases in program volume.
Cost of Revenues. Cost of revenues increased $271 million from fiscal 2021 to fiscal 2022 primarily due to an 
increase in volume on existing contracts and the acquisitions of Unisys Federal (which occurred in the first quarter 
of the prior year period) and Halfaker. Cost of revenues as a percentage of revenues decreased due to improved 
profitability across our contract portfolio, net favorable changes in contract estimates, and the accelerated 
amortization on certain off-market liability contracts, partially offset by higher indirect costs. 
Selling, General and Administrative Expenses. SG&A decreased $8 million from fiscal 2021 to fiscal 2022 primarily 
due to decreased intangible asset amortization related to the acquisition of Unisys Federal and lower bid and 
proposal costs in the current year, partially offset by intangible amortization related to the acquisition of Halfaker, 
gains related to the resolution of certain legal matters in the prior year, and the acquisitions of Unisys Federal (which 
occurred in the first quarter of the prior year period) and Halfaker.
Operating Income. Operating income as a percentage of revenues increased to 6.2% for fiscal 2022, compared to 
5.5% for fiscal 2021, primarily due to improved profitability across our contract portfolio, net favorable changes in 
contract estimates, benefit from a net favorable settlement of prior indirect rate years, and the accelerated 
amortization on certain off-market liability contracts, partially offset by higher indirect costs in the current year and 
gains related to the resolution of certain legal and other program contract matters in the prior year.
Cash Flows Provided by Operating Activities. Cash flows provided by operating activities were $518 million for fiscal 
2022, which represented a decrease of $237 million from fiscal 2021. The decrease was primarily due to higher 
cash provided by the Master Accounts Receivable Purchase Agreement (MARPA Facility) in the prior year ($170 
million), when we initially entered into the facility, and working capital impact related to the deferred payroll taxes 
allowed under the CARES Act, partially offset by lower cash paid for income taxes and higher net earnings.
Non-GAAP Measures
Earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA are non-GAAP 
financial measures. While we believe that these non-GAAP financial measures may be useful in evaluating our 
financial information, they should be considered as supplemental in nature and not as a substitute for financial 
information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
25

are useful to management and investors are provided below. Other companies may define similar measures 
differently.
EBITDA and Adjusted EBITDA. The performance measure EBITDA is calculated by taking net income and 
excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. 
Adjusted EBITDA is a performance measure that excludes costs that we do not consider to be indicative of our 
ongoing performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition and integration 
costs, impairments, restructuring costs, and any other material non-recurring costs. Integration costs are costs to 
integrate acquired companies including costs of strategic consulting services, facility consolidation and employee 
related costs such as retention and severance costs. The acquisition and integration costs relate to the Company’s 
acquisitions of Engility Holdings, Inc., Unisys Federal, Halfaker, and Koverse. See Note 5 to the consolidated 
financial statements contained within this report for description of our restructuring and impairment costs.
We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in 
assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-
term financial performance of the Company.
EBITDA and adjusted EBITDA for the periods presented were calculated as follows:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Net income
$ 
279 
$ 
211 
$ 
229 
Interest expense and loss on sale of receivables
 
107 
 
124 
 
90 
Interest income
 
— 
 
(1) 
 
(4) 
Provision for income taxes
 
79 
 
60 
 
57 
Depreciation and amortization
 
165 
 
179 
 
131 
EBITDA
 
630 
 
573 
 
503 
EBITDA as a percentage of revenues
 8.5 %
 8.1 %
 7.9 %
Acquisition and integration costs
 
56 
 
54 
 
48 
Restructuring and impairment costs
 
2 
 
4 
 
— 
Depreciation included in acquisition and integration costs
 
(1) 
 
(1) 
 
(5) 
Recovery of acquisition and integration costs and restructuring and 
impairment costs(1)
 
(1) 
 
(3) 
 
(8) 
Adjusted EBITDA
$ 
686 
$ 
627 
$ 
538 
Adjusted EBITDA as a percentage of revenues
 9.3 %
 8.9 %
 8.4 %
(1) 
Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered 
through the Company's indirect rates in accordance with Cost Accounting Standards.
Adjusted EBITDA as a percentage of revenues increased to 9.3% for fiscal 2022, compared to 8.9% for fiscal 2021, 
driven by a net increase in profitability across our existing contract portfolio, net favorable changes in contract 
estimates, benefit from a net favorable settlement of prior indirect rate years, and revenue resulting from the 
accelerated amortization on certain off-market liability contracts, partially offset by higher indirect costs in the current 
year and gains related to the resolution of certain legal and other program contract matters in the prior year.
Other Key Performance Measures
In addition to the financial measures described above, we believe that bookings and backlog are useful measures 
for management and investors to evaluate our potential future revenues. We also consider measures such as 
contract types and cost of revenues mix to be useful for management and investors to evaluate our operating 
income and performance.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
26

Net Bookings and Backlog. Net bookings represent the estimated amount of revenues to be earned in the future 
from funded and negotiated unfunded contract awards that were received during the period, net of adjustments to 
estimates on previously awarded contracts. We calculate net bookings as the period’s ending backlog plus the 
period’s revenues less the prior period’s ending backlog and initial backlog obtained through acquisitions.
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is 
performed. We do not include in backlog estimates of revenues to be derived from IDIQ contracts, but rather record 
backlog and bookings when task orders are awarded on these contracts. Given that much of our revenue is derived 
from IDIQ contract task orders that renew annually, bookings on these contracts tend to refresh annually as the task 
orders are renewed. Additionally, we do not include in backlog contract awards that are under protest until the 
protest is resolved in our favor.
We segregate our backlog into two categories as follows:
•
Funded Backlog. Funded backlog for contracts with government agencies primarily represents estimated 
amounts of revenue to be earned in the future from contracts for which funding is appropriated less 
revenues previously recognized on these contracts. It does not include the unfunded portion of contracts in 
which funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. 
government and other customers even though the contract may call for performance over a number of 
years. Funded backlog for contracts with non-government customers represents the estimated value on 
contracts, which may cover multiple future years, under which we are obligated to perform, less revenues 
previously recognized on these contracts.
•
Negotiated Unfunded Backlog. Negotiated unfunded backlog represents estimated amounts of revenue to 
be earned in the future from negotiated contracts for which funding has not been appropriated or otherwise 
authorized and from unexercised priced contract options. Negotiated unfunded backlog does not include 
any estimate of future potential task orders expected to be awarded under IDIQ, GSA Schedules or other 
master agreement contract vehicles.
We expect to recognize revenue from a substantial portion of our funded backlog within the next twelve months. 
However, the U.S. government can adjust the scope of services of or cancel contracts at any time. Similarly, certain 
contracts with commercial customers include provisions that allow the customer to cancel prior to contract 
completion. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our 
incurred costs and fees (contract profit) for work performed.
The estimated value of our total backlog as of the dates presented was:
January 28, 
2022
January 29, 
2021
(in millions)
Funded backlog
$ 
3,491 $ 
3,024 
Negotiated unfunded backlog
 
20,601  
18,524 
Total backlog
$ 
24,092 $ 
21,548 
We had net bookings worth an estimated $9.4 billion and $11.9 billion during fiscal 2022 and 2021, respectively. 
Fiscal 2022 total backlog has increased from the prior year primarily due to several large awards received during 
the period from the U.S. Army and U.S. Navy. In addition, $0.6 billion of acquired backlog from Halfaker was 
recorded as an increase to backlog as of the acquisition date.
Contract Types. Our earnings and profitability may vary materially depending on changes in the proportionate 
amount of revenues derived from each type of contract. For a discussion of the types of contracts under which we 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
27

generate revenues, see “Business—Contract Types” in Part I of this report. The following table summarizes 
revenues by contract type as a percentage of revenues for the periods presented:
 
Year Ended
 
January 28, 
2022
January 29, 
2021
January 31, 
2020
Cost reimbursement
 54 %
 54 %
 57 %
Time and materials (T&M)
 20 %
 22 %
 20 %
Firm-fixed price (FFP)
 26 %
 24 %
 23 %
Total
 100 %
 100 %
 100 %
Our contract mix reflects an increase in firm-fixed price type contracts due in part to the acquisitions of Unisys 
Federal (which occurred in the first quarter of the prior year period) and Halfaker, which historically had a higher 
proportion of these contracts.
Cost of Revenues Mix. We generate revenues by providing a customized mix of services to our customers. The 
profit generated from our service contracts is affected by the proportion of cost of revenues incurred from the efforts 
of our employees (which we refer to below as labor-related cost of revenues), the efforts of our subcontractors and 
the cost of materials used in the performance of our service obligations under our contracts. Contracts performed 
with a higher proportion of SAIC labor are generally more profitable. The following table presents cost mix for the 
periods presented:
 
Year Ended
 
January 28, 
2022
January 29, 
2021
January 31, 
2020
 
(as a % of total cost of revenues)
Labor-related cost of revenues
 54 %
 55 %
 54 %
Subcontractor-related cost of revenues
 29 %
 29 %
 29 %
Supply chain materials-related cost of revenues
 8 %
 8 %
 11 %
Other materials-related cost of revenues
 9 %
 8 %
 6 %
Total
 100 %
 100 %
 100 %
Cost of revenues mix for fiscal 2022 remained consistent with the prior year.
Liquidity and Capital Resources
As a services provider, our business generally requires minimal infrastructure investment. We expect to fund our 
ongoing working capital, commitments and any other discretionary investments with cash on hand, future operating 
cash flows and, if needed, borrowings under our $400 million Revolving Credit Facility and $300 million MARPA 
Facility.
We anticipate that our future cash needs will be for working capital, capital expenditures, and contractual and other 
commitments. We consider various financial measures when we develop and update our capital deployment 
strategy, which include evaluating cash provided by operating activities, free cash flow and financial leverage. When 
our cash generation enables us to exceed our target average minimum cash balance, we intend to deploy excess 
cash through dividends, share repurchases, debt prepayments or strategic acquisitions.
Our ability to fund these needs will depend, in part, on our ability to generate cash in the future, which depends on 
our future financial results. Our future results are subject to general economic, financial, competitive, legislative and 
regulatory factors that may be outside of our direct control. Although we believe that the financing arrangements in 
place will permit us to finance our operations on acceptable terms and conditions for at least the next year, our 
future access to, and the availability of financing on acceptable terms and conditions will be impacted by many 
factors (including our credit rating, capital market liquidity and overall economic conditions). Therefore, we cannot 
ensure that such financing will be available to us on acceptable terms or that such financing will be available at all. 
Nevertheless, we believe that our existing cash on hand, generation of future operating cash flows, and access to 
bank financing and capital markets will provide adequate resources to meet our short-term liquidity and long-term 
capital needs.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
28

Upon the acquisition of Halfaker, we drew $100 million on our incremental senior secured Term Loan A2 Facility due 
October 2023. The proceeds were used for the purchase of Halfaker.
Upon the acquisition of Unisys Federal in fiscal 2021, we drew $600 million on our incremental senior secured Term 
Loan B2 Facility due March 2027 and issued $400 million of Senior Notes due 2028. In addition, in February 2020 
we sold $200 million of accounts receivable under our MARPA Facility. The proceeds were used for the purchase of 
Unisys Federal.
Borrowings under our Term Loan Facilities, our MARPA Facility and, if used in the future, our Revolving Credit 
Facility incur interest at a variable rate. In accordance with our risk management objectives, we hold fixed interest 
rate swap agreements to hedge the variability in interest payment cash flows on a substantial portion of our 
outstanding variable rate debt. These instruments are accounted for as cash flow hedges. Under the swap 
agreements, we pay the fixed rate and the counterparties to the agreement pay a floating interest rate.
Our Credit Facility contains customary terms and conditions including financial covenants and covenants restricting 
the Company's ability to merge or consolidate with another entity or undertake other fundamental changes, enter 
into property sale and leaseback transactions, and incur liens. The Company’s dividends and share repurchases 
may be limited under certain leverage ratios, and we may be required to make an annual debt prepayment based 
on our cash flows from operating activities. See Note 11 to the consolidated financial statements contained within 
this report for a more complete understanding of our Credit Facility.
We currently maintain credit ratings from major U.S. rating agencies. Failure to maintain acceptable ratings could 
have an adverse effect on the Company’s future cost of capital and any significant increase in the level of our 
borrowings could negatively impact these ratings.
Beginning in fiscal 2023, the Tax Cuts and Jobs Act of 2017 requires the capitalization of research and development 
costs for tax purposes, which can then be amortized over five years. Congress has proposed tax legislation to delay 
the effective date of this change to 2026, but it is uncertain whether the proposed legislation will ultimately be 
enacted into law. If the current effective date remains in place, the Company's initial assessment is that the 
Company would experience a material decrease in cash from operations in fiscal 2023, but our net deferred tax 
assets will increase by a similar amount. Management is currently evaluating the potential impact on our operating 
cash flows.
During fiscal 2022, we repurchased approximately 2.4 million shares of our common stock for $211 million from the 
open market in connection with our existing share repurchase program. Since the program’s inception in December 
of 2013, we have repurchased 14.4 million shares for $946 million.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
29

The following table summarizes our principal contractual commitments as of January 28, 2022:
Total
Due in Fiscal 2023
(in millions)
Long-term debt including current portion
$ 
2,540 $ 
148 
Interest payments on long-term debt(1)
 
338  
77 
Operating lease obligations
 
265  
59 
Estimated purchase obligations(2)
 
114  
76 
Other liabilities(3)
 
155  
98 
Total contractual obligations
$ 
3,412 $ 
458 
(1)
Amounts include an estimate of future variable interest payments on the Term Loan Facilities based on scheduled 
outstanding principal amounts, current applicable margin and projected 1-month LIBOR as of January 28, 2022. The 
amounts presented in this table exclude the effects of interest rate swaps used to hedge against changes in 1-month 
LIBOR.
(2)
Excludes purchase orders for services or products to be delivered pursuant to U.S. government contracts in which we 
have full recourse under normal contract termination clauses. 
(3)
Other liabilities primarily consist of liabilities associated with deferred compensation plan obligations, liabilities for 
unrecognized tax benefits, and the deferral of certain payroll tax payments as permitted by the CARES Act. Deferred 
compensation plan obligations due in fiscal 2023 are based on participants’ payment elections on retirement and 
estimated retirement ages. Liabilities for unrecognized tax benefits due in fiscal 2023 are based on the fiscal year in which 
the statute of limitations is currently expected to expire. 
See respective notes to the consolidated financial statements contained within this report for further information 
about our long-term debt (Note 11), lease payment obligations (Note 15), liabilities for unrecognized tax benefits 
(Note 10), and letters of credit and surety bonds (Note 17).
Historical Cash Flow Trends
The following table summarizes our cash flows:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Net cash provided by operating activities
$ 
518 $ 
755 $ 
458 
Net cash used in investing activities
 
(292)  
(1,231)  
(47) 
Net cash (used in) provided by financing activities
 
(301)  
464  
(455) 
Total decrease in cash, cash equivalents and restricted cash
$ 
(75) $ 
(12) $ 
(44) 
Cash Provided by Operating Activities. Refer to “Results of Operations” above for a discussion of the changes in 
cash provided by operating activities between fiscal 2022 and 2021.
Cash Used in Investing Activities. Cash used in investing activities decreased in fiscal 2022 compared to the prior 
year period primarily due to cash paid for the acquisition of Unisys Federal in the prior year period, partially offset by 
cash paid for the acquisitions of Halfaker and Koverse in the current year period.
Cash Used in/Provided by Financing Activities. Cash used in financing activities in fiscal 2022 was $301 million 
compared to cash provided by financing activities of $464 million in fiscal 2021. This change is primarily due 
to proceeds from borrowings obtained to finance the Unisys Federal acquisition in the prior year period and higher 
share repurchases in the current year period, partially offset by higher voluntary principal prepayments in the prior 
year period and borrowings to finance the Halfaker acquisition in the current year period.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
30

Commitments and Contingencies
We are subject to a number of reviews, investigations, claims, lawsuits and other uncertainties related to our 
business. For a discussion of these items, see Note 17 to the consolidated financial statements contained within this 
report.
Critical Accounting Policies
Our discussion and analysis of our financial condition and results of operations are based on our consolidated 
financial statements, which are prepared in accordance with U.S. generally accepted accounting principles. The 
preparation of these financial statements requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and the disclosure of contingencies, as well as the reported amounts of 
revenues, expenses, gains and losses during the reporting periods. Management evaluates these estimates and 
assumptions on an ongoing basis. Our estimates and assumptions have been prepared on the basis of the most 
current reasonably available information and, in some cases, are our basis for making judgments about the carrying 
values of assets and liabilities that are not readily apparent from other sources. Estimates and assumptions may 
change in the future as more current information is available.
Management believes that our critical accounting policies are those that are both material to the presentation of our 
financial condition and results of operations and require management’s most difficult, subjective and complex 
judgments. Typically, the circumstances that make these judgments difficult, subjective and complex have to do with 
making estimates about the effect of matters that are inherently uncertain. These policies are described below.
Revenue Recognition. We generate our revenues primarily from long-term contracts in which we provide technical, 
engineering and enterprise IT services directly for the U.S. government and as a subcontractor with other 
contractors engaged in work for the U.S. government. We evaluate the nature of the contract and the services 
provided when determining the accounting method utilized for each contract. We recognize a significant portion of 
our revenues using a cost input measure of progress that requires us to rely on the skill and expertise of our 
engineers, program managers and business management professionals in the many areas of cost estimation. 
These estimates of costs can span several years and take into account many factors including the availability, 
productivity and cost of labor, potential delays in our performance and the level of future indirect cost allocations. 
We provide for anticipated losses on long-term production type contracts and service contracts with the U.S. 
government by recording an expense for the total expected contract loss during the period when the loss is 
determined. Contract costs incurred for U.S. government contracts (including allocated indirect costs) are subject to 
audit and adjustment through negotiations with government representatives. Revenues on U.S. government 
contracts have been recorded in amounts that are expected to be realized on final settlement.
Many of our contracts include forms of variable consideration such as reimbursable costs, award and incentive fees, 
usage-based pricing, service-level penalties, performance bonuses, and other provisions that can either increase or 
decrease the transaction price. Variable amounts are generally determined upon our achievement of certain 
performance metrics, program milestones or cost targets and may be based upon customer discretion. At contract 
inception, we estimate the transaction price and may include variable consideration in the transaction price only to 
the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the 
uncertainty associated with the variable consideration is resolved. When developing these estimates, we consider 
the customer, contract terms, the complexity of the work and related risks, the extent of customer discretion, 
historical experience and the potential of a significant reversal of revenue.
Changes in Estimates on Contracts. Changes in estimates of revenues, cost of revenues or profits related to 
performance obligations satisfied over time are recognized in operating income in the period in which such changes 
are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the 
performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to 
unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, 
such as variable amounts for incentive or award fees; and performance being better or worse than previously 
estimated. Many of the Company's contracts recognize revenue on performance obligations using a cost input 
measure (cost-to-cost), which requires estimates of total costs at completion. In cases when total expected costs 
exceed total estimated revenues for a performance obligation, the Company recognizes the total estimated loss in 
the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, 
only if they increase the amount of the loss. Aggregate net changes in contract estimates increased operating 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
31

income by $13 million, $9 million and $22 million for fiscal 2022, 2021 and 2020, respectively. For additional 
information related to changes in estimates on contracts, including gross favorable and unfavorable adjustments as 
well as the impact to earnings per share, see Note 3 to the consolidated financial statements contained within this 
report.
Business Combinations. We record all tangible and intangible assets acquired and liabilities assumed in a business 
combination at fair value as of the acquisition date. The excess amount of the aggregated purchase consideration 
paid over the fair value of the net of assets acquired and liabilities assumed is recorded as goodwill.
The fair values of assets acquired and liabilities assumed are determined using either an income, cost or market 
approach. Each of these valuation methods requires significant judgment, including analysis of historical 
performance and estimates of future performance. Estimates can be affected by contract performance and other 
factors that may cause final amounts to differ materially from original estimates.
Under the income approach, fair value is based on the present value of future cash flows to be generated over the 
remaining economic life of an asset or liability being measured. This method includes estimates for projections of 
revenues and expenses, royalty rates, tax rates, contributory asset charges, discount rates, and tax amortization 
benefits. Under the cost approach, fair value is measured by determining the replacement cost of an asset. Under 
the market approach, the fair value reflects the price and other relevant information of market transactions for 
comparable assets, liabilities or groups of assets and liabilities. Valuation techniques consistent with the market 
approach often use market multiples derived from a set of comparables.
The valuations are based on information that existed as of the acquisition date. During the measurement period that 
shall not exceed one year from the acquisition date, we may adjust provisional amounts recorded for assets 
acquired and liabilities assumed to reflect new information that we have subsequently obtained regarding facts and 
circumstances that existed as of the acquisition date.
Goodwill and Intangible Assets. Goodwill is recorded as the difference between the aggregate consideration paid for 
an acquisition and the fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill 
is not amortized, but rather tested for potential impairment annually at the beginning of the fourth quarter, or 
whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
The goodwill impairment test is performed at the reporting unit level. The Company estimates and compares the fair 
value of each reporting unit to its respective carrying value including goodwill. If the fair value is less than the 
carrying value, the amount of impairment expense is equal to the difference between the reporting unit’s fair value 
and the reporting unit’s carrying value.
Determining the fair value of each reporting unit involves judgment and the use of estimates and assumptions. We 
estimate the fair value of our reporting units using either a market approach, income approach, or a combination of 
both. For our annual impairment analysis, we reconcile the aggregate fair value of all of our reporting units to our 
market capitalization as of the measurement date.
Under the income approach, we estimate the fair value of a reporting unit using a multi-year discounted cash flow 
model that involves assumptions about projected future revenue growth, operating margins, income tax rates, 
capital expenditures, discount rate and terminal value. The discount rate is an estimate of the cost of capital that a 
market participant would expect for the respective reporting unit. The terminal value represents the present value in 
the last year of the projection period of all subsequent cash flows into perpetuity.
Under the market approach, we estimate the fair value of a reporting unit based on multiples of earnings derived 
from observable market data of comparable public companies. We evaluate companies within our industry that have 
operations with observable and comparable economic characteristics and are similar in nature, scope and size to 
the reporting unit being compared. We analyze historical acquisitions in our industry to estimate a control premium 
that we incorporate into the fair value estimate of a reporting unit under the market approach.
During the fourth quarter of fiscal 2022, we completed our annual goodwill impairment testing and determined that 
each reporting unit's fair value significantly exceeded its carrying value.
In addition, determining the carrying value of each reporting unit requires judgment and involves the assignment of 
assets and liabilities to the reporting units based on a systematic and rational allocation methodology. Certain 
assets and liabilities may be specifically identified and assigned to a reporting unit based on the information 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
32

contained within our financial systems; whereas, other assets and liabilities may be allocated using measurable 
relationships or other basis for allocation.
Intangible assets with finite lives are amortized using the method that best reflects how their economic benefits are 
utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their 
estimated useful lives. Intangible assets with finite lives are assessed for impairment whenever events or changes 
in circumstances indicate that the carrying value may not be recoverable.
Income Taxes. Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax 
benefits reflect our best estimate of current and future taxes to be paid and includes judgments related to matters 
for which ultimate resolution may not become known until the final resolution of an examination by taxing authorities 
or the statute of limitations lapses.
We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In 
making this determination, we consider all available positive and negative evidence, including future reversals of 
existing taxable temporary differences, projected future taxable income, tax planning strategies and recent 
operating results. If we were to determine that we would be able to realize our deferred income tax assets in the 
future in excess of their net recorded amount or would no longer be able to realize our deferred income tax assets in 
the future as currently recorded, we would make an adjustment to the valuation allowance, which would either 
decrease or increase, respectively, the provision for income taxes.
Recently Issued But Not Yet Adopted Accounting Pronouncements
For information on recently issued but not yet adopted accounting pronouncements, see Note 1 to the consolidated 
financial statements contained within this report.
Effects of Inflation
For any of the most recent three fiscal years ended January 28, 2022, inflation has not had a significant impact on 
revenues or costs. Most of our contracts are paid in U.S. dollars and our cost to perform on these contracts are 
generally paid in U.S. dollars, so inflation risk is generally limited to that which is related to the U.S. dollar. 
Approximately 54% of our revenues for fiscal 2022 were derived from cost-reimbursement type contracts, which 
have limited inflation risk because our contracts generally entail the provision of labor on a reimbursable basis, and, 
when materials are acquired, they provide for billing to the customer during the period in which the materials were 
received. Bids for longer-term FFP and T&M contracts typically include sufficient provisions for labor and other cost 
escalations to cover anticipated cost increases over the period of performance. As a result, if we were to experience 
significant levels of inflation, our revenues and costs for cost-type contracts would generally both increase 
commensurate with inflation and operating income as a percentage of total revenues would not be significantly 
affected. Operating income as a percentage of total revenues would not be significantly affected for longer-term FFP 
and T&M contracts to the extent that bid contract cost escalations are sufficient to cover heightened inflation levels.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to certain market risks in the normal course of business. The following information about our 
market sensitive financial instruments contains forward-looking statements.
Foreign Currency Risk
Since the substantial majority of our business is conducted in U.S. dollars, a 10% change in any foreign currency 
exchange rates would not have a material impact to our financial condition or results of operations.
Interest Rate Risk
Debt obligations. Our financial risk management objective is to reduce variability in earnings from changes in 
interest rates, which we may manage through operational means or the use of financial instruments, such as 
interest rate swaps. We have approximately $2.1 billion of variable rate debt. The fair value of our outstanding long-
term debt obligations approximates its carrying value. In connection with the issuances of our variable rate Term 
Loan A and Term Loan B Facilities, we entered into fixed interest rate swap agreements, effectively converting a 
substantial portion of our variable rate debt to fixed rate debt in order to mitigate our exposure to fluctuations in 
interest rates. We regularly evaluate our outstanding debt and swap agreements to meet our risk management 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
33

objective. A hypothetical 50 basis points (bps) change to interest rates would not materially change our results of 
operations or cash flows. For additional information related to our debt and interest rate swap agreements, see Note 
11 and Note 12, respectively, to the consolidated financial statements contained in this report.
Derivatives. As of January 28, 2022, the fair value of our fixed interest rate swaps was $51 million (liability). Under 
the swap agreements, we pay a fixed rate and the counterparties to the agreements pay a floating interest rate 
based on 1-month LIBOR. A hypothetical 50 bps change in the 1-month LIBOR curve would change the fair value of 
the fixed interest rate swaps up to $16 million. Since the interest rate swaps are accounted for as cash flow hedges, 
the change in fair value is reported as a component of equity (accumulated other comprehensive income or loss). 
We do not hold or issue derivative financial instruments for trading or speculative purposes. For additional 
information related to calculating the fair value of our interest rate swaps, see Note 12 to the consolidated financial 
statements included in this report.
Cash equivalents. A 10% unfavorable interest rate movement for interest earned on our cash and cash equivalents 
would not materially impact the value of our cash holdings and would have a negligible impact on interest income at 
current market interest rates.
Inflation Risk
We have generally been able to anticipate increases in costs when pricing our contracts. Bids for longer-term FFP 
contracts typically include labor and other cost escalations in amounts that historically have been sufficient to cover 
cost increases over the period of contract performance.
Item 8. Financial Statements and Supplementary Data
See our consolidated financial statements attached hereto and listed on the index found on page F-1 of this report.
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
No information is required in response to this item.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer (our Chief Executive Officer) and principal 
financial officer (our Chief Financial Officer), has evaluated the effectiveness of our disclosure controls and 
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of 
January 28, 2022, and our principal executive officer and principal financial officer have concluded that our 
disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the 
reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and 
reported within the time periods specified in the rules and forms of the SEC. These disclosure controls and 
procedures include, without limitation, controls and procedures designed to ensure that information required to be 
disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and 
communicated to our management, including our principal executive officer and our principal financial officer, as 
appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the fourth quarter of fiscal 2022 
that materially affected, or are likely to materially affect, our internal control over financial reporting.
Management’s Report On Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. 
Internal control over financial reporting is a process designed to provide reasonable assurance regarding the 
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with 
GAAP.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
34

Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of 
records that, in reasonable detail, completely, accurately and fairly reflect the transactions and dispositions of our 
assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the 
financial statements in accordance with GAAP; (iii) provide reasonable assurance that our receipts and 
expenditures are made only in accordance with the authorization of our management and directors; and (iv) provide 
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of 
assets that could have a material effect on the consolidated financial statements. Internal control over financial 
reporting includes the controls themselves, monitoring and internal auditing practices and actions taken to correct 
deficiencies as identified.
Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated the 
effectiveness of our internal control over financial reporting as of January 28, 2022 based on the framework 
established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring 
Organizations of the Treadway Commission. Our management has assessed in its evaluation the effectiveness of 
our internal control over financial reporting as of January 28, 2022 and has concluded that our internal control over 
financial reporting was effective.
Ernst & Young LLP, an independent registered public accounting firm, audited our consolidated financial statements 
included in this report and our internal control over financial reporting, and the firm’s report on our internal control 
over financial reporting are set forth below this report.
Although our management, including the Chief Executive Officer and the Chief Financial Officer, is responsible for 
establishing and maintaining adequate internal control over financial reporting, because of inherent limitations, our 
management does not expect that our internal controls over financial reporting will prevent or detect all errors and 
all fraud. Also, projections of any evaluation of effectiveness in such assessment to future periods are subject to the 
risk that controls may be inadequate because of changes in conditions or that the degree of compliance with the 
policies or procedures may deteriorate.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
35

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Science Applications International Corporation
Opinion on Internal Control Over Financial Reporting 
We have audited Science Applications International Corporation's internal control over financial reporting as of 
January 28, 2022, based on criteria established in Internal Control — Integrated Framework issued by the 
Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our 
opinion, Science Applications International Corporation (the Company) maintained, in all material respects, effective 
internal control over financial reporting as of January 28, 2022, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United 
States) (PCAOB), the consolidated balance sheets of the Company as of January 28, 2022 and January 29, 2021, 
the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the three 
years in the period ended January 28, 2022, and the related notes and our report dated March 28, 2022 expressed 
an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for 
its assessment of the effectiveness of internal control over financial reporting included in the accompanying 
Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on 
the Company’s internal control over financial reporting based on our audit. We are a public accounting firm 
registered with the PCAOB and are required to be independent with respect to the Company in accordance with the 
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission 
and the PCAOB. 
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and 
perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting 
was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a 
material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on 
the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We 
believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting 
A company’s internal control over financial reporting is a process designed to provide reasonable assurance 
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in 
accordance with generally accepted accounting principles. A company’s internal control over financial reporting 
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, 
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable 
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance 
with generally accepted accounting principles, and that receipts and expenditures of the company are being made 
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable 
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s 
assets that could have a material effect on the financial statements. 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. 
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may 
become inadequate because of changes in conditions, or that the degree of compliance with the policies or 
procedures may deteriorate.
/s/ Ernst & Young LLP
Tysons, Virginia
March 28, 2022
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
36

Item 9B. Other Information
No information is required in response to this item.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
No information is required in response to this item.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
37

Part III
Item 10. Directors, Executive Officers, and Corporate Governance
Our executive officers as of March 28, 2022, are listed below, along with their ages on that date, positions and 
offices held and business experience during at least the past five years. All such persons have been elected to 
serve until their successors are elected and qualified or until their earlier resignation or removal.
Name of officer
Age
Position(s) with the Company and prior business experience
Nazzic S. Keene
61
Chief Executive Officer (CEO) since July 2019. Prior to this role Ms. Keene served as 
Chief Operating Officer (COO) from June 2017 to July 2019, as Sector President, 
Global Markets and Missions from September 2013 to June 2017, and Leidos 
Holding Inc. (formerly SAIC, Inc.) Senior Vice President for Corporate Strategy and 
Planning from August 2012 to September 2013. Prior to joining us, Ms. Keene was 
the Senior Vice President and General Manager for U.S. Enterprise Markets at CGI 
Group, Inc.
Steven G. Mahon
60
General Counsel and Corporate Secretary since November 2015. Mr. Mahon 
previously served as General Counsel, Chief Compliance Officer and Corporate 
Secretary at MTS Systems Corporation (MTS) from October 2011 to November 2015. 
Prior to MTS, Mr. Mahon was Assistant General Counsel for Alliant Techsystems Inc. 
and is a retired Colonel from the U.S. Army where he served in the U.S. Judge 
Advocate’s General’s Corps, practicing law in a variety of roles on active duty and in 
the U.S. Army Reserve.
Prabu Natarajan
51
Chief Financial Officer (CFO) since January 2021. Prior to joining us, Mr. Natarajan 
was Vice President of Financial Planning and Merger and Acquisition for Northrop 
Grumman from January 2016 to December 2020. Mr. Natarajan joined Northrop 
Grumman in August 2011 and was also Vice President of Business Management and 
CFO for the Information Systems Sector from August 2014 to January 2016 and Vice 
President, Treasurer and Taxes from August 2011 to August 2014. Mr. Natarajan has 
held positions at The AES Corporation and PricewaterhouseCoopers LLP.
Michelle A. O'Hara
46
Chief Human Resources Officer since October 2019. Prior to this role, Ms. O’Hara 
served as Senior Vice President for Human Resources, after serving as head of 
talent strategy, total rewards, learning and development, diversity, executive 
compensation, and talent acquisition. Prior to joining SAIC, Ms. O’Hara served as the 
head of talent acquisition at Bearingpoint.
Robert S. Genter
46
President, Defense and Civilian Sector, since 2016. Mr. Genter is responsible for 
strategy, business development, and program execution for the portfolio including the 
majority of the Department of Defense, the FAA, Department of State, USDA, EPA, 
DOE, Commerce, DHS, GSA, and FTRB. Mr. Genter previously served as the Senior 
Vice President and General Manager of Strategic Growth Markets customer group. 
From 2004 to 2013, Mr. Genter held various leadership and P&L roles at CGI, 
ultimately serving as Vice President of Consulting Services for Commercial Markets, 
and prior to joining CGI, held several finance and operations roles at American 
Management Systems.
Michael W. 
LaRouche
56
President, National Security and Space Sector, since 2019. Mr. LaRouche is 
responsible for supporting a variety of Intelligence Community customers, NASA and 
the U.S. Air Force. Before joining SAIC, Mr. LaRouche led multiple large business 
units at Raytheon, where he served as Vice President for 11 years. Earlier in his 
career, LaRouche served in leadership positions with Lockheed Martin and Hughes.
For additional information required by Item 10 with respect to executive officers and directors, including audit 
committee and audit committee financial experts, procedures by which stockholders may recommend nominees to 
the Board of Directors, and compliance with Section 16(a) of the Securities Exchange Act of 1934, see the 
information set forth under the captions “Proposal 1—Election of Directors,” “Corporate Governance” and “Other 
Information” in the 2022 Definitive Proxy Statement, which information is incorporated by reference into this report.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
38

We have adopted a code of conduct, which describes our standards for protecting SAIC and customer assets, 
fostering a safe and healthy work environment, dealing fairly with customers and others, conducting international 
business properly, reporting misconduct and protecting employees from retaliation. This code applies to all 
executive officers and employees and forms the foundation of our corporate policies and procedures designed to 
promote ethical behavior in all aspects of our business. To obtain copies of the Code of Conduct, visit our website at 
www.saic.com and click on the link titled “Corporate Governance” and then “Code of Conduct.” We intend to post on 
our website any material changes to or waivers from our code of business ethics. The information on our website is 
not incorporated by reference into and is not a part of this report.
Item 11. Executive Compensation
For information required by Item 11 with respect to executive compensation, see the information set forth under the 
captions “Compensation Discussion and Analysis,” “Executive Compensation” and “Corporate Governance” in the 
2022 Definitive Proxy Statement, which information is incorporated by reference into this report.
For information required by Item 11 with respect to compensation committee interlocks and insider participation, see 
the information set forth under the caption “Corporate Governance” in the 2022 Definitive Proxy Statement, which 
information is incorporated by reference into this report.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder 
Matters
For information required by Item 12 with respect to the security ownership of certain beneficial owners and 
management, see the information set forth under the caption “Other Information” in the 2022 Definitive Proxy 
Statement, which information is incorporated by reference into this report.
We currently maintain four shareholder-approved equity compensation plans that issue stock-based awards 
including the 2013 Equity Incentive Plan, the Management Stock Compensation Plan, the 2013 Employee Stock 
Purchase Plan and the 2012 Long Term Performance Plan. For summaries of these plans, see Note 8 to the 
consolidated financial statements contained within this report. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
39

The following table provides the number of shares of our common stock to be issued, the weighted-average 
exercise price of the outstanding stock options and the number of shares remaining for future award grants as of 
January 28, 2022:
Equity Compensation Plan Information
Plan Category
Number of 
securities to be 
issued upon 
exercise of 
outstanding 
options, warrants 
and rights(1)
Weighted-
average exercise 
price of 
outstanding
options, warrants
and rights(2)
Number of 
securities 
remaining 
available for future 
issuance under 
equity 
compensation 
plans (excluding 
securities reflected
 in column (a))(3)
(a)
(b)
(c)
Equity compensation plans approved by security holders
 
2,166,387 $ 
72.34  
5,557,369 
Equity compensation plans not approved by security holders
 
—  
—  
— 
Total
 
2,166,387 $ 
72.34  
5,557,369 
(1)
This amount includes 612,984 stock options outstanding and 1,553,403 shares issuable for other stock-based awards 
under the 2013 Equity Incentive Plan. This amount does not include shares to be issued pursuant to purchase rights 
under the 2013 Employee Stock Purchase Plan.
(2)
Does not include shares to be issued for stock-based awards, other than stock options, which will not require any payment 
upon issuance of those shares.
(3)
Includes 2,514,092 shares of our common stock available for issuance under the 2013 Employee Stock Purchase Plan 
(ESPP). The maximum number of shares initially available for issuance under the ESPP was 1 million. The ESPP 
provides for an automatic increase to the share reserve on the first day of each fiscal year beginning on February 1, 2014 
in an amount equal to the lesser of (i) 1 million shares, (ii) two percent of the number of shares of our common stock 
outstanding on the last day of the immediately preceding fiscal year or (iii) a number determined by the Compensation 
Committee of the Board of Directors. The amount authorized for issuance under the ESPP increased 500,000, 916,198 
and 973,477 during fiscal 2017, 2016 and 2015 respectively. There was no increase to the amount authorized for 
issuance under the ESPP during fiscal 2018 - 2022. In addition, this includes 2,027,513 shares of our common stock 
available for issuance under the 2013 Equity Incentive Plan (EIP). The maximum number of shares initially available for 
issuance under the EIP was 5.7 million, which was increased by 2.8 million per the amended and restated 2013 Equity 
Incentive Plan, adopted June 4, 2014, amounting to a total authorized for issuance of 8.5 million. Lastly, this includes 
1,015,764 shares of our common stock available for issuance under the 2012 Long Term Performance Plan (LTPP), see 
Note 8 to the consolidated financial statements contained within this report. The shares outstanding under the LTPP relate 
to assumed awards from the Engility Holdings, Inc. acquisition, and as of the acquisition date, January 14, 2019, the 
maximum number of shares available for issuance under the LTPP was 1,198,010. We expect that the number of shares 
actually issued under the EIP and LTPP will be significantly less than the number of total awards outstanding under the 
respective plans because (a) a net option exercise results in a smaller portion of the number of award shares being issued 
when a participant uses award shares, rather than cash, to pay the exercise price, which historically most participants 
have elected to do, (b) most participants historically have elected to let the Company retain award shares to pay for taxes 
due on the exercise of options and all participants are required to use award shares to pay for taxes upon the vesting of 
restricted stock or restricted stock units, (c) some participants may terminate employment with the Company before the 
vesting of awards resulting in awards being forfeited and (d) some participants may not exercise stock options before the 
expiration date for a variety of reasons, including if the exercise price exceeds the then current market price of shares. 
Item 13. Certain Relationships and Related Transactions, and Director Independence
For information required by Item 13 with respect to certain relationships and related transactions and the 
independence of directors and nominees, see the information set forth under the caption “Corporate Governance” in 
the 2022 Definitive Proxy Statement, which information is incorporated by reference into this report.
Item 14. Principal Accounting Fees and Services
For information required by Item 14 with respect to principal accounting fees and services, see the information set 
forth under the caption “Audit Matters” in the 2022 Definitive Proxy Statement, which information is incorporated by 
reference into this report.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
40

Part IV
Item 15. Exhibits, Financial Statement Schedules
(a)
Documents filed as part of the report
1. Financial Statements
Our consolidated financial statements are attached hereto and listed on the Index to Consolidated 
Financial Statements set forth on page F-1 of this report.
2. Financial Statement Schedules
Financial statement schedules are omitted because they are not applicable or the required 
information is shown in our consolidated financial statements or the notes thereto.
3. Exhibits
See Exhibit Index at the end of this report.
Item 16. Form 10-K Summary
None.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
41

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly 
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Science Applications International Corporation
By
/s/    Prabu Natarajan
Prabu Natarajan
Chief Financial Officer
Dated: March 28, 2022 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the 
following persons on behalf of the registrant in the capacities and on the dates indicated. 
Signature
Title
Date
/s/    Nazzic S. Keene
Principal Executive Officer and Director
March 28, 2022
Nazzic S. Keene
/s/    Prabu Natarajan
Principal Financial Officer and
Principal Accounting Officer
March 28, 2022
Prabu Natarajan
/s/    Donna S. Morea
Chair of the Board
March 28, 2022
Donna S. Morea
/s/    Robert A. Bedingfield
Director
March 28, 2022
Robert A. Bedingfield
/s/    Carol A. Goode
Director
March 28, 2022
Carol A. Goode
/s/    Garth N. Graham
Director
March 28, 2022
Garth N. Graham
/s/    John J. Hamre
Director
March 28, 2022
John J. Hamre
/s/    Yvette M. Kanouff
Director
March 28, 2022
Yvette M. Kanouff
/s/    Timothy J. Mayopoulos
Director
March 28, 2022
Timothy J. Mayopoulos
/s/    Katharina G. McFarland
Director
March 28, 2022
Katharina G. McFarland
/s/    Milford W. McGuirt
Director
March 28, 2022
Milford W. McGuirt
/s/    Steven R. Shane
Director
March 28, 2022
Steven R. Shane
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
42

CONSOLIDATED FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
F-2
Consolidated Statements of Income
F-5
Consolidated Statements of Comprehensive Income
F-6
Consolidated Balance Sheets
F-7
Consolidated Statements of Equity
F-8
Consolidated Statements of Cash Flows
F-9
Notes to the Consolidated Financial Statements
F-11
Note 1—Business Overview and Summary of Significant Accounting Policies
F-11
Note 2—Earnings Per Share, Share Repurchases and Dividends
F-19
Note 3—Revenues
F-20
Note 4—Acquisitions
F-22
Note 5—Restructuring and Impairment
F-24
Note 6—Goodwill and Intangible Assets
F-25
Note 7—Property, Plant, and Equipment
F-26
Note 8—Stock-Based Compensation
F-26
Note 9—Retirement Plans
F-30
Note 10—Income Taxes
F-34
Note 11—Debt Obligations
F-36
Note 12—Derivative Instruments Designated as Cash Flow Hedges
F-38
Note 13—Changes in Accumulated Other Comprehensive Loss by Component
F-39
Note 14—Sale of Receivables
F-39
Note 15—Leases
F-40
Note 16—Business Segment Information
F-42
Note 17—Legal Proceedings and Commitments and Contingencies
F-42
Financial statement schedules are omitted because they are not applicable or the required information is shown in 
our consolidated financial statements or the notes thereto.
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Science Applications International Corporation
Opinion on the Financial Statements 
We have audited the accompanying consolidated balance sheets of Science Applications International Corporation 
(the Company) as of January 28, 2022 and January 29, 2021, the related consolidated statements of income, 
comprehensive income, equity, and cash flows for each of the three years in the period ended January 28, 2022, 
and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the 
consolidated financial statements present fairly, in all material respects, the financial position of the Company at 
January 28, 2022 and January 29, 2021, and the results of its operations and its cash flows for each of the three 
years in the period ended January 28, 2022, in conformity with U.S. generally accepted accounting principles. 
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United 
States) (PCAOB), the Company’s internal control over financial reporting as of January 28, 2022, based on criteria 
established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the 
Treadway Commission (2013 framework) and our report dated March 28, 2022 expressed an unqualified opinion 
thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an 
opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with 
the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal 
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the 
PCAOB. 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan 
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material 
misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of 
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that 
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and 
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and 
significant estimates made by management, as well as evaluating the overall presentation of the financial 
statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial 
statements that were communicated or required to be communicated to the audit committee and that: (1) relate to 
accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, 
subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion 
on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit 
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which 
they relate.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
F-2

Revenue recognition based on a cost input measure of progress
Description of 
the Matter
The Company recognizes a significant portion of its revenues using a cost input 
(cost-to-cost) measure of progress. Under the cost-to-cost measure of progress, 
revenue is recognized based on the ratio of costs incurred to the total estimated 
costs at completion. The transaction price used as the basis for revenue is the 
estimated amount of consideration expected to be received for performance and may 
include variable consideration such as reimbursable costs, award fees, incentive 
fees, or other provisions that can either increase or decrease the transaction price. 
As described in Note 1 to the consolidated financial statements, recognizing revenue 
on long-term contracts involves significant judgments and estimates. Changes in 
estimates (as quantified in Note 3 to the consolidated financial statements) can 
routinely occur due to changes in the estimated transaction price or estimated costs 
to completion and for a variety of reasons including changes in scope, changes in 
cost estimates due to unanticipated cost growth or reassessments of risks impacting 
costs, and changes in the estimated transaction price, such as variable amounts for 
incentive or award fees. A significant change in an estimate on one or more contracts 
could have a material effect on the Company’s results of operations. 
Auditing the Company’s accounting for revenue using the cost input measure of 
progress was complex due to the judgment involved in estimating the transaction 
price and total estimated costs at completion for these contracts. The transaction 
price may include variable consideration. Additionally, management estimates total 
costs at completion by making assumptions regarding the complexity of the work to 
be performed, the schedule and associated tasks, labor productivity and availability, 
increases in wages and prices of materials, execution by subcontractors, overhead 
cost rates, and other variables. 
How We 
Addressed the 
Matter in Our 
Audit
We obtained an understanding, evaluated the design and tested the operating 
effectiveness of controls over the Company’s recognition of revenue using the cost 
input measure of progress. For example, we tested controls over management’s 
review of the estimated transaction price and estimated costs at completion used in 
determining revenue using the cost input measure of progress. We also tested 
internal controls that management executes to validate the data used in determining 
this revenue was complete and accurate.
To test the accuracy of the Company’s estimated transaction price and estimated 
costs at completion, our audit procedures included, among others, comparing 
estimates of labor costs, subcontractor costs, materials and variable consideration to 
historical results of similar contracts, and agreeing the key terms, including the terms 
of the variable consideration, to contract documentation and management’s 
estimates. Our audit procedures also included, among others, evaluating the nature, 
timing and extent of the amounts of revenue and costs recorded to date, including 
any changes in transaction price or estimated costs at completion from the prior 
period. For example, to test a change in estimate, we inspected underlying evidence 
for the reason for the change in estimate and the timing of such change, and we 
recalculated the inception-to-date effect recorded. We also evaluated whether a lack 
of change in estimate was appropriate, where applicable, on contracts. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
F-3

Unrecognized tax benefits
Description of 
the Matter
As discussed in Notes 1 and 10 to the consolidated financial statements, the 
Company files income tax returns in the U.S. Federal jurisdiction and various state 
jurisdictions. The Company recognizes liabilities for uncertainty in income taxes when 
it is more likely than not that a tax position will not be sustained on examination and 
settlement with various taxing authorities. During the year ended January 28, 2022, 
the Company has recorded additional unrecognized tax benefits of $12 million, 
resulting in a total liability of $78 million. 
Auditing these reserves was challenging due to the significant judgment in applying 
the tax law and inherent uncertainty involved in predicting the ultimate resolution of 
the matters with the taxing authority. Changes to the liability resulting from ongoing or 
future audits by the taxing authorities could have a material effect on the Company’s 
results of operations.
How We 
Addressed the 
Matter in Our 
Audit
We obtained an understanding, evaluated the design and tested the operating 
effectiveness of controls over the Company’s process of accounting for income taxes, 
including unrecognized tax benefits, during the year. For example, we tested 
management’s controls over the review of tax positions taken by the Company to 
determine whether they met the threshold for recognition within the consolidated 
financial statements, as well as determination of the measurement of the 
unrecognized tax liability.
To test the recognition of the Company’s unrecognized tax benefits and 
measurement of unrecognized tax benefits, we involved tax professionals with 
specialized skills and knowledge to assess the technical merits of the Company’s 
material tax positions. We performed audit procedures that included, among others, 
evaluating communications with relevant taxing authorities, evaluating whether 
management appropriately considered new information that could significantly 
change the recognition, measurement, or disclosure of the unrecognized tax benefits, 
and testing the assumptions used by management in estimating the valuation of any 
associated liability.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2018.
Tysons, Virginia
March 28, 2022
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
F-4

Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions, except per share amounts)
Revenues
$ 
7,394 $ 
7,056 $ 
6,379 
Cost of revenues
 
6,535  
6,264  
5,673 
Selling, general and administrative expenses
 
344  
352  
288 
Acquisition and integration costs
 
56  
54  
48 
Other operating income
 
(3)  
(4)  
— 
Operating income
 
462  
390  
370 
Interest expense
 
105  
122  
90 
Other (income) expense, net
 
(1)  
(3)  
(6) 
Income before income taxes
 
358  
271  
286 
Provision for income taxes
 
(79)  
(60)  
(57) 
Net income
$ 
279 $ 
211 $ 
229 
Net income attributable to non-controlling interest
 
2  
2  
3 
Net income attributable to common stockholders
$ 
277 $ 
209 $ 
226 
Earnings per share:
Basic
$ 
4.81 $ 
3.60 $ 
3.87 
Diluted
$ 
4.77 $ 
3.56 $ 
3.83 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
F-5

Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Net income
$ 
279 $ 
211 $ 
229 
Other comprehensive income (loss), net of tax:
Net unrealized gain (loss) on derivative instruments
 
48  
(19)  
(53) 
Defined benefit obligation adjustment
 
4  
2  
(5) 
Total other comprehensive income (loss), net of tax
 
52  
(17)  
(58) 
Comprehensive income
$ 
331 $ 
194 $ 
171 
Comprehensive income attributable to non-controlling interest
 
2  
2  
3 
Comprehensive income attributable to common stockholders
$ 
329 $ 
192 $ 
168 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
F-6

January 28,
2022
January 29,
2021
(in millions)
ASSETS
Current assets:
Cash and cash equivalents
$ 
106 $ 
171 
Receivables, net
 
1,015  
962 
Inventories, net
 
64  
78 
Prepaid expenses
 
57  
56 
Other current assets
 
21  
22 
Total current assets
 
1,263  
1,289 
Goodwill
 
2,913  
2,787 
Intangible assets, net
 
1,132  
1,138 
Property, plant, and equipment, net
 
100  
108 
Operating lease right of use assets
 
209  
236 
Other assets
 
129  
165 
Total assets
$ 
5,746 $ 
5,723 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable
$ 
612 $ 
517 
Accrued payroll and other employee benefits
 
227  
196 
Accrued vacation
 
137  
150 
Other accrued liabilities
 
228  
344 
Long-term debt, current portion
 
148  
68 
Total current liabilities
 
1,352  
1,275 
Long-term debt, net of current portion
 
2,370  
2,447 
Operating lease liabilities
 
192  
205 
Deferred income taxes
 
43  
2 
Other long-term liabilities
 
160  
242 
Commitments and contingencies (Note 17)
Equity:
Common stock, $0.0001 par value, 1 billion shares authorized, 56 million shares 
and 58 million shares issued and outstanding as of January 28, 2022 and 
January 29, 2021, respectively
 
—  
— 
Additional paid-in capital
 
838  
1,004 
Retained earnings
 
818  
627 
Accumulated other comprehensive loss
 
(37)  
(89) 
Total common stockholders' equity
 
1,619  
1,542 
Non-controlling interest
 
10  
10 
Total stockholders' equity
 
1,629  
1,552 
Total liabilities and stockholders' equity
$ 
5,746 $ 
5,723 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED BALANCE SHEETS
F-7

Shares of 
common 
stock
Additional 
paid-in 
capital
Retained
 earnings
Accumulated
 other
 comprehensive
 loss
Non-
controlling 
Interest
Total
(in millions)
Balance at February 1, 2019
 
60 $ 1,132 $ 367 $ 
(14) $ 
14 $ 1,499 
Net income
 
—  
—  
226  
—  
3  
229 
Issuances of stock
 
—  
12  
—  
—  
—  
12 
Other comprehensive loss, net of tax
 
—  
—  
—  
(58)  
—  
(58) 
Cash dividends of $1.48 per share
 
—  
—  
(87)  
—  
—  
(87) 
Stock-based compensation
 
—  
21  
—  
—  
—  
21 
Repurchases of stock
 
(2)  
(182)  
—  
—  
—  
(182) 
Distributions to non-controlling interest
 
—  
—  
—  
—  
(7)  
(7) 
Balance at January 31, 2020
 
58  
983  
506  
(72)  
10  
1,427 
Net income
 
—  
—  
209  
—  
2  
211 
Issuances of stock
 
—  
14  
—  
—  
—  
14 
Other comprehensive loss, net of tax
 
—  
—  
—  
(17)  
—  
(17) 
Cash dividends of $1.48 per share
 
—  
—  
(88)  
—  
—  
(88) 
Stock-based compensation
 
—  
30  
—  
—  
—  
30 
Repurchases of stock
 
—  
(23)  
—  
—  
—  
(23) 
Distributions to non-controlling interest
 
—  
—  
—  
—  
(2)  
(2) 
Balance at January 29, 2021
 
58  
1,004  
627  
(89)  
10  
1,552 
Net income
 
—  
—  
277  
—  
2  
279 
Issuances of stock
 
1  
16  
—  
—  
—  
16 
Other comprehensive income, net of tax
 
—  
—  
—  
52  
—  
52 
Cash dividends of $1.48 per share
 
—  
—  
(86)  
—  
—  
(86) 
Stock-based compensation
 
—  
32  
—  
—  
—  
32 
Repurchases of stock
 
(3)  
(214)  
—  
—  
—  
(214) 
Distributions to non-controlling interest
 
—  
—  
—  
—  
(2)  
(2) 
Balance at January 28, 2022
 
56 $ 
838 $ 818 $ 
(37) $ 
10 $ 1,629 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF EQUITY
F-8

Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Cash flows from operating activities:
Net income
$ 
279 
$ 
211 
$ 
229 
Adjustments to reconcile net income to net cash provided by operating 
activities:
Depreciation and amortization
 
165 
 
179 
 
131 
Amortization of off-market customer contracts
 
(33)  
(15)  
— 
Amortization of debt issuance costs
 
7 
 
21 
 
7 
Deferred income taxes
 
59 
 
12 
 
44 
Stock-based compensation expense
 
46 
 
42 
 
37 
(Gain) loss on divestitures
 
(2)  
10 
 
— 
Impairment of assets
 
18 
 
2 
 
5 
Increase (decrease) resulting from changes in operating assets and 
liabilities, net of the effect of the acquisitions:
Receivables
 
(31)  
221 
 
(50) 
Inventory, prepaid expenses, and other current assets
 
14 
 
8 
 
(10) 
Other assets
 
(3)  
(14)  
(34) 
Accounts payable and accrued liabilities
 
30 
 
(76)  
62 
Accrued payroll and employee benefits
 
10 
 
95 
 
3 
Operating lease assets and liabilities, net
 
5 
 
(5)  
(4) 
Other long-term liabilities
 
(46)  
64 
 
38 
Net cash provided by operating activities
 
518 
 
755 
 
458 
Cash flows from investing activities:
Expenditures for property, plant, and equipment
 
(36)  
(46)  
(21) 
Purchases of marketable securities
 
(9)  
(6)  
(24) 
Sales of marketable securities
 
6 
 
9 
 
3 
Cash paid for acquisitions, net of cash acquired
 
(255)  
(1,202)  
— 
Proceeds from divestitures
 
8 
 
17 
 
— 
Other
 
(6)  
(3)  
(5) 
Net cash used in investing activities
 
(292)  
(1,231)  
(47) 
Cash flows from financing activities:
Dividend payments to stockholders
 
(86)  
(87)  
(87) 
Principal payments on borrowings
 
(119)  
(399)  
(274) 
Issuances of stock
 
16 
 
13 
 
10 
Stock repurchased and retired or withheld for taxes on equity awards
 
(226)  
(34)  
(197) 
Proceeds from borrowings
 
116 
 
1,000 
 
100 
Debt issuance costs
 
— 
 
(27)  
— 
Distributions to non-controlling interest
 
(2)  
(2)  
(7) 
Net cash (used in) provided by financing activities
 
(301)  
464 
 
(455) 
Net decrease in cash, cash equivalents and restricted cash
 
(75)  
(12)  
(44) 
Cash, cash equivalents and restricted cash at beginning of period
 
190 
 
202 
 
246 
Cash, cash equivalents and restricted cash at end of period
$ 
115 
$ 
190 
$ 
202 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
F-9

Supplementary cash flow disclosure:
Cash paid for interest
$ 
98 
$ 
96 
$ 
86 
Cash paid for income taxes
$ 
7 
$ 
39 
$ 
32 
Non-cash investing and financing activities:
Increase (decrease) in accrued plan share repurchases
$ 
2 
$ 
1 
$ 
(1) 
(Decrease) increase in accrued property, plant, and equipment
$ 
(2) $ 
(1) $ 
3 
See accompanying notes to consolidated financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
F-10

Note 1—Business Overview and Summary of Significant Accounting Policies:
Overview
Description of Business. Science Applications International Corporation (collectively, with its consolidated 
subsidiaries, the “Company”) is a leading provider of technical, engineering and enterprise information technology 
(IT) services primarily to the U.S. government. The Company provides engineering and integration services for 
large, complex projects and offers a broad range of services with a targeted emphasis on higher-end, differentiated 
technology services. The Company is organized as a matrix comprised of two customer facing operating sectors 
supported by an enterprise solutions and operations organization. Each of the Company’s two customer facing 
operating sectors is focused on providing the Company’s comprehensive technical, engineering and enterprise IT 
service offerings to one or more agencies of the U.S federal government. The Company's operating sectors are 
aggregated into one reportable segment for financial reporting purposes, see Note 16.
Acquisitions. On July 2, 2021, the Company completed the acquisition of Halfaker and Associates, LLC (Halfaker), a 
mission focused, pure-play health IT company. On May 3, 2021, the Company completed the acquisition of 
Koverse, a software company that provides a data management platform enabling artificial intelligence and machine 
learning on complex sensitive data. On March 13, 2020, the Company completed the acquisition of Unisys Federal, 
a former operating unit of Unisys Corporation, which enhances our capabilities in government priority areas, 
expands our portfolio of intellectual property and technology-driven offerings, and increases our access to current 
and new customers. See Note 4 for additional information. 
Principles of Consolidation and Basis of Presentation
References to “financial statements” refer to the consolidated financial statements of the Company, which include 
the statements of income and comprehensive income, balance sheets, statements of equity and statements of cash 
flows. These financial statements were prepared in accordance with U.S. generally accepted accounting principles 
(GAAP). All intercompany transactions and account balances within the Company have been eliminated. Certain 
amounts in the prior year financial statements have been reclassified to conform to the current year presentation.
Non-controlling Interest.  The Company holds a 50.1% majority interest in Forfeiture Support Associates J.V. (FSA). 
The results of operations of FSA are included in the Company's consolidated statements of income and 
comprehensive income and statements of cash flows. The non-controlling interest reported on the consolidated 
balance sheets represents the portion of FSA’s equity that is attributable to the non-controlling interest.
Use of Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and 
assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date 
of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. 
Significant estimates inherent in the preparation of the financial statements may include, but are not limited to, 
estimated profitability of long-term contracts, income taxes, fair value measurements, fair value of goodwill and 
other intangible assets, pension and defined benefit plan obligations, and contingencies. Estimates have been 
prepared by management on the basis of the most current and best available information at the time of estimation 
and actual results could differ from those estimates.
Reporting Periods
The Company utilizes a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters 
typically consisting of 13 weeks. Fiscal 2022 began on January 30, 2021 and ended on January 28, 2022, fiscal 
2021 began on February 1, 2020 and ended on January 29, 2021, and fiscal 2020 began on February 2, 2019 and 
ended on January 31, 2020. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-11

Revenue Recognition
The Company provides technical, engineering and enterprise IT services under long-term service arrangements 
primarily with the U.S. government, including subcontracts with other contractors engaged in work for the U.S. 
government. The Company also serves a number of state and local governments, foreign governments and U.S. 
commercial customers. 
The Company provides services under various contract types, including firm-fixed price (FFP), time-and-materials 
(T&M), cost-plus-fixed-fee, cost-plus-award-fee and cost-plus-incentive-fee contracts. Our service arrangements 
typically involve an annual base period of performance followed by renewal option periods that upon exercise are 
generally accounted for as separate contracts.  
To determine the proper revenue recognition, the Company first evaluates whether we have a duly approved and 
enforceable contract with a customer, in which rights of parties and payment terms are identified and collectability is 
probable. We also evaluate whether two or more contracts should be combined and accounted for as a single 
contract and whether modifications to existing contracts should be accounted for as part of the original contract or 
as a separate contract. Contract modifications that create new enforceable rights and obligations are accounted for 
prospectively. Contract modifications that do not add distinct goods or services are accounted for through 
cumulative catch-up adjustments.
The Company recognizes revenue when, or as, we satisfy our performance obligations under a contract. A 
performance obligation is the unit of account for revenue recognition and refers to a promise in a contract to transfer 
a distinct service or good to the customer. The majority of the Company’s contracts contain a single performance 
obligation involving a significant integration of various activities that are performed together to deliver a combined 
service or solution. Performance obligations may be satisfied over time or at a point in time, but the majority of the 
Company’s performance obligations are satisfied over time. The Company selects the appropriate measure of 
progress for revenue recognition based on the nature of the performance obligation, contract type and other 
pertinent contract terms.
Over time performance obligations may involve a series of recurring services, such as network operations and 
maintenance, operation and program support services, IT outsourcing services, and other IT arrangements where 
the Company is standing ready to provide support, when-and-if needed. Such performance obligations are satisfied 
over time because the customer simultaneously receives and consumes the benefits of our performance as 
services are provided. Alternatively, over time performance obligations may involve the completion of a contract 
deliverable. Examples include systems integration, network engineering, network design, and engineering and build 
services. Deliverable-based performance obligations are satisfied over time when the Company’s performance 
creates or enhances an asset that is controlled by the customer, or when the Company’s performance creates an 
asset that is customized to the customer’s specifications and the Company has a right to payment, including profit, 
for work performed to date. 
For recurring services performance obligations, the Company measures progress using either a cost input measure 
(cost-to-cost), a time-elapsed output measure, or the as-invoiced practical expedient. A cost input measure typically 
is applied to the Company’s cost-reimbursable contracts. Revenue is recognized based on the ratio of costs 
incurred to total estimated costs at completion. Award or incentive fees are allocated to the distinct periods to which 
they relate. For fixed-price contracts, a time-elapsed output measure is applied to fixed consideration, such that 
revenue is recognized ratably over the period of performance. Where fixed-price contracts also provide for 
reimbursement of certain costs, such as travel or other direct costs, consideration may be attributed only to a 
distinct subset of time within the performance period. The Company’s time-and-material and fixed price-level of 
effort contracts generally qualify for the as-invoiced practical expedient. Revenue is recognized in the amount to 
which the Company has a contractual right to invoice. 
For deliverable-based performance obligations satisfied over time, the Company recognizes revenue using a cost 
input measure of progress (cost-to-cost), regardless of contract type. Revenue is recognized based on the ratio of 
costs incurred to total estimated costs at completion, except for certain contracts for which the costs associated with 
significant materials or hardware procurements are excluded from the measure of progress and revenue is 
recognized on an adjusted cost-to-cost basis.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-12

For performance obligations in which the Company does not transfer control over time, we recognize revenue at the 
point-in-time when the customer obtains control of the related asset, usually at the time of shipment or upon 
delivery. The Company accrues for shipping and handling costs occurring after the point-in-time control transfers to 
the customer. 
Recognizing revenue on long-term contracts involves significant estimates and judgments. The transaction price is 
the estimated amount of consideration we expect to receive for performance under our contracts. Contract terms 
may include variable consideration, such as reimbursable costs, award and incentive fees, usage-based fees, 
service-level penalties, performance bonuses, or other provisions that can either increase or decrease the 
transaction price. Variable amounts are generally determined upon our achievement of certain performance metrics, 
program milestones or cost targets and may be based upon customer discretion. When making our estimates, the 
Company considers the customer, contract terms, the complexity of the work and related risks, the extent of 
customer discretion, historical experience and the potential of a significant reversal of revenue. The Company 
includes variable consideration in the transaction price only to the extent it is probable that a significant reversal of 
cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is 
resolved.
Estimating costs at completion is complex due to the nature of the services being performed and the length of 
certain contracts. Contract costs generally include direct costs, such as labor, subcontract costs and materials, and 
indirect costs identifiable with or allocable to a specific contract. Management must make assumptions regarding 
the complexity of the work to be performed, the schedule and associated tasks, labor productivity and availability, 
increases in wages and prices of materials, execution by our subcontractors, overhead cost rates, and other 
variables. Contract costs incurred for U.S. government contracts, including indirect costs, are subject to audit and 
adjustment by the Defense Contract Audit Agency (DCAA).
The Company provides for anticipated losses on contracts with the U.S. government by recording an expense for 
the total expected loss during the period in which the losses are first determined.
For contracts with multiple performance obligations, the Company allocates transaction price to each performance 
obligation based on the relative standalone selling price of each distinct performance obligation within the contract. 
Since the Company typically provides customized services and solutions that are specific to a single customer’s 
requirements, standalone selling price is most often estimated based on expected costs plus a reasonable profit 
margin.
Changes in Estimates on Contracts
Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time 
are recognized in operating income in the period in which such changes are made for the inception-to-date effect of 
the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, 
which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of 
risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award 
fees; and performance being better or worse than previously estimated. 
Many of the Company's contracts recognize revenue on performance obligations using a cost input measure (cost-
to-cost), which requires estimates of total costs at completion. In cases when total expected costs exceed total 
estimated revenues for a performance obligation, the Company recognizes the total estimated loss in the quarter 
identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they 
increase the amount of the loss.
Contract Balances
The timing of revenue recognition may differ from the timing of billing and cash receipts from customers. Amounts 
are invoiced as work progresses, typically biweekly or monthly in arrears, or upon achievement of contractual 
milestones. We record a contract asset when revenue is recognized prior to invoicing, or a contract liability when 
cash is received in advance of recognizing revenue. A contract asset is a right to consideration that is conditional 
upon factors other than the passage of time. Contract assets include unbillable receivables and contract retentions, 
but exclude billed and billable receivables. Billed and billable receivables are rights to consideration, which are 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-13

unconditional other than to the passage of time. Contract liabilities include customer advances, billings in excess of 
revenues and deferred revenue. Contract assets and liabilities are recorded net on a contract-by-contract basis and 
are generally classified as current based on our contract operating cycle. Deferred revenue attributable to long-term 
contract material renewal options may be classified as non-current when the option renewal period will not occur 
within one year of the balance sheet date.
Deferred Costs
Certain eligible costs, such as costs to obtain and costs to fulfill our service contracts, are capitalized when the 
costs relate directly to the contract, are expected to be recovered, and generate or enhance resources to be used in 
satisfying the performance obligation. These costs primarily consist of commissions, transition and set-up costs. 
Capitalized costs to obtain and fulfill a contract are amortized on a straight-line basis over the expected period of 
benefit, which generally includes the contract base period and anticipated renewals. 
The Company performs periodic reviews to assess the recoverability of deferred contract transition and setup costs. 
The carrying amount of the asset is compared to the remaining amount of consideration the Company expects to 
receive for the services to which the asset relates, less the costs that relate directly to providing those services that 
have not yet been recognized. If the carrying amount is not recoverable, an impairment loss is recognized.
Costs Allocated to Contracts
The Company classifies indirect costs as overhead (included in cost of revenues) or general and administrative 
expenses in the same manner as such costs are defined in the Company’s Disclosure Statements under U.S. 
government Cost Accounting Standards (CAS).
Stock-based Compensation
The Company issues stock-based awards as compensation to employees and directors. Stock-based awards 
include stock options, vesting stock awards and performance share awards. These awards are accounted for as 
equity awards. The Company recognizes stock-based compensation expense net of estimated forfeitures on a 
straight-line basis over the underlying award’s requisite service period, as measured using the award’s grant date 
fair value. For performance share awards, the Company reassesses the probability of achieving the performance 
conditions at each reporting period end and adjusts compensation expense based on the number of shares the 
Company expects to ultimately issue. 
Income Taxes
The Company accounts for income taxes under the asset and liability method of accounting, which requires the 
recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences 
between the carrying amounts and the tax bases of assets and liabilities. Under this method, changes in tax rates 
and laws are recognized in income in the period such changes are enacted. The provision for federal, state, local 
and foreign income taxes is calculated on income before income taxes based on current tax law and includes the 
cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and 
liabilities. Such provision differs from the amounts currently payable because certain items of income and expense 
are recognized in different reporting periods for financial reporting purposes than for income tax purposes. 
Recording the provision for income taxes requires management to make significant judgments and estimates for 
matters for which the ultimate resolution may not become known until the final resolution of an examination by 
taxing authorities or the statute of limitations lapses. Additionally, recording liabilities for uncertainty in income taxes 
involves significant judgment in evaluating the Company’s tax positions and developing the best estimate of the 
taxes ultimately expected to be paid. Tax penalties and interest are included in income tax expense.
The Company records net deferred tax assets to the extent these assets will more likely than not be realized. In 
making such determination, the Company considers all available positive and negative evidence, including future 
reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and 
recent results of operations. If it is determined that the Company would be able to realize the deferred income tax 
assets in the future in excess of their net recorded amount or would no longer be able to realize the deferred income 
tax assets in the future as currently recorded, an adjustment would be made to the valuation allowance, which 
would decrease or increase the provision for income taxes.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-14

The Company has also recognized liabilities for uncertainty in income taxes when it is more likely than not that a tax 
position will not be sustained on examination and settlement with various taxing authorities. Liabilities for uncertainty 
in income taxes are measured based on the largest amount of benefit that is greater than 50% likely of being 
realized upon ultimate settlement. Deferred tax assets and liabilities are netted by taxable jurisdiction and classified 
as noncurrent on the consolidated balance sheets.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents are comprised of cash in banks and highly liquid instruments, which primarily consist of 
bank deposits and investments in institutional money market funds. The Company includes outstanding payments 
within cash and cash equivalents and accounts payable on the consolidated balance sheets and as of January 28, 
2022 and January 29, 2021 these amounts were $54 million and $25 million, respectively. The Company does not 
invest in high yield or high risk securities. The cash in bank accounts at times may exceed federally insured limits.
Restricted cash consists of cash on deposit in rabbi trusts that are contractually restricted from use in operations, 
but are subject to future claims of creditors. Restricted cash will be used primarily to fund future payment obligations 
related to deferred compensation plans and our voluntary disability insurance plan in California. The following table 
provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the consolidated 
balance sheets for the periods presented: 
 
January 28, 
2022
January 29, 
2021
 
(in millions)
Cash and cash equivalents
$ 
106 $ 
171 
Restricted cash included in other current assets
 
5  
5 
Restricted cash included in other assets
 
4  
14 
Cash, cash equivalents and restricted cash
$ 
115 $ 
190 
Receivables
Receivables include billed and billable receivables, and unbilled receivables. The Company’s receivables are 
primarily due from the U.S. government, or from prime contractors on which we are subcontractors and the end 
customer is the U.S. government, and are generally considered collectable from the perspective of the customer’s 
ability to pay. The Company does not have a material credit risk exposure.
Unbilled receivables, substantially all of which are expected to be billed and collected within one year, are stated at 
their estimated realizable value and consist of costs and fees billable on contract completion or the occurrence of a 
specified event, other than the passage of time. Legal title to the related accumulated costs of contracts in progress 
generally vests with the U.S. government on the Company’s receipt of progress payments. Progress payments 
received of $76 million and $28 million offset unbilled receivables as of January 28, 2022 and January 29, 2021, 
respectively. Contract retentions are billed when contract conditions have been met and may relate to uncompleted 
indirect cost negotiations with the U.S. government. Based on historical experience, the majority of retention 
balances are expected to be collected beyond one year. Retention is presented in other assets on the consolidated 
balance sheets, see Note 3. Write-offs of retention balances have not been significant. 
Receivable balances are written-off in the period during which management determines they are uncollectable, and, 
at that time, such balances are removed from billed receivables and, if previously reserved, from the allowance.
Inventory
Inventory is substantially comprised of finished goods inventory purchased for resale to customers, such as tires 
and lubricants, and is valued at the lower of cost or net realizable value, generally using the average method. The 
Company evaluates current inventory against historical and planned usage to estimate the appropriate provision for 
obsolete inventory.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-15

Business Combinations
The Company records all tangible and intangible assets acquired and liabilities assumed in a business combination 
at fair value as of the acquisition date, which is determined using a cost, market or income approach. The excess 
amount of the aggregated purchase consideration paid over the fair value of the net of assets acquired and liabilities 
assumed is recorded as goodwill. Acquisition date fair value represents the price that would be received to sell an 
asset or paid to transfer a liability in an orderly transaction between market participants as measured on the 
acquisition date.
The valuations are based on information that existed as of the acquisition date. During the measurement period that 
shall not exceed one year from the acquisition date, the Company may adjust provisional amounts recorded for 
assets acquired and liabilities assumed to reflect new information that the Company has subsequently obtained 
regarding facts and circumstances that existed as of the acquisition date.
Acquisition and Integration Costs
Acquisition-related costs that are not part of the purchase price consideration are generally expensed as incurred, 
except for certain costs that are deferred in connection with the issuance of debt. These costs typically include 
transaction-related costs, such as finder’s fees, legal, accounting and other professional costs. Integration-related 
costs represent costs directly related to combining the Company and its acquired businesses. Integration-related 
costs typically include strategic consulting services, facility consolidation, employee related costs, such as retention 
and severance, costs to integrate information technology infrastructure, enterprise planning systems, processes, 
and other non-recurring integration-related costs. Acquisition and integration costs are presented together as 
acquisition and integration costs on the consolidated statements of income.
The amounts recognized in acquisition and integration costs on the consolidated statements of income are as 
follows:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Acquisition(1)
$ 
3 $ 
20 $ 
2 
Integration(2)(3)
 
53  
34  
46 
Total acquisition and integration costs
$ 
56 $ 
54 $ 
48 
(1) Acquisition expenses recognized for fiscal 2022 were related to the acquisitions of Halfaker and Koverse. Acquisition 
expenses recognized for fiscal 2021 and 2020 were related to the acquisition of Unisys Federal. See Note 4 for additional 
information related to the acquisitions.  
(2) Integration expenses for fiscal 2021 include an $11 million loss associated with the sale of certain non-strategic international 
operations.
(3) Integration expenses include $6 million and $16 million of restructuring costs for fiscal 2021 and 2020, respectively, and 
$17 million, $1 million and $5 million for the impairment of assets for fiscal 2022, 2021 and 2020, respectively. See Note 5 
for additional information related to restructuring costs and impairments.
Goodwill and Intangible Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the 
fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill and indefinite-lived 
intangible assets are not amortized, but rather are tested for potential impairment annually at the beginning of the 
Company's fourth quarter, or whenever events or changes in circumstances indicate that the carrying value may not 
be recoverable. There were no impairments during the periods presented.
The goodwill impairment test is performed at the reporting unit level. The Company estimates and compares the fair 
value of each reporting unit to its respective carrying value including goodwill. The fair value of the Company’s 
reporting units are determined using either a market approach, income approach, or a combination of both, which 
involves the use of estimates and assumptions, including projected future operating results and cash flows, the cost 
of capital, and financial measures derived from observable market data of comparable public companies. If the fair 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-16

value is less than the carrying value, the amount of impairment expense is equal to the difference between the 
reporting unit’s fair value and the reporting unit’s carrying value.
Intangible assets with finite lives are amortized using the method that best reflects how their economic benefits are 
utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their 
estimated useful lives. Intangible assets with finite lives are assessed for impairment whenever events or changes 
in circumstances indicate that the carrying value may not be recoverable.
Impairment of Long-lived Assets
The Company evaluates its long-lived assets for potential impairment whenever there is evidence that events or 
changes in circumstances indicate that the carrying value may not be recoverable and the carrying amount of the 
asset exceeds its estimated future undiscounted cash flows. When the carrying amount of the asset exceeds its 
estimated future undiscounted cash flows, an impairment loss is recognized to reduce the asset’s carrying amount 
to its estimated fair value based on the present value of its estimated future cash flows.
In circumstances in which the Company has the ability and intent to sublease an exited facility, the Company 
performs an impairment test of the asset group (mainly consisting of right of use lease assets and leasehold 
improvements) on the earlier of the cease use date or sublease inception date by comparing the carrying amount of 
the asset group to the undiscounted cash flows associated with the asset group (mainly sublease income). When 
the carrying amount of the asset group exceeds its estimated future undiscounted cash flows, an impairment loss is 
recognized to reduce the asset group’s carrying amount to its estimated fair value based on the present value of 
estimated future cash flows. In circumstances in which the Company does not have the ability or intent to sublease 
an exited facility, the Company adjusts the estimated useful life of the facility related assets to end on the cease use 
date and recognizes accelerated depreciation and amortization.
Commitments and Contingencies
Accruals for commitments and loss contingencies are recorded when it is both probable that they will occur and the 
amounts can be reasonably estimated. In addition, legal fees are accrued for cases where a loss is probable and 
the related fees can be reasonably estimated. Significant judgment is required to determine both the probability and 
the estimated amount of loss. The Company reviews these accruals quarterly and adjusts the accruals to reflect the 
impact of negotiations, settlements, rulings, advice of legal counsel and other updated information.
Pension and Defined Benefit Plans
The Company measures plan assets and benefit obligations as of the month-end that is closest to its fiscal year-
end. Accounting and reporting for the Company's pension and defined benefit plans requires the use of 
assumptions, including but not limited to, a discount rate and an expected return on assets. These assumptions are 
reviewed at least annually based on reviews of current plan information and consultation with the Company's 
independent actuary and the plans’ investment advisor. If these assumptions differ materially from actual results, the 
Company's obligations under the pension and defined benefit plans could also differ materially, potentially requiring 
the Company to record an additional liability. The Company's pension and defined benefit plan liabilities are 
developed from actuarial valuations performed each year.
Fair Value Measurements
The Company utilizes fair value measurement guidance prescribed by GAAP to value its financial instruments. The 
accounting standard for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the 
inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); 
inputs other than the quoted prices in active markets that are observable either directly or indirectly (Level 2); and 
unobservable inputs in which there is little or no market data, which requires the Company to develop its own 
assumptions (Level 3).
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-17

The carrying amounts of cash and cash equivalents, receivables, accounts payable and other amounts included in 
other current assets and current liabilities that meet the definition of a financial instrument approximate fair value 
due to the short-term nature of these amounts. The carrying value of the Company’s outstanding debt obligations 
approximates its fair value, which is calculated using Level 2 inputs, based on interest rates available for debt with 
terms and maturities similar to the Company’s existing debt arrangements.
Non-financial assets acquired and liabilities assumed in a business combination were measured at fair value using 
income, market and cost valuation methodologies. See Note 4 for additional information. The fair value 
measurements were estimated using significant inputs that are not observable in the market and thus represent a 
Level 3 measurement.
Marketable Securities
Investments in marketable securities consist of equity securities, which are recorded at fair value using observable 
inputs such as quoted prices in active markets (Level 1). As of January 28, 2022 and January 29, 2021, the fair 
value of our investments total $28 million and $27 million, respectively, and was included in other assets on the 
consolidated balance sheets. The Company's investments are primarily held in a custodial account, which includes 
investments to fund our deferred compensation plan liabilities.
Derivative Instruments Designated as Cash Flow Hedges
Derivative instruments are recorded on the consolidated balance sheets at fair value. Unrealized gains and losses 
on derivatives designated as cash flow hedges are reported in other comprehensive income (loss) and reclassified 
to earnings in a manner that matches the timing of the earnings impact of the hedged transactions.
The Company’s fixed interest rate swaps are considered over-the-counter derivatives, and their fair value is 
calculated using a standard pricing model for interest rate swaps with contractual terms for maturities, amortization 
and interest rates. Level 2, or market observable inputs (such as yield and credit curves), are used within the 
standard pricing models in order to determine fair value. The fair value is an estimate of the amount that the 
Company would pay or receive as of a measurement date if the agreements were transferred to a third party or 
canceled. See Note 12 for further discussion on the Company’s derivative instruments designated as cash flow 
hedges.
Operating Cycle
The Company’s operating cycle may be greater than one year and is measured by the average time intervening 
between the inception and the completion of contracts. 
Research and Development
The Company conducts research and development activities under customer-funded contracts and with company-
funded independent research and development (IR&D) funds. IR&D efforts consist of projects involving basic 
research, applied research, development, and systems and other concept formulation studies. Company-funded 
IR&D expense is included in selling, general and administrative expenses (SG&A) and was $4 million, $6 million 
and $7 million in fiscal 2022, 2021 and 2020, respectively. Customer-funded research and development activities 
performed under customer contracts are charged directly to cost of revenues for those particular contracts.
Accounting Standards Updates
In October 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 
No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from 
Contracts with Customers, which requires contract assets and contract liabilities acquired in a business combination 
to be recognized and measured at the acquisition date in accordance with Topic 606 as if the acquirer had 
originated the contracts. ASU 2021-08 becomes effective for the Company in the first quarter of fiscal 2024 and is 
required to be adopted on a prospective basis with early adoption permitted. The Company is currently evaluating 
the impact of the adoption of this standard on its financial statements.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-18

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects 
of Reference Rate Reform on Financial Reporting. This standard provides optional expedients and exceptions for 
applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank 
Offered Rate (LIBOR) or other reference rates expected to be discontinued due to reference rate reform. The 
Company adopted this standard on a prospective basis in the fourth quarter of fiscal 2021, and the adoption did not 
have a material impact on the Company’s financial statements. The Company’s credit facility, derivative instruments 
and Master Accounts Receivable Purchase Agreement (MARPA Facility) reference LIBOR-based rates. Although 
the Company does not expect the transition from LIBOR to have a material impact on its financial statements, it will 
continue to monitor the impact until transition is completed.
Other Accounting Standards Updates effective after January 28, 2022 are not expected to have a material effect on 
the Company’s financial statements.
Note 2—Earnings Per Share, Share Repurchases and Dividends:
Earnings Per Share (EPS)
Basic EPS is computed by dividing net income attributable to common stockholders by the basic weighted-average 
number of shares outstanding. Diluted EPS is computed similarly to basic EPS, except the weighted-average 
number of shares outstanding is increased to include the dilutive effect of outstanding stock options and other stock-
based awards.
A reconciliation of the weighted-average number of shares outstanding used to compute basic and diluted EPS was:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Basic weighted-average number of shares outstanding
 
57.6  
58.1  
58.4 
Dilutive common share equivalents - stock options and other stock-
based awards
 
0.5  
0.6  
0.6 
Diluted weighted-average number of shares outstanding
 
58.1  
58.7  
59.0 
 The following antidilutive stock-based awards were excluded from the weighted-average number of shares 
outstanding used to compute diluted EPS:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Antidilutive stock options excluded
 
—  
0.3  
0.3 
Share Repurchases
The Company may repurchase shares in accordance with established repurchase plans. The Company retires its 
common stock upon repurchase with the excess over par value allocated to additional paid-in capital. The Company 
has not made any material purchases of common stock other than in connection with established share repurchase 
plans. On March 27, 2019, the number of shares of our common stock that may be repurchased under our existing 
repurchase plan was increased by approximately 4.6 million shares, bringing the total authorized shares to be 
repurchased under the plan to approximately 16.4 million shares. As of January 28, 2022, the Company has 
repurchased approximately 14.4 million shares of common stock under the plan. 
Dividends
The Company declared and paid quarterly dividends of $0.37 per share every quarter for the years presented. Total 
dividends declared and paid were $1.48 per share during fiscal 2022, 2021 and 2020.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-19

Subsequent to the end of fiscal 2022, on March 23, 2022, the Company’s Board of Directors declared a cash 
dividend of $0.37 per share of the Company’s common stock payable on April 29, 2022 to stockholders of record on 
April 14, 2022.
Note 3—Revenues:
Changes in Estimates on Contracts
Aggregate net changes in estimates on contracts accounted for using the cost-to-cost method of accounting were 
recognized in operating income as follows:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions, except per share amounts)
Favorable adjustments
$ 
40 $ 
41 $ 
39 
Unfavorable adjustments
 
(27)  
(32)  
(17) 
Net favorable adjustments
 
13  
9  
22 
Income tax effect
 
(3)  
(2)  
(4) 
Net favorable adjustments, after tax
 
10  
7  
18 
Basic EPS impact
$ 
0.17 $ 
0.12 $ 
0.31 
Diluted EPS impact
$ 
0.17 $ 
0.12 $ 
0.31 
Revenues were $21 million, $21 million and $23 million higher for fiscal 2022, 2021 and 2020, respectively, due to 
net revenue recognized from performance obligations satisfied in prior periods. 
Disaggregation of Revenues
The Company's revenues are generated primarily from long-term contracts with the U.S. government including 
subcontracts with other contractors engaged in work for the U.S. government. The Company disaggregates 
revenues by customer, contract-type and prime vs. subcontractor to the federal government.  
Disaggregated revenues by customer were as follows:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Department of Defense
$ 
3,578 $ 
3,292 $ 
3,330 
Other federal government agencies
 
3,671  
3,611  
2,920 
Commercial, state and local
 
145  
153  
129 
Total
$ 
7,394 $ 
7,056 $ 
6,379 
Disaggregated revenues by contract-type were as follows:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Cost reimbursement
$ 
4,020 $ 
3,773 $ 
3,644 
Time and materials (T&M)
 
1,473  
1,557  
1,280 
Firm-fixed price (FFP)
 
1,901  
1,726  
1,455 
Total
$ 
7,394 $ 
7,056 $ 
6,379 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-20

Disaggregated revenues by prime vs. subcontractor were as follows:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Prime contractor to federal government
$ 
6,683 $ 
6,337 $ 
5,662 
Subcontractor to federal government
 
566  
566  
588 
Other
 
145  
153  
129 
Total
$ 
7,394 $ 
7,056 $ 
6,379 
Contract Balances
Contract balances for the periods presented were as follows:
Balance Sheet line item
January 28,
2022
January 29,
2021
 
(in millions)
Billed and billable receivables, net(1)
Receivables, net
$ 
615 $ 
600 
Contract assets - unbillable receivables
Receivables, net
 
400  
362 
Contract assets - contract retentions
Other assets
 
17  
18 
Contract liabilities - current
Other accrued liabilities
 
55  
82 
Contract liabilities - non-current
Other long-term liabilities
$ 
9 $ 
17 
(1) 
Net of allowance of $4 million and $3 million as of January 28, 2022 and January 29, 2021, respectively. 
The changes in the Company's contract assets and contract liabilities during the current period primarily result from 
timing differences between the Company's performance, invoicing and customer payments. During fiscal 2022 and 
2021, the Company recognized revenues of $75 million and $30 million relating to amounts that were included in 
the opening balance of contract liabilities as of January 29, 2021 and January 31, 2020, respectively. 
Deferred Costs
Deferred costs for the periods presented were as follows:
 
Balance Sheet line item
January 28,
2022
January 29,
2021
 
(in millions)
Pre-contract costs
Other current assets
$ 
4 $ 
2 
Fulfillment costs - non-current
Other assets
 
16  
15 
Costs to obtain
Other assets
$ 
3 $ 
— 
Pre-contract costs of $4 million and $8 million were expensed during fiscal 2022 and 2021, respectively. Fulfillment 
costs of $6 million and $4 million were amortized during fiscal 2022 and 2021, respectively. Costs to obtain of $1 
million were amortized during fiscal 2022 and were not material for fiscal 2021. 
Remaining Performance Obligations
As of January 28, 2022, the Company had $5.3 billion of remaining performance obligations. Remaining 
performance obligations exclude any variable consideration that is allocated entirely to unsatisfied performance 
obligations on our supply chain contracts. The Company expects to recognize revenue on approximately 85% of the 
remaining performance obligations over the next 12 months and approximately 95% over the next 24 months, with 
the remaining recognized thereafter.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-21

Note 4—Acquisitions:
Halfaker
On July 2, 2021, the Company completed the acquisition of Halfaker, a mission focused, pure-play health IT 
company for a preliminary purchase price of $228 million, net of $3 million cash acquired, subject to post-closing 
adjustments. The Company funded the transaction from increased borrowings (as discussed in Note 11) and cash 
on hand. The allocation of the preliminary purchase price resulted in goodwill of $106 million and intangible assets 
of $112 million, both of which are deductible for income tax purposes. During fiscal 2022, the Company increased 
goodwill by $14 million, which consisted of $11 million in estimated fair value adjustments to certain acquired 
assets, and a $3 million increase resulting from finalization of net working capital adjustments. The recognized 
goodwill is primarily associated with future customer relationships and an acquired assembled work force. The 
intangible assets consist of customer relationships of $95 million and backlog of $17 million that will be amortized 
over a period of nine years and one year, respectively. As of January 28, 2022, the Company has not yet finalized 
the determination of fair values allocated to the acquired assets and liabilities, including but not limited to the 
valuation of acquired intangible assets. The Company made additional cash payments of $21 million in March 2022 
associated with certain change in control provisions that are recognized as post-combination expense.
Koverse
On May 3, 2021, the Company acquired Koverse, a software company that provides a data management platform 
enabling artificial intelligence and machine learning on complex sensitive data, for a purchase price of $30 million, 
net of $2 million cash acquired. The purchase price includes $3 million of contingent consideration, representing the 
acquisition date fair value recognized for up to $27 million gross of potential future earnout payments based on the 
achievement of certain revenue targets over the next four years. The allocation of the purchase price has been 
finalized by the Company and resulted in goodwill of $21 million and intangible assets of $10 million, which are both 
not deductible for income tax purposes. The goodwill is primarily associated with intellectual capital, future customer 
relationships, and an acquired assembled work force. The intangible assets, which primarily consist of developed 
technology, are being amortized over a weighted average period of seven years. The Company is recognizing an 
additional $13 million in post-combination compensation expense over the next two years associated with employee 
retention agreements.
Unisys Federal
On March 13, 2020, the Company completed the acquisition of Unisys Federal, a former operating unit of Unisys 
Corporation. Unisys Federal provides infrastructure modernization, cloud migration, managed services, and 
enterprise IT-as-a-service solutions to U.S. federal civilian agencies and the Department of Defense. The Company 
purchased substantially all of the assets and liabilities of Unisys Federal for an aggregate purchase price of 
$1.2 billion. The Company used the net proceeds from its offering of Senior Notes and borrowings under the Term 
Loan B2 Facility, proceeds from the sale of receivables under its MARPA Facility, and cash on its balance sheet to 
finance the acquisition and pay related fees and expenses. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-22

The Company completed the purchase accounting valuation for this transaction in fiscal 2021 and recorded final 
purchase accounting entries as follows: 
(in millions)
Receivables
$ 
114 
Prepaid expenses
 
15 
Goodwill
 
654 
Intangible assets
 
574 
Property, plant, and equipment
 
4 
Operating lease right of use assets
 
43 
Other assets
 
7 
Total assets acquired
 
1,411 
Accounts payable
 
42 
Accrued vacation
 
7 
Other accrued liabilities
 
62 
Operating lease liabilities
 
30 
Other long-term liabilities
 
68 
Total liabilities assumed
 
209 
Net assets acquired
$ 
1,202 
Amount of tax deductible goodwill
$ 
593 
Goodwill resulting from the acquisition of Unisys Federal was primarily associated with intellectual capital, an 
acquired assembled work force, and future customer relationships. The identifiable intangible assets and a portion 
of the goodwill acquired by the Company are amortizable for tax purposes.
The following table summarizes the fair value of intangible assets and the related weighted-average useful lives as 
of the acquisition date:
Amount
Weighted-Average Amortization Period
(in millions)
(in years)
Customer relationships
$ 
520 
13
Backlog
 
47 
1
Developed technology
 
7 
1
Total intangible assets
$ 
574 
12
The backlog intangible asset is comprised solely of funded backlog as of the acquisition date. The customer 
relationships intangible asset consists of unfunded backlog as of the acquisition date and estimated future renewals 
and recompetes. The backlog and customer relationships intangible assets were valued using the excess earnings 
method (income approach) in which the value is derived from an estimation of the after-tax cash flows specifically 
attributable to the intangible asset being valued. The analysis included assumptions for projections of revenues and 
expenses, tax rates, contributory asset charges, discount rates, and a tax amortization benefit.
The developed technology asset was valued using the relief from royalty method (income approach) in which the 
value is derived by estimation of the after-tax royalty savings attributable to owning the developed technology asset. 
Assumptions in this analysis included projections of revenues, royalty rates representing costs avoided due to 
ownership of the developed technology asset, discount rates, a tax amortization benefit, and future obsolescence of 
the technology.
The Company recorded a $67 million provision for certain off-market customer contracts whose terms were 
unfavorable compared to the current market terms as of the acquisition date. An income approach was used to 
estimate fair value, involving estimates for future costs to complete the remaining performance under the contract 
as well as a market participant profit rate of return. The provision for off-market customer contracts is included in 
other long-term liabilities and is being amortized over the remaining contractual terms as an increase to revenue. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-23

During fiscal 2022, the Company accelerated the amortization for certain off-market customer contracts as a result 
of a change in the expected contractual terms which resulted in additional amortization of $15 million during fiscal 
2022. Amortization for the next three fiscal years is expected to be as follows: $9 million in fiscal 2023, $8 million in 
fiscal 2024 and $2 million in fiscal 2025.
The Company incurred $49 million in acquisition-related costs associated with the acquisition of Unisys Federal, 
including $27 million of debt issue costs (as discussed in Note 11).
The amount of Unisys Federal's revenue and net income attributable to common stockholders included in the 
consolidated statements of income for fiscal 2021 was $669 million and $62 million, respectively.
The following unaudited pro forma financial information presents the combined results of operations for Unisys 
Federal and the Company for the twelve months ended January 29, 2021 and January 31, 2020, respectively: 
Year Ended
January 29,
2021
January 31,
2020
(in millions)
Revenues
$ 
7,146 $ 
7,105 
Net income attributable to common stockholders
$ 
258 $ 
193 
The unaudited pro forma combined financial information presented above has been prepared from historical 
financial statements that have been adjusted to give effect to the acquisition of Unisys Federal as though it had 
occurred on February 2, 2019. They include adjustments for intangible asset amortization; interest expense and 
debt issuance costs on long-term debt; acquisition and other transaction costs; and certain costs allocated from the 
former parent. The unaudited pro forma financial information is not intended to reflect the actual results of 
operations that would have occurred if the acquisition had occurred on February 2, 2019, nor is it indicative of future 
operating results.
Note 5—Restructuring and Impairment:
Restructuring and impairment costs recognized were as follows:
Year Ended
Statement of Income line item
January 
28, 2022
January 
29, 2021
January 
31, 2020
(in millions)
2022 Restructuring:
Other associated costs
SG&A
$ 
1 $ 
— $ 
— 
2021 Restructuring:
Severance and other employee costs
SG&A
 
—  
4  
— 
2019 Restructuring:
Severance and other employee costs
Acquisition and integration costs
 
—  
2  
9 
Other associated costs
Acquisition and integration costs
 
—  
4  
7 
Total restructuring costs
 
1  
10  
16 
Impairment of assets
SG&A
 
1  
1  
— 
Impairment of assets
Acquisition and integration costs
 
17  
1  
5 
Total impairment of assets
 
18  
2  
5 
Total restructuring costs and impairment
$ 
19 $ 
12 $ 
21 
In fiscal 2022, the Company initiated and completed restructuring activities (the “2022 Restructuring”) associated 
with the optimization and consolidation of certain facilities. The 2022 Restructuring included total restructuring costs 
of $1 million which were fully paid as of January 28, 2022. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-24

In fiscal 2021, the Company initiated and completed restructuring activities (the "2021 Restructuring") associated 
with an internal reorganization. As of January 29, 2021, the remaining liability associated with this restructuring was 
$4 million. During fiscal 2022, the Company made cash payments to fully settle this liability.
In fiscal 2019, the Company initiated restructuring activities (the "2019 Restructuring") to realize cost synergies from 
the integration of Engility Holdings, Inc. (collectively with its consolidated subsidiaries, "Engility," which we acquired 
on January 14, 2019), which included employee termination costs and other costs associated with the optimization 
and consolidation of facilities. The 2019 Restructuring included total restructuring costs of $51 million, comprised of 
$40 million for severance and other employee costs and $11 million of other associated costs, such as contract 
terminations and costs incurred for facility consolidation. Cash paid for severance and other employee costs was $3 
million and $12 million during fiscal 2021 and 2020, respectively. Cash paid for other associated costs was $4 
million and $7 million during fiscal 2021 and 2020, respectively. The 2019 Restructuring was completed in fiscal 
2021 and there was no remaining liability associated with this restructuring as of January 28, 2022 and January 29, 
2021.
During fiscal 2022, 2021 and 2020, the Company recognized impairment charges for certain assets associated with 
exited facilities of $18 million, $2 million and $5 million, respectively.
Note 6—Goodwill and Intangible Assets:
Goodwill
Goodwill had a carrying value of $2,913 million and $2,787 million as of January 28, 2022 and January 29, 2021, 
respectively. Goodwill increased by $126 million during fiscal 2022, primarily due to the acquisitions of Halfaker 
($106 million) and Koverse ($21 million) as discussed in Note 4. There were no impairments of goodwill during the 
periods presented.
Intangible Assets
Intangible assets, all of which were finite-lived, consisted of the following:
January 28, 2022
January 29, 2021
Gross carrying 
value
Accumulated 
amortization
Net carrying 
value
Gross carrying 
value
Accumulated 
amortization
Net carrying 
value
(in millions)
Customer relationships
$ 
1,467 $ 
(351) $ 
1,116 $ 
1,371 $ 
(241) $ 
1,130 
Backlog
 
17  
(10)  
7  
47  
(41)  
6 
Developed technology
 
10  
(2)  
8  
9  
(7)  
2 
Trade name
 
1  
—  
1  
—  
—  
— 
Total intangible assets
$ 
1,495 $ 
(363) $ 
1,132 $ 
1,427 $ 
(289) $ 
1,138 
Amortization expense related to intangible assets was $128 million, $147 million and $95 million for fiscal 2022, 
2021 and 2020, respectively. There were no impairments of intangible assets during the periods presented. 
Intangible assets with a gross carrying value of $54 million became fully amortized during fiscal 2022 and are no 
longer reflected in the gross carrying value and accumulated amortization as of January 28, 2022. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-25

As of January 28, 2022, the estimated future annual amortization expense related to intangible assets is as follows:
Fiscal Year
(in millions)
2023
$ 
125 
2024
 
115 
2025
 
115 
2026
 
115 
2027
 
114 
Thereafter
 
548 
Total
$ 
1,132 
Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, 
divestitures, impairments and other factors.
Note 7—Property, Plant, and Equipment:
Property, plant, and equipment are carried at cost net of accumulated depreciation and amortization. Purchases of 
property, plant, and equipment, as well as costs associated with major renewals and betterments, are capitalized. 
Maintenance, repairs and minor renewals and betterments are expensed as incurred. When assets are sold or 
otherwise disposed of, the cost and related accumulated depreciation or amortization are removed and any 
resulting gain or loss is recognized. 
Depreciation and amortization is recognized using the methods and estimated useful lives as follows: 
Depreciation or
amortization method
Estimated useful 
lives (in years)
January 28,
2022
January 29,
2021
(in millions)
Computer equipment
Straight-line or
declining balance
3-10
$ 
97 $ 
90 
Capitalized software and software licenses
Straight-line or
declining balance
3-10
 
47  
45 
Leasehold improvements
Straight-line
Shorter of lease 
term or 10
 
94  
92 
Office furniture and fixtures
Straight-line or
declining balance
3-10
 
20  
17 
Buildings and improvements
Straight-line
40
 
7  
7 
Construction in process
 
16  
14 
Land
 
1  
1 
Property, plant, and equipment
 
282  
266 
Accumulated depreciation and amortization
 
(182)  
(158) 
Property, plant, and equipment, net
$ 
100 $ 
108 
Depreciation and amortization expense for property, plant, and equipment was $37 million, $32 million and $36 
million in fiscal 2022, 2021 and 2020, respectively.
Note 8—Stock-Based Compensation:
Plan Summaries
Certain of the Company’s employees participate in the following four stock-based compensation plans: “2013 Equity 
Incentive Plan” (EIP), “Management Stock Compensation Plan,” “2013 Employee Stock Purchase Plan” (ESPP), 
and the "2012 Long Term Performance Plan" (LTPP), which are herein referred to together as the “Plans.” The 
Company issues new shares on the vesting of stock awards or exercise of stock options under these Plans.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-26

The EIP provides the Company’s employees and directors the opportunity to receive various types of stock-based 
compensation and cash awards. The terms of the stock-based awards granted to employees and directors are the 
same, except that those for directors cliff vest within one year of the grant date. As of January 28, 2022, the 
Company has outstanding stock options, vested and vesting stock awards, and performance share awards under 
this plan. Stock options granted under the EIP generally become exercisable 33%, 33% and 33% after one, two and 
three years, respectively, while vesting stock awards granted prior to fiscal 2020 generally vest 25%, 25%, 25% and 
25% after one, two, three and four years, respectively. Vesting stock awards granted in fiscal 2020 and thereafter 
generally vest 33%, 33% and 33% after one, two and three years, respectively. The maximum contractual term for 
stock options granted under the EIP is ten years, but historically the Company has granted stock options with a 
seven-year contractual term. Vesting may be accelerated for employees meeting retirement eligibility conditions. 
Vesting accelerates for eligible officers upon termination of employment, subject to certain conditions set forth in the 
Company’s Executive Severance, Change in Control and Retirement Policy effective July 1, 2020. Stock-based 
awards generally provide for accelerated vesting if there is a change in control (as defined in the EIP). Vesting stock 
awards and performance share awards have forfeitable rights to dividends. In June 2014, the EIP was amended 
and restated to increase the total authorized shares of common stock for issuance under the EIP from 5.7 million to 
8.5 million.
The Company grants performance-based stock awards to certain officers and key employees under the EIP. 
Performance shares are rights to receive shares of the Company’s stock on the satisfaction of certain requirements. 
Performance-based stock awards granted prior to fiscal 2022 include service and performance conditions. These 
awards cliff vest at the end of the third fiscal year following the grant date, subject to meeting the minimum service 
requirements and the achievement of certain annual and cumulative financial metrics of the Company’s 
performance, with the number of shares ultimately issued, if any, ranging up to 200% of the specified target shares. 
If performance is below the minimum threshold level of performance, no shares will be issued. For all performance 
share awards granted, the annual financial metrics are based on operating cash flows and the cumulative financial 
metrics are based on a measure of earnings. Performance-based stock awards granted in fiscal 2022 also include 
market conditions in addition to the service and performance conditions described above. The market conditions are 
based on the Company’s total shareholder return over the three year performance period as compared to the total 
shareholder return for a specified index of companies over the same period.
The Management Stock Compensation Plan provides for awards in share units to eligible employees. Benefits are 
payable in shares of the Company’s stock that are held in a trust for the purpose of funding benefit payments to the 
participants. During fiscal 2017 all remaining outstanding awards in the Management Stock Compensation Plan 
vested. The Board of Directors may at any time amend or terminate the Management Stock Compensation Plan. In 
the event of a change in control of the Company (as defined by the Management Stock Compensation Plan), 
participant accounts will be immediately distributed, otherwise participant accounts will generally be distributed upon 
retirement based on the participant’s payout election, or upon termination. The Management Stock Compensation 
Plan does not provide for a maximum number of shares available for future issuance.
The Company’s ESPP allows eligible employees to purchase shares of the Company’s stock at a discount of up to 
15% of the fair market value on the date of purchase. During the three fiscal years ended January 28, 2022, the 
discount was 5% of the fair market value on the date of purchase for purchases made under the Company’s ESPP, 
thereby resulting in the ESPP being non-compensatory. As of January 28, 2022, 3.4 million shares of the 
Company’s stock are authorized for issuance under the ESPP.
The LTPP provides certain employees of the Company the opportunity to receive various types of stock-based 
compensation awards. Vesting stock awards issued under the LTPP generally cliff vest at the end of the third fiscal 
year following the grant date. Vesting may be accelerated for employees meeting retirement eligibility conditions. 
Vesting stock awards under the LTPP have forfeitable rights to dividends. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-27

Expense and Related Tax Benefits Recognized
Stock-based compensation expense and related tax benefits recognized under the Plans were:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Stock-based compensation expense:
Stock options
$ 
1 $ 
3 $ 
4 
Vesting stock awards
 
36  
32  
29 
Performance share awards
 
9  
7  
4 
Total stock-based compensation expense
$ 
46 $ 
42 $ 
37 
Tax benefits recognized from stock-based compensation
$ 
15 $ 
14 $ 
13 
Stock Options
Stock options are granted with their exercise price equal to the closing market price of the Company’s stock on the 
last trading day preceding the grant date.
Stock option activity for the year ended January 28, 2022 was:
Shares of 
stocks under 
stock options
Weighted-average 
exercise price
Weighted-average 
remaining 
contractual term
Aggregate 
intrinsic value
(in millions)
(in years)
(in millions)
Outstanding at January 29, 2021
 
0.7 $ 
68.57 
3.9
$ 
20 
Options granted
 
—  
— 
Options forfeited or expired
 
—  
— 
Options exercised
 
(0.1)  
45.21 
Outstanding at January 28, 2022
 
0.6 $ 
72.34 
3.3
$ 
6 
Exercisable at January 28, 2022
 
0.5 $ 
71.96 
3.0
$ 
5 
Vested and expected to vest at January 28, 2022
 
0.6 $ 
72.33 
3.3
$ 
6 
As of January 28, 2022, the unrecognized compensation cost, net of estimated forfeitures, related to stock options 
was not material.
The following table summarizes activity related to exercises of stock options:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Cash received from exercises of stock options
$ 
1 $ 
— $ 
— 
Stock exchanged at fair value upon exercises of stock options
$ 
1 $ 
1 $ 
2 
Tax benefits from exercises of stock options
$ 
1 $ 
2 $ 
3 
Total intrinsic value of options exercised
$ 
4 $ 
8 $ 
16 
 The fair value of stock option awards granted under the Company’s plan were valued using the Black-Scholes 
option-pricing model based on the following assumptions:
Expected Term--The expected term was calculated from the Company's historical settlement data.
Expected Volatility--The expected volatility is based on the historical volatility of the Company over a period 
commensurate with the expected term of the stock option as of the date of grant.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-28

Risk-Free Interest Rate--The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury 
bond with a maturity equal to the expected term of the stock option on the date of grant.
Dividend Yield--The dividend yield assumed over the expected term of the option is calculated based on the 
most recently announced dividend as of the grant date.
The weighted-average grant date fair value and assumptions used to determine the fair value of stock options 
granted for the periods presented were:
Year Ended
January 29,
2021
January 31,
2020
Weighted-average grant-date fair value
$ 
17.54 
$ 
16.88 
Expected term (in years)
3.8
4.2
Expected volatility
 35.5% 
 30.0% 
Risk-free interest rate
 0.3% 
 2.2% 
Dividend yield
 1.8% 
 2.0% 
Vesting Stock Awards
Vesting stock award activity for the year ended January 28, 2022 was:
Shares of stock under stock 
awards
Weighted-average grant 
date fair value
(in millions)
Unvested at January 29, 2021
 
1.0 $ 
76.73 
Awards granted
 
0.6  
83.65 
Awards forfeited
 
(0.1)  
79.41 
Awards vested
 
(0.5)  
76.07 
Unvested at January 28, 2022
 
1.0 $ 
80.78 
 The grant date fair value of vesting stock awards is based on the closing market price of the Company’s stock on 
the last trading day preceding the grant date. The weighted-average grant date fair value of the vesting stock 
awards granted in fiscal 2022, 2021 and 2020 was $83.65, $76.41 and $76.01, respectively. As of January 28, 2022 
there was $38 million of unrecognized compensation cost, net of estimated forfeitures, related to vesting stock 
awards, which is expected to be recognized over a weighted-average period of 1.7 years. The fair value of vesting 
stock awards that vested in fiscal 2022, 2021 and 2020 was $39 million, $32 million and $35 million, respectively.
Performance Share Awards
Performance share award activity for the year ended January 28, 2022 was:
Shares of stock under 
performance shares
Weighted-average grant 
date fair value
(in millions)
Unvested performance shares at January 29, 2021
 
0.2 $ 
76.54 
Performance shares granted
 
0.1  
80.57 
Performance shares forfeited
 
—  
— 
Performance shares vested
 
(0.1)  
79.04 
Performance shares adjustment
 
—  
— 
Unvested performance shares at January 28, 2022
 
0.2 $ 
78.13 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-29

For performance share awards granted in fiscal 2022 and 2021, the actual number of shares to be issued upon 
vesting range between 0-200% of the specified target shares. For performance share awards granted prior to fiscal 
2021, the actual number of shares to be issued upon vesting range between 0-150% of the specified target shares. 
The number of performance shares are presented at 100% of the specified target shares in the table above, except 
for performance shares that vested and performance shares adjustment. Performance shares vested reflects the 
number of shares to be issued based on the actual achievement of the performance goals for shares that vested 
during the period. Performance shares adjustment reflects the increase or decrease in the number of performance 
shares vested compared to the number of performance shares that would have vested at target. 
The weighted-average grant date fair value of the performance share awards granted in fiscal 2022, 2021 and 2020 
was $80.57, $74.40 and $79.04, respectively. For performance shares granted prior to fiscal 2022, the grant date 
fair value was based on the closing market price of the Company’s common stock on the last trading day preceding 
the grant date. For performance share awards granted in fiscal 2022, the grant date fair value was determined using 
a Monte Carlo simulation model that incorporated multiple valuation assumptions, including the probability of 
achieving the total shareholder return market condition. The primary assumptions included an expected volatility of 
39.73% and a risk-free interest rate of 0.32%. The expected volatility was based on the historical volatility of the 
Company over a period commensurate with the expected term of the award as of the date of grant. The risk-free 
interest rate was based on the yield curve of a zero-coupon U.S. Treasury bond with a maturity equal to the 
expected term of the award on the date of grant.
The fair value of performance share awards that vested in fiscal 2022 was $7 million. For unvested performance 
shares as of January 28, 2022 the Company expects to issue 0.2 million shares of stock in the future based on 
estimated future achievement of the performance goals. As of January 28, 2022 there was $9.6 million of 
unrecognized compensation cost, net of estimated forfeitures, related to performance share awards, which is 
expected to be recognized over a weighted-average period of 1.7 years.
Note 9—Retirement Plans:
Defined Contribution Plans
The Company sponsors the Science Applications International Corporation Retirement Plan (a qualified defined 
contribution 401(k) plan) and an employee stock ownership plan, in which most employees are eligible to 
participate. There are a variety of investment options available, including the Company's stock.
The Science Applications International Corporation Retirement Plan allows eligible participants to contribute a 
portion of their income through payroll deductions and the Company makes matching company contributions and 
may also make discretionary contributions. The Company contributions expensed for defined contribution plans 
were $79 million, $73 million and $65 million in fiscal 2022, 2021 and 2020, respectively.
Deferred Compensation Plans
The Company has established the Science Applications International Corporation Deferred Compensation Plan 
(DCP) effective January 1, 2015, providing certain eligible employees and directors an opportunity to defer some or 
all of their compensation on an unfunded, nonqualified basis. Participant deferrals are fully vested and diversified at 
the participant’s direction among the investment options offered under the DCP. Participant accounts are credited 
with a rate of return based on the performance of the investment options selected. Distributions are made in cash. 
Deferred balances are paid on retirement based on the participant’s payout election, or upon termination. The 
Company may provide discretionary contributions to participants, but no Company contributions have been made.
The Science Applications International Corporation Key Executive Stock Deferral Plan (KESDP) was closed on 
December 31, 2014, and no further deferrals are allowed. Benefits from the KESDP are payable in shares of the 
Company’s stock that may be held in trust for the purpose of funding benefit payments to KESDP participants. 
Vested deferred balances are paid on retirement based on the participant’s payout election, or upon termination.
The Science Applications International Corporation 401(k) Excess Deferral Plan (Excess Plan) was also closed on 
December 31, 2014, and no further deferrals are allowed. Participant deferrals are fully vested and diversified at the 
participant’s direction among the investment options offered under the Excess Plan. Deferred balances are paid on 
retirement or termination.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-30

Defined Benefit Plans
In connection with the acquisition of Engility on January 14, 2019, SAIC assumed two defined benefit plans 
sponsored by Engility for certain current and former employees: a Defined Benefit Pension Plan (Pension Plan) and 
a Retiree Health Reimbursement Account Plan (RHRA Benefit Plan). Membership and participants' calculated 
pension benefit are frozen in the Pension Plan and membership in the RHRA Benefit Plan is frozen. 
Our funding policy is to contribute at least the minimum amount required by the Employee Retirement income 
Security Act of 1974. Additional amounts are contributed to assure that plan assets will be adequate to provide 
retirement benefits. During fiscal 2023, the Company expects to contribute $1 million to fund the RHRA Benefit 
Plan.
During fiscal 2022, the Company recognized a net gain of $5 million on its retirement plans within other 
comprehensive income. The gain was comprised of a $4 million gain due to an increase in discount rates and a 
$1 million gain from the excess in actual investment return over the expected return.
During fiscal 2021, the Company recognized a net gain of $2 million on its retirement plans within other 
comprehensive loss. The gain was primarily comprised of a $3 million gain due to assumption changes other than 
discount rates, $2 million gain from the excess in actual investment return over the expected return, and $1 million 
in settlement charges, partially offset by a $4 million increase in liability caused by a decrease in the discount rates. 
The settlement charges were driven by the Company transferring out $6 million of assets to settle the obligations of 
certain retirees within the Pension Plan.
During fiscal 2020, the Company recognized net losses of $5 million and $1 million within other comprehensive loss 
due to changes in the net benefit obligations for the Pension Plan and RHRA Benefit Plan, respectively. The net loss 
of $6 million was attributable to a $9 million increase in the projected benefit obligation due to a decrease in the 
discount rate, partially offset by an actual investment return in excess of the expected return of $3 million. 
Net Periodic Benefit Costs
The net periodic benefit cost was as follows:
Pension Plan
RHRA Benefit Plan
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Interest cost on projected benefit obligation $ 
1 $ 
2 $ 
3 $ 
1 $ 
— $ 
1 
Expected return on plan assets
 
(3)  
(3)  
(3)  
—  
—  
— 
Settlement cost
 
—  
1  
—  
—  
—  
— 
Net periodic benefit cost
$ 
(2) $ 
— $ 
— $ 
1 $ 
— $ 
1 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-31

Obligations and Funded Status
The projected benefit obligation, fair value of plan assets and funded status for each plan are as follows:
Pension Plan
RHRA Benefit Plan
January 28, 
2022
January 29, 
2021
January 28, 
2022
January 29, 
2021
(in millions)
Change in benefit obligation:
Benefit obligation at beginning of year
$ 
70 $ 
76 $ 
14 $ 
17 
Interest cost
 
1  
2  
1  
— 
Benefits paid
 
(5)  
(5)  
(1)  
(1) 
Actuarial (gain) loss
 
(3)  
3  
(1)  
(2) 
Settlements
 
—  
(6)  
—  
— 
Benefit obligation at end of year
$ 
63 $ 
70 $ 
13 $ 
14 
Change in plan assets:
Fair value of plan assets at beginning of year
 
55  
53  
—  
— 
Actual return on plan assets
 
4  
5  
—  
— 
Employer contributions
 
—  
8  
1  
1 
Benefits paid
 
(5)  
(5)  
(1)  
(1) 
Settlements
 
—  
(6)  
—  
— 
Fair value of plan assets at end of year
$ 
54 $ 
55 $ 
— $ 
— 
Unfunded status
$ 
9 $ 
15 $ 
13 $ 
14 
Amounts recognized in the consolidated balance sheets consist of:
Pension Plan
RHRA Benefit Plan
January 28, 
2022
January 29, 
2021
January 28, 
2022
January 29, 
2021
(in millions)
Other accrued liabilities
$ 
— $ 
— $ 
1 $ 
1 
Other long-term liabilities
 
9  
15  
12  
13 
Net amount recognized
$ 
9 $ 
15 $ 
13 $ 
14 
Assumptions
The Company uses the spot rate approach to measure liabilities and interest costs for defined benefit obligations. 
Under the spot rate approach, the Company uses individual spot rates along the yield curve that correspond with 
the timing of each benefit payment.
The discount rates represent the estimated rate at which we could effectively settle our defined benefit obligations 
using a high quality bond yield curve.
The assumed long-term rate of return on plan assets, which is the average return expected on the funds invested or 
to be invested to provide future benefits to pension plan participants, is determined by an annual review of historical 
returns on plan assets. In selecting the expected long-term rate of return on assets used for the Pension Plan, the 
Company considered its investment return goals stated in the Pension Plan's investment policy. This process 
included determining expected returns for the various asset classes that comprise the Pension Plan's target asset 
allocation.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-32

The following assumptions were used to determine the benefit obligations and net periodic benefit costs:
Pension Plan
RHRA Benefit Plan
January 28, 
2022
January 29, 
2021
January 31, 
2020
January 28, 
2022
January 29, 
2021
January 31, 
2020
Discount rate
 3.13% 
 2.47% 
 2.87% 
 2.78% 
 1.86% 
 2.56% 
Interest cost effective rate
 1.72% 
 2.47% 
 3.70% 
 1.35% 
 2.27% 
 3.58% 
Expected rate of return on assets
 5.50% 
 5.50% 
 5.50% 
N/A
N/A
N/A
Pension Plan Assets
The Company's investment policy includes a periodic review of the Pension Plan's investment in the various asset 
classes. During fiscal 2022, the Company's overall investment strategy was for plan assets to achieve a long-term 
rate of return of 5.50%, with a wide diversification of asset types, fund strategies and fund managers. The target 
allocation for the plan assets is 44% in domestic equity securities, 20% international equity, 31% in fixed income 
securities and 5% in cash and cash equivalents. The risk management practices include regular evaluations of fund 
managers to ensure the risk assumed is commensurate with the given investment style and objectives. According to 
the plan's investment policy, performance will be evaluated across all time periods, with a particular emphasis on 
longer-term returns relative to associated peers and benchmarks.
The fair value measurement of plan assets by category is as follows:
Asset Category
Fair Value Hierarchy
January 28, 2022
January 29, 2021
(in millions)
Mutual funds
Equity
Level 1
$ 
34 $ 
37 
Fixed income
Level 1
 
9  
8 
Guaranteed deposit account
Level 3
 
3  
3 
Subtotal
 
46  
48 
Collective trust - fixed income(1)
Measured at NAV
 
8  
7 
Total
$ 
54 $ 
55 
(1)
Collective trusts are measured at fair value using net asset value (NAV) as a practical expedient and have not been 
categorized in the fair value hierarchy.
Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
A reconciliation of the beginning and ending balances of the Guaranteed Deposit Account (GDA) is as follows:
Guaranteed 
Deposit Account
(in millions)
Balance at January 31, 2020
$ 
2 
Purchases
 
12 
Sales
 
(11) 
Balance at January 29, 2021
 
3 
Purchases
 
5 
Sales
 
(5) 
Balance at January 28, 2022
$ 
3 
The GDA is designed to provide liquidity and safety of principal with a competitive guaranteed rate of return. The fair 
value of the GDA approximates the market value of underlying investments by discounting expected future 
investment cash flow from both investment income and repayment of principal for each investment purchased 
directly for the defined benefit segment of the General Account. Principal and accumulated interest are fully 
guaranteed by Prudential Retirement Insurance and Annuity Company (PRIAC). The declared interest rate is 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-33

announced each year in advance and is determined by PRIAC. The GDA invests in a broadly diversified, fixed-
income portfolio within PRIAC's general account. The portfolio is invested in public bonds, commercial mortgages 
and private placement bonds.
Estimated Future Benefit Payments
The following table sets forth the expected timing of benefit payments by fiscal year:
Fiscal Year
Pension Plan
RHRA Benefit Plan
Total
(in millions)
2023
$ 
5 $ 
1 $ 
6 
2024
 
5  
1  
6 
2025
 
5  
1  
6 
2026
 
5  
1  
6 
2027
 
5  
1  
6 
Five subsequent fiscal years
$ 
21 $ 
6 $ 
27 
Note 10—Income Taxes:
Substantially all of the Company’s income before income taxes for the three years ended January 28, 2022 is 
subject to taxation in the United States. The provision for income taxes for each of the periods presented include the 
following:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Current:
Federal
$ 
13 $ 
34 $ 
10 
State
 
7  
14  
3 
Deferred:
Federal
 
48  
10  
32 
State
 
11  
2  
12 
Total
$ 
79 $ 
60 $ 
57 
A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income 
tax rate to income before income taxes for each of the periods presented was as follows:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Amount computed at the statutory federal income tax rate
$ 
75 
$ 
57 
$ 
60 
State income taxes, net of federal tax benefit
 
16 
 
13 
 
14 
Research and development and other federal credits
 
(9) 
 
(8) 
 
(11) 
Non-deductible compensation
 
3 
 
3 
 
2 
Excess tax benefits for stock-based compensation
 
(3) 
 
(3) 
 
(4) 
Foreign-derived intangible income
 
(6) 
 
(1) 
 
(1) 
Other
 
3 
 
(1) 
 
(3) 
Total
$ 
79 
$ 
60 
$ 
57 
Effective income tax rate
 22.1 %
 22.1 %
 20.0 %
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-34

The effective income tax rate for fiscal 2022 is consistent with the rate in fiscal 2021. Federal and state tax expense 
is higher in fiscal 2022 as compared to fiscal 2021 because of increased income before taxes. This is partially offset 
by research and development tax credits and increased tax benefits from the deduction of foreign-derived intangible 
income as a result of increased qualifying foreign sales income. 
Deferred income taxes are recorded for differences in the basis of assets and liabilities for financial reporting 
purposes and tax reporting purposes. Deferred tax assets (liabilities) were comprised of:
January 28,
2022
January 29,
2021
(in millions)
Accrued vacation and bonuses
$ 
30 $ 
33 
Accrued liabilities
 
12  
16 
Deferred compensation
 
18  
20 
Stock awards
 
10  
11 
Net operating loss and other carryforwards
 
94  
105 
Deferred revenue
 
17  
14 
Lease liability
 
63  
65 
Payroll tax deferral
 
—  
11 
Accumulated other comprehensive loss
 
13  
30 
Valuation allowance
 
(7)  
(7) 
Total deferred tax assets
 
250  
298 
Payroll tax deferral
 
(2)  
— 
Purchased intangible assets
 
(235)  
(198) 
Fixed asset basis difference
 
(3)  
(4) 
Right of use assets
 
(53)  
(61) 
Total deferred tax liabilities
 
(293)  
(263) 
Net deferred tax (liabilities) assets
$ 
(43) $ 
35 
For fiscal 2022, net deferred tax liabilities are presented as deferred income taxes on the consolidated balance 
sheets. For fiscal 2021, net deferred tax assets are presented in other assets on the consolidated balance sheets. 
Deferred tax assets for both periods include state tax credit carryforwards for which the Company has set up a 
valuation allowance.
The changes in the unrecognized tax benefits, excluding accrued interest and penalties, were:
Year Ended
January 28,
2022
January 29,
2021
January 31,
2020
(in millions)
Unrecognized tax benefits at beginning of the year
$ 
66 $ 
51 $ 
13 
Additions for tax positions related to prior years
 
2  
8  
32 
Additions for tax positions related to the current year
 
10  
9  
8 
Reductions for prior year tax positions related to statute 
expiration
 
—  
(2)  
(2) 
Unrecognized tax benefits at end of the year
$ 
78 $ 
66 $ 
51 
Unrecognized tax benefits that, if recognized, would affect the 
effective income tax rate
$ 
70 $ 
66 $ 
48 
Over the next 12 months, the Company does not expect a significant increase or decrease in the unrecognized tax 
benefits recorded at January 28, 2022. During the year ended January 28, 2022, we recognized an increase in 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-35

unrecognized tax benefits of approximately $12 million related to an increase in available tax credits in fiscal year 
2022. The Company recognizes net interest and penalties as a component of income tax expense.
The Company has filed income tax returns in the U.S. and various state jurisdictions, which may be subject to 
routine compliance reviews by the Internal Revenue Service (IRS) and other taxing authorities. While the Company 
believes it has adequate accruals for uncertain tax positions, the tax authorities may determine that the Company 
owes taxes in excess of recorded accruals or the recorded accruals may be in excess of the final settlement 
amounts agreed to by tax authorities. The Company’s tax returns for fiscal years 2016 through 2021 remain subject 
to examination by the IRS and various other tax jurisdictions. The Company is currently under examination by the 
IRS for fiscal years 2016 through 2019.
As of January 28, 2022, the Company has approximately $72 million of tax effected federal loss carryforwards, $12 
million of tax effected state loss carryforwards and approximately $8 million of state credit carryforwards that will 
begin to expire in fiscal 2027. The valuation allowance of $7 million at January 28, 2022 relates to these state credit 
carryforwards. 
Note 11—Debt Obligations:
The Company’s long-term debt as of the periods presented was as follows:
January 28, 2022
January 29, 2021
Stated 
interest 
rate
Effective 
interest 
rate
Principal
Unamortized 
debt 
issuance 
costs
Net
Principal
Unamortized 
debt 
issuance 
costs
Net
(in millions)
Term Loan A Facility due 
October 2023
 1.85 %
 2.18 % $ 
785 $ 
(5) $ 780 $ 844 $ 
(6) $ 838 
Term Loan A2 Facility due 
October 2023
 1.85 %
 2.01 %  
100  
—  
100  
—  
—  
— 
Term Loan B Facility due 
October 2025
 1.98 %
 2.18 %  
983  
(7)  
976  1,026  
(9)  1,017 
Term Loan B2 Facility due 
March 2027
 1.98 %
 2.37 %  
272  
(5)  
267  
272  
(6)  
266 
Senior Notes due April 2028
 4.88 %
 5.04 %  
400  
(5)  
395  
400  
(6)  
394 
Total long-term debt
$ 2,540 $ 
(22) $ 2,518 $ 2,542 $ 
(27) $ 2,515 
Less current portion
 
148  
—  
148  
68  
—  
68 
Total long-term debt, net of 
current portion
$ 2,392 $ 
(22) $ 2,370 $ 2,474 $ 
(27) $ 2,447 
As of January 28, 2022, the Company has a $2.5 billion credit facility (the Credit Facility) consisting of a $785 million 
secured Term Loan A Facility due October 2023, a $100 million secured Term Loan A2 Facility due October 2023, a 
$983 million secured Term Loan B Facility due October 2025, a $272 million secured Term Loan B2 Facility due 
March 2027 (together, the Term Loan Facilities), and a $400 million secured Revolving Credit Facility due October 
2023. The Revolving Credit Facility is available to the Company through October 2023 and there is no balance 
outstanding as of January 28, 2022. Any obligations under the Credit Facility are secured by liens on substantially 
all of the assets of the Company and its subsidiaries. As of January 28, 2022, the Company was in compliance with 
the covenants under its Credit Facility. 
During fiscal 2019, the Company entered into the Third Amended and Restated Credit Agreement (Third Amended 
Credit Agreement). Borrowings under the Term Loan A Facility due October 2023 amortize quarterly beginning on 
January 31, 2020 at 1.25% of the original borrowed amount thereunder, with such quarterly amortization payments 
increasing to 1.875% on January 31, 2021 and then to 2.50% on January 31, 2022. Beginning January 31, 2019, 
the Term Loan B Facility due October 2025 amortizes quarterly at 0.25% of the original borrowed amount. 
The scheduled principal repayments for the Term Loan A and Term Loan B facilities may be further reduced or 
eliminated by annual mandatory prepayments of a portion of SAIC’s Excess Cash Flow (as defined in the Third 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-36

Amended Credit Agreement). Mandatory principal prepayments are allocated to the Term Loan A and Term Loan B 
facilities on a pro rata basis and reduce the remaining scheduled principal installments for each facility. Voluntary 
principal prepayments may be applied to either or both loans at the Company’s direction. During fiscal year 2020, 
the Company made $150 million of voluntary principal prepayments on the Term Loan A Facility due October 2023. 
During fiscal 2020, the Company borrowed and repaid $100 million under the Revolving Credit Facility. During fiscal 
2022, the Company made $35 million of voluntary principal prepayments on the Term Loan B Facility due October 
2025.
Borrowings under the Third Amended Credit Agreement bear interest at a variable rate of interest based on LIBOR 
or a base rate, plus in each case an applicable margin. Applicable margins with respect to borrowings under the 
Term Loan B Facility due October 2025 are 1.75% for LIBOR loans and 0.75% for base rate loans. Applicable 
margins with respect to borrowings under the Term Loan A Facility due October 2023 and the Revolving Credit 
Facility due October 2023 range from 1.25% to 2.00% for LIBOR loans and 0.25% to 1.00% for base rate loans, in 
each case based on the then applicable Leverage Ratio (as defined in the Third Amended Credit Agreement). The 
Company also pays a commitment fee with respect to undrawn amounts under the Revolving Credit Facility due 
October 2023 ranging from 0.20% to 0.35%.
The Third Amended Credit Agreement contains certain restrictive covenants applicable to the Company and its 
subsidiaries including a requirement to maintain a Senior Secured Leverage Ratio (as defined in the Third Amended 
Credit Agreement) of not greater than 3.75 to 1.00 until the effectiveness of the acquisition of Engility, not greater 
than 4.50 to 1.00 upon the effectiveness of the acquisition and for the succeeding six fiscal quarters, and not greater 
than 4.00 to 1.00 thereafter, unless a Permitted Acquisition (as defined in the Third Amended Credit Agreement) 
occurs in which case not greater than 4.25 to 1.00 for three consecutive quarters following such a transaction.
On March 13, 2020, the Company entered into the Second Amendment to the Third Amended and Restated Credit 
Agreement (Second Amendment), which established, among other things, a new $600 million senior secured term 
loan "B" credit facility commitment (the Term Loan B2 Facility due March 2027) that was funded in full 
contemporaneously with the closing of the acquisition of Unisys Federal (see Note 4). The Term Loan B2 Facility 
due March 2027 bears interest at a variable rate of interest based on LIBOR or a base rate, plus an applicable 
margin of 2.25% for LIBOR loans and 1.25% for base rate loans. Effective upon funding the Term Loan B2 Facility 
due March 2027, the applicable margin for the Term Loan B Facility due October 2025 was increased from 1.75% to 
1.875% for LIBOR loans and from 0.75% to 0.875% for base rate loans.
Borrowings under the Term Loan B2 Facility due March 2027 amortize quarterly beginning on July 31, 2020 at 
0.25% of the original borrowed amount with the remaining unamortized balance due in full upon its maturity, March 
13, 2027. The Term Loan B2 Facility due March 2027 is subject to the same mandatory prepayments as the 
Company’s existing term loans under the Credit Facility and is subject to the same covenants and events of default 
as the Company's Term Loan B Facility due October 2025. During fiscal 2021, the Company made voluntary 
principal prepayments on the Term Loan B2 Facility due March 2027 of $325 million. The Company wrote off debt 
issuance costs associated with the voluntary principal prepayments of $8 million.
On March 13, 2020, to partially finance the acquisition of Unisys Federal, the Company issued $400 million of 
unsecured 4.875% Senior Notes due 2028 (the Senior Notes) through a private offering. Interest is payable semi-
annually on April 1 and October 1 of each year, commencing on October 1, 2020, and the principal is due on April 1, 
2028.
The Company incurred $27 million of debt issue costs associated with the Second Amendment, the issuance of the 
Senior Notes, and an undrawn bridge facility that terminated upon the consummation of the acquisition of Unisys 
Federal. The Company deferred $22 million of financing fees and recognized $5 million of expenses associated with 
the undrawn bridge facility, which was included in interest expense. Deferred financing fees are amortized to 
interest expense utilizing the effective interest method.
On March 1, 2021, the Company executed the Third Amendment to the Third Amended and Restated Credit 
Agreement, which reduced the applicable margin for the Term Loan B2 Facility due March 2027 for LIBOR loans 
from 2.25% to 1.875% and for base rate loans from 1.25% to 0.875%.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-37

On July 2, 2021, the Company executed the Fourth Amendment to the Third Amended and Restated Credit 
Agreement, which established a new senior secured incremental term loan credit facility commitment in the amount 
of $100 million (the Term Loan A2 Facility due October 2023). The entirety of the Term Loan A2 Facility due October 
2023 was borrowed by the Company and the proceeds were immediately used to pay a portion of the purchase 
price of Halfaker (see Note 4).
The Term Loan A2 Facility due October 2023 will amortize quarterly beginning October 31, 2021 at 0.3125% of the 
original borrowed amount thereunder. The Term Loan A2 Facility due October 2023 may be prepaid at any time 
without penalty and is subject to the same mandatory prepayments, including from excess cash flow, as the 
Company's existing term loans under the Credit Facility. The Term Loan A2 Facility due October 2023 will mature 
and be due and payable in full on October 31, 2023.
The Term Loan A2 Facility due October 2023 will bear interest at a variable rate of interest based on LIBOR or a 
base rate, plus an applicable margin of 1.25% to 2.00% for LIBOR loans and 0.25% to 1.00% for base rate loans, 
dependent upon the Company's leverage ratio. The Term Loan A2 Facility due October 2023 is subject to the same 
covenants and events of default as the Company's existing term loans under the Credit Facility.
Maturities of long-term debt as of January 28, 2022 are:
Fiscal Year
Total
(in millions)
2023
$ 
148 
2024
 
760 
2025
 
11 
2026
 
949 
2027
 
— 
Thereafter
 
672 
Total principal payments
$ 
2,540 
Note 12—Derivative Instruments Designated as Cash Flow Hedges:
The Company’s derivative instruments designated as cash flow hedges consist of:
Fair Value of Liability(1)
 at
Notional 
Amount at 
January 28, 
2022
Pay Fixed 
Rate
Receive 
Variable Rate
Settlement and 
Termination
January 28,
2022
January 29,
2021
(in millions)
(in millions)
Interest rate swaps #1
$ 
— 
 2.78 %
1-month 
LIBOR
Monthly through 
July 30, 2021
$ 
— $ 
(3) 
Interest rate swaps #2
 
685 
 3.07 %
1-month 
LIBOR
Monthly through 
October 31, 2025
 
(39)  
(81) 
Interest rate swaps #3
 
563 
 2.49 %
1-month 
LIBOR
Monthly through 
October 31, 2023
 
(12)  
(33) 
Total
$ 
1,248 
$ 
(51) $ 
(117) 
(1)
The fair value of the fixed interest rate swaps liability is included in other accrued liabilities on the consolidated balance 
sheets.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-38

The Company is party to fixed interest rate swap instruments that are designated and accounted for as cash flow 
hedges to manage risks associated with interest rate fluctuations on a portion of the Company’s floating rate debt. 
The counterparties to all swap agreements are financial institutions. See Note 13 for the unrealized change in fair 
values on cash flow hedges recognized in other comprehensive (loss) income and the amounts reclassified from 
accumulated other comprehensive (loss) income into earnings for the current and comparative periods presented. 
The Company estimates that it will reclassify $25 million of unrealized losses from accumulated other 
comprehensive loss into earnings in the twelve months following January 28, 2022. 
Note 13—Changes in Accumulated Other Comprehensive Loss by Component:
The following table presents the changes in accumulated other comprehensive loss attributable to the Company’s 
defined benefit plans and fixed interest rate swap cash flow hedges that are discussed in Note 9 and Note 12, 
respectively.
 
Unrealized Gains 
(Losses) on Fixed 
Interest Rate 
Swap Cash Flow 
Hedges(1)
Defined Benefit 
Obligation 
Adjustment(2)
Total
(in millions)
Balance at February 1, 2019
$ 
(14) $ 
— $ 
(14) 
Other comprehensive loss before reclassifications
 
(76)  
(6)  
(82) 
Amounts reclassified from accumulated other comprehensive 
loss
 
4  
—  
4 
Income tax impact
 
19  
1  
20 
Net other comprehensive loss
 
(53)  
(5)  
(58) 
Balance at January 31, 2020
$ 
(67) $ 
(5) $ 
(72) 
Other comprehensive (loss) income before reclassifications
 
(55)  
1  
(54) 
Amounts reclassified from accumulated other comprehensive 
loss
 
29  
1  
30 
Income tax impact
 
7  
—  
7 
Net other comprehensive (loss) income
 
(19)  
2  
(17) 
Balance at January 29, 2021
$ 
(86) $ 
(3) $ 
(89) 
Other comprehensive income before reclassifications
 
31  
5  
36 
Amounts reclassified from accumulated other comprehensive 
loss
 
34  
—  
34 
Income tax impact
 
(17)  
(1)  
(18) 
Net other comprehensive income
 
48  
4  
52 
Balance at January 28, 2022
$ 
(38) $ 
1 $ 
(37) 
(1)
The amount reclassified from accumulated other comprehensive loss is included in interest expense.
(2)
The amount reclassified from accumulated other comprehensive loss is included in other (income) expense, net.
Note 14—Sale of Receivables:
On January 21, 2020 the Company entered into the MARPA Facility with MUFG Bank, Ltd. (the Purchaser) for the 
sale of up to a maximum amount of $200 million of certain designated eligible receivables with the U.S. government. 
On March 17, 2020, the Company amended the MARPA Facility to increase the aggregate facility limit from 
$200 million to $300 million. The receivables sold under the MARPA Facility are without recourse for any U.S. 
government credit risk. The MARPA Facility had an initial term of one year, but effective with the renewal on January 
21, 2021 will automatically renew each year unless one of the parties gives prior notice to terminate.
The Company accounts for receivable transfers under the MARPA Facility as sales under ASC 860, Transfers and 
Servicing, and removes the sold receivables from its balance sheet. The fair value of the sold receivables 
approximated their book value due to their short-term nature. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-39

The Company does not retain an ongoing financial interest in the transferred receivables other than cash collection 
and administrative services. The Company estimated that its servicing fee was at fair value and therefore has not 
recognized a servicing asset or liability as of January 28, 2022 and January 29, 2021. Proceeds from the sale of 
receivables are reflected as cash flows from operating activities on the consolidated statements of cash flows. 
During fiscal 2022 and 2021, the Company incurred purchase discount fees of $2 million, which are presented in 
other (income) expense, net on the consolidated statements of income.
MARPA Facility activity consisted of the following:
Year Ended
January 28, 
2022
January 29, 
2021
(in millions)
Beginning balance
$ 
185 $ 
— 
Sale of receivables
 
3,224  
3,226 
Cash collections
 
(3,209)  
(3,041) 
Outstanding balance sold to Purchaser(1)
 
200  
185 
Cash collected, not remitted to Purchaser(2)
 
(23)  
(25) 
Remaining sold receivables
$ 
177 $ 
160 
(1) For fiscal 2022 and 2021, the Company recorded a net increase to cash flows from operating activities of $15 million and 
$185 million, respectively, from sold receivables. 
(2) Primarily represents the cash collected on behalf of but not yet remitted to the Purchaser as of January 28, 2022 and 
January 29, 2021. This balance is included in accounts payable on the consolidated balance sheets as of January 28, 2022 
and January 29, 2021. 
Note 15—Leases:
The Company occupies most of its facilities under operating leases. Certain equipment is also leased under short-
term or cancelable operating leases.
The Company recognizes a right of use (ROU) asset and a lease liability upon the commencement of its operating 
leases. The initial lease liability is equal to the future fixed minimum lease payments discounted using the 
Company’s incremental borrowing rate on a secured basis. The lease term includes option renewal periods and 
early termination payments when it is reasonably certain that the Company will exercise those rights. The initial 
measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less 
any lease incentives. 
The Company recognizes lease costs on a straight-line basis over the remaining lease term, except for variable 
lease payments that are expensed in the period in which the obligation for those payments is incurred.
For its facility leases, the Company combines and accounts for lease and non-lease components together as a 
single component. The Company does not recognize lease liabilities and ROU assets for leases with original terms 
of 12 months or less. ROU assets are evaluated for impairment as a long-lived asset.
Total operating lease cost is comprised of the following:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Operating lease cost
$ 
92 $ 
74 $ 
64 
Variable lease cost
 
17  
21  
15 
Short-term lease cost
 
9  
35  
4 
Sublease income
 
(1)  
(2)  
(3) 
Total lease cost
$ 
117 $ 
128 $ 
80 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-40

Lease cost and sublease income are included primarily in cost of revenues and SG&A, except for $12 million, 
$1 million and $5 million of impairment of right of use assets for fiscal 2022, 2021, and 2020, respectively, that are 
included in acquisition and integration costs. 
The Company's ROU assets and lease liabilities consisted of the following:
Balance Sheet line item
January 28, 
2022
January 29, 
2021
(in millions)
Operating lease ROU asset
Operating lease right of use assets
$ 
209 $ 
236 
Operating lease current liability
Other accrued liabilities
 
52  
49 
Operating lease non-current liability
Operating lease liabilities
 
192  
205 
Total operating lease liabilities
$ 
244 $ 
254 
Other supplemental operating lease information consists of the following:
Year Ended
January 28, 
2022
January 29, 
2021
January 31, 
2020
(in millions)
Cash paid for amounts included in the measurement of operating lease 
liabilities
$ 
74 $ 
77 $ 
64 
ROU assets obtained in exchange for new operating lease obligations
$ 
54 $ 
110 $ 
79 
Maturities of operating lease liabilities as of January 28, 2022 were as follows:
Fiscal Year
Total
(in millions)
2023
$ 
59 
2024
 
59 
2025
 
44 
2026
 
37 
2027
 
31 
Thereafter
 
35 
Total minimum lease payments
 
265 
Less: imputed interest
 
(21) 
Present value of operating lease liabilities
$ 
244 
The weighted-average remaining lease term and the weighted-average discount rate was 5 years and 3.1% as of 
January 28, 2022, respectively, and 5 years and 3.5% as of January 29, 2021, respectively.
The Company leases IT equipment and hardware to its customers. All of the Company’s lessor arrangements are 
operating leases. Operating lease revenue is recognized on a straight-line basis over the term of the lease. 
During fiscal 2022 and 2021, operating lease income was $18 million and $40 million, respectively. Operating lease 
income is reported as revenue on the consolidated statements of income. As of January 28, 2022, the undiscounted 
future payments from our lessor arrangements are $3 million, which are expected to be received during fiscal 2023.
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-41

Note 16—Business Segment Information:
The Company is organized as a matrix comprised of two customer facing operating sectors supported by an 
enterprise solutions and operations organization. The two operating sectors are responsible for customer 
relationships, business development and program management, and delivery and execution, while the enterprise 
solutions and operations organization manages the development of our offerings, solutions and capabilities. Each of 
the Company’s two operating sectors is focused on providing the Company’s comprehensive technical, engineering 
and enterprise IT service offerings to one or more agencies of the U.S federal government. The Company's 
operating sectors are aggregated into one reportable segment because they have similar economic characteristics 
and meet the other aggregation criteria including similarities in the nature of the services provided, methods of 
service delivery, customers served and the regulatory environment in which they operate.
Substantially all of the Company’s revenues were generated by, and tangible long-lived assets owned by, entities 
located in the United States. As such, financial information by geographic location is not presented.
In each of fiscal 2022, 2021 and 2020, 98% of our total revenues were attributable to prime contracts with the U.S. 
government or to subcontracts with other contractors engaged in work for the U.S. government.
Note 17—Legal Proceedings and Commitments and Contingencies:
Legal Proceedings
The Company is involved in various claims and lawsuits arising in the normal conduct of its business, none of which 
the Company’s management believes, based on current information, is expected to have a material adverse effect 
on the Company’s financial position, results of operations or cash flows.
AAV Termination for Convenience
On August 27, 2018, the Company received a stop-work order from the United States Marine Corps on the Assault 
Amphibious Vehicle (AAV) contract and on October 3, 2018 the program was terminated for convenience by the 
customer. The Company is continuing to negotiate with the Marine Corps to recover costs associated with the 
termination.
Government Investigations, Audits and Reviews
The Company is routinely subject to investigations and reviews relating to compliance with various laws and 
regulations with respect, in particular, to its role as a contractor to federal, state and local government customers 
and in connection with performing services in countries outside of the United States. U.S. government agencies, 
including the DCAA, the Defense Contract Management Agency and others, routinely audit and review a 
contractor’s performance on government contracts, indirect rates and pricing practices, and compliance with 
applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the 
contractor’s compliance with government standards for its business systems. Adverse findings in these 
investigations, audits, or reviews can lead to criminal, civil or administrative proceedings, and the Company could 
face disallowance of previously billed costs, penalties, fines, compensatory damages, and suspension or debarment 
from doing business with governmental agencies. Due to the Company’s reliance on government contracts, adverse 
findings could also have a material impact on the Company’s business, including its financial position, results of 
operations and cash flows.
The indirect cost audits by the DCAA of the Company’s business remain open for certain prior years and the current 
year. Although the Company has recorded contract revenues based on an estimate of costs that the Company 
believes will be approved on final audit, the Company does not know the outcome of any ongoing or future audits. If 
future completed audit adjustments exceed the Company’s reserves for potential adjustments, the Company’s 
profitability could be materially adversely affected.
The Company has recorded reserves for estimated net amounts to be refunded to customers for potential 
adjustments for indirect cost audits and compliance with CAS. As of January 28, 2022, the Company has recorded a 
total liability of $17 million, which is presented in other accrued liabilities on the consolidated balance sheet. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-42

Letters of Credit and Surety Bonds
The Company has outstanding obligations relating to letters of credit of $10 million as of January 28, 2022, 
principally related to guarantees on insurance policies. The Company also has outstanding obligations relating to 
surety bonds in the amount of $19 million, principally related to performance and payment bonds on the Company’s 
contracts. 
Table of Contents
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
F-43

Exhibit
Number
Description of Exhibit
2.1
Distribution Agreement dated September 25, 2013, between the Company (formerly SAIC Gemini, 
Inc.) and Leidos Holdings, Inc. (formerly SAIC, Inc.). Incorporated by reference to Exhibit 2.1 to the 
Company’s Current Report on Form 8-K as filed with the SEC on October 1, 2013.
2.2
Agreement and Plan of Merger, dated September 9, 2018, by and among Science Applications 
International Corporation, Inc., a Delaware corporation, Engility, a Delaware corporation, and 
Raptors Merger Sub, Inc., a Delaware corporation. (Pursuant to Item 601(b)(2) of Regulation S-K, 
the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission 
upon request any omitted schedule or exhibit to the Agreement and Plan of Merger.) Incorporated 
by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K as filed with the SEC on 
September 10, 2018.
2.3
Asset Purchase Agreement, dated February 5, 2020, by and among Science Applications 
International Corporation, Inc., a Delaware corporation and Unisys Corporation, a Delaware 
corporation. Incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K 
as filed with the SEC on February 6, 2020.
3.1
Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the 
Company’s Current Report on Form 8-K as filed with the SEC on October 1, 2013.
3.2
Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Company’s Current 
Report on Form 8-K as filed with the SEC on June 8, 2017.
4.1
Description of Securities. Incorporated by reference to Exhibit 4.1 to the Company's Annual Report 
on Form 10-K as filed with the SEC on March 27, 2020.
4.2
Indenture, dated March 13, 2020, by and among Science Applications International Corporation, the 
guarantors party thereto and U.S. Bank National Association, as trustee. Incorporated by reference 
to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 16, 2020.
10.1
Fourth Amendment to the Third Amended and Restated Credit Agreement, dated July 2, 2021, by 
and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other 
lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current 
Report on Form 8-K filed with the SEC on July 7, 2021.
10.2
Third Amended and Restated Credit Agreement by and among SAIC, Citibank, as administrative 
agent and collateral agent, and certain other agents and lenders party thereto, dated October 31, 
2018. Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as 
filed with the SEC on November 5, 2018.
10.3
First Amendment to the Third Amended and Restated Credit Agreement by and among SAIC, 
Citibank, as administrative agent and collateral agent, and certain other agents and lenders party 
thereto, dated February 19, 2020. Incorporated by reference to Exhibit 10.1 to the Company’s 
Current Report on Form 8-K filed with the SEC on February 24, 2020.
10.4
Second Amendment, dated March 13, 2020, to Third Amended and Restated Credit Agreement, 
dated October 31, 2018 by and among Science Applications International Corporation, Citibank, 
N.A., as administrative agent and collateral agent, and certain other agents and lenders party 
thereto. Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K 
filed with the SEC on March 16, 2020.
10.5
Third Amendment to the Third Amended and Restated Credit Agreement, dated March 1, 2021, by 
and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other 
lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current 
Report on Form 8-K filed with the SEC on March 5, 2021.
10.6
Second Amended and Restated Credit Agreement, dated May 4, 2015 by and among the Company, 
Citibank N.A. as administrative agent and collateral agent, and Bank of America, N.A., as a 
syndication agent, and certain other lenders and parties thereto. Incorporated by reference to 
Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on May 4, 2015.
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
F-44

Exhibit
Number
Description of Exhibit
10.7
First Amendment to the Second Amended and Restated Credit Agreement, dated August 23, 2016 
by and among the Company, Citibank N.A. as administrative agent and collateral agent, and certain 
other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company’s 
Current Report on Form 8-K as filed with the SEC on August 25, 2016.
10.8
Second Amendment to the Second Amended and Restated Credit Agreement, dated February 7, 
2018 by and among the Company, Citibank N.A. as administrative agent and collateral agent, and 
certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the 
Company’s Current Report on Form 8-K as filed with the SEC on February 9, 2018.
10.9
Master Accounts Receivable Purchase Agreement, dated January 21, 2020, among Science 
Applications International Corporation, Engility Services, LLC, and MUFG Bank, Ltd. Incorporated 
by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on 
February 12, 2020.
10.10
Performance Undertaking, January 21, 2020, made by Science Applications International 
Corporation in favor of MUFG Bank, Ltd. Incorporated by reference to Exhibit 10.2 to the 
Company’s Current Report on Form 8-K as filed with the SEC on February 12, 2020.
10.11
Amendment No.1 to Master Accounts Receivable Purchase Agreement, dated March 17, 2020, 
among Science Applications International Corporation, Engility Services, LLC, and MUFG Bank, 
Ltd. Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as 
filed with the SEC on March 26, 2020.
10.12*
Science Applications International Corporation Management Stock Compensation Plan, effective 
September 27, 2013. Incorporated by reference to Exhibit 4.4 to the Company’s Registration 
Statement on Form S-8 as filed with the SEC on September 27, 2013.
10.13*
Science Applications International Corporation Key Executive Stock Deferral Plan, effective 
September 27, 2013. Incorporated by reference to Exhibit 4.5 to the Company’s Registration 
Statement on Form S-8 as filed with the SEC on September 27, 2013.
10.14*
Science Applications International Corporation 2013 Employee Stock Purchase Plan, effective 
October 1, 2013. Incorporated by reference to Exhibit 4.7 to the Company’s Registration Statement 
on Form S-8 as filed with the SEC on September 27, 2013.
10.15*
Science Applications International Corporation 401(k) Excess Deferral Plan, effective September 
27, 2013. Incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on 
Form S-8 as filed with the SEC on September 27, 2013.
10.16*
Science Applications International Corporation Retirement Plan, effective September 27, 2013. 
Incorporated by reference to Exhibit 4.9 to the Company’s Registration Statement on Form S-8 as 
filed with the SEC on September 27, 2013.
10.17*
Science Applications International Corporation Amended and Restated 2013 Equity Incentive Plan, 
effective June 4, 2014. Incorporated by reference to Appendix A to the Company’s Definitive Proxy 
Statement on Schedule 14A as filed with the SEC on April 24, 2014.
10.18*
Form of Restricted Stock Unit Award Agreement of the Science Applications International 
Corporation 2013 Equity Incentive Plan. Incorporated by reference to Exhibit 10.12 to the 
Company’s Annual Report on Form 10-K as filed with the SEC on April 9, 2014.
10.19*
Form of Nonstatutory Stock Option Agreement of the Science Applications International Corporation 
2013 Equity Incentive Plan. Incorporated by reference to Exhibit 10.14 to the Company’s Annual 
Report on Form 10-K as filed with the SEC on April 9, 2014.
10.20*
Form of Performance Share Award Agreement of the Science Applications International Corporation 
2013 Equity Incentive Plan. Incorporated by reference to Exhibit 10.15 to the Company’s Annual 
Report on Form 10-K as filed with the SEC on April 9, 2014.
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
F-45

Exhibit
Number
Description of Exhibit
10.21*
Form of Restricted Stock Unit Award Agreement of the Science Applications International 
Corporation 2013 Amended and Restated Equity Incentive Plan.
10.22*
Form of Performance Share Award Agreement of the Science Applications International Corporation 
2013 Amended and Restated Equity Incentive Plan.
10.23*
Deferred Compensation Plan, effective January 1, 2015. Incorporated by reference to Exhibit 10.17 
of the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2015.
10.24*
SAIC Executive Severance, Change in Control and Retirement Policy, effective July 1, 2020. 
Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed 
with the SEC on July 2, 2020.
10.25
Master Transition Services Agreement dated September 25, 2013, between the Company (formerly 
SAIC Gemini, Inc.) and Leidos Holdings, Inc. (formerly SAIC, Inc.). Incorporated by reference to 
Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the SEC on October 1, 
2013.
10.26*
Science Applications International Corporation Third Amended and Restated 2012 Long Term 
Performance Plan. Incorporated by reference to Exhibit 10.19 to the Company's Annual Report on 
Form 10-K as filed with the SEC on March 29, 2019.
10.27
Master Transitional Contracting Agreement between the Company (formerly SAIC Gemini, Inc.) and 
Leidos Holdings, Inc. (formerly SAIC, Inc.) dated September 25, 2013. Incorporated by reference to 
Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on December 
13, 2013.
10.28*
Form of Performance Unit Award Agreement of the Science Applications International Corporation 
2012 Long Term Performance Plan. Incorporated by reference to Exhibit 10.21 to the Company's 
Annual Report on Form 10-K as filed with the SEC on March 29, 2019.
10.29*
Form of Restricted Stock Unit Agreement of the Science Applications International Corporation 2012 
Long Term Performance Plan. Incorporated by reference to Exhibit 10.22 to the Company's Annual 
Report on Form 10-K as filed with the SEC on March 29, 2019.
21
Subsidiaries of Registrant.
23.1
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
31.1
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to 
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to 
Section 906 of the Sarbanes-Oxley Act of 2002.
101
Interactive Data File. The instance document does not appear in the Interactive Data File because 
its XBRL tags are embedded within the Inline XBRL document.
104
The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL.
* Compensation Plans and Arrangements
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
F-46

CORPORATE HEADQUARTERS
Science Applications International Corporation (SAIC)
12010 Sunset Hills Road 
Reston, VA 20190
703.676.4300
Website: www.saic.com
STOCK LISTING
SAIC common stock is traded on the New York Stock  
Exchange (NYSE) under the trading symbol SAIC.
TRANSFER AGENT AND REGISTRAR
Computershare
Suite 1600
462 S. 4th Street
Louisville, KY 40202
855.679.7242
Website: www.computershare.com/saicaccess
INDEPENDENT REGISTERED  
PUBLIC ACCOUNTING FIRM
Ernst & Young LLP
1775 Tysons Boulevard  
McLean, VA 22102
VIRTUAL ANNUAL MEETING
The Annual Meeting of Stockholders is scheduled to be held 
virtually via webcast on June 8, 2022 (9:00 am E.T.) at  
www.virtualshareholdermeeting.com/SAIC2022.
Instructions on how to participate online will be included  
in the Proxy Statement.
© Science Applications International Corporation. All rights reserved. The SAIC logo is a registered trademark of Science Applications 
International Corporation in the United States and/or other countries.
Printed on paper that contains recycled fiber.
CERTIFICATIONS
The CEO/CFO certifications required to be filed with the 
Securities and Exchange Commission pursuant to Section 
302 of the Sarbanes-Oxley Act are included as Exhibits 
31.1 and 31.2 on our Annual Report on Form 10-K. In 
addition, an annual CEO certification was submitted 
by the company’s CEO to the NYSE on June 3, 2021 in 
accordance with the company’s listing standards.
INVESTOR RELATIONS
Questions from stockholders, analysts,  
and others can be directed to:
Joseph W. DeNardi 
Vice President of Investor Relations
SAIC
12010 Sunset Hills Road 
Reston, VA 20190
703.488.8528
investorrelations@saic.com
Website: https://investors.saic.com/overview
STOCKHOLDER INFORMATION